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Estrogen receptors (ER) are detected in approximately 50%-80% of primary breast 
cancers, with most of them also being progesterone receptor (PR) positive. It has been 
established that estrogen stimulates tumor growth in ER-positive breast cancers via 
ER-targeted signaling cascades, while the effects of PR ligands on breast cancer 
remain controversial. Therefore, current breast cancer endocrine therapy mainly 
focuses on antiestrogenic pathways and selective ER modulators (SERM) including 
antiestrogens have been used clinically for decades. Nonetheless, 
antiestrogen-induced remissions are often followed by acquisition of antiestrogen 
resistance and ultimately the disease will relapse. The development of strategies for 
the effective treatment of endocrine-resistant breast cancer is one of the main 
challenges in breast cancer research. 
This study demonstrates a novel antiestrogenic mechanism of PR. Overexpressing PR 
by stable transfection or adenovirus infection in ER- and PR-positive breast cancer 
MCF-7 cells reveals that PR isoform B (PR-B) is the critical PR isoform which 
functions antiestrogenically. Recombinant PR possibly exerts the antiestrogenic 
potentials via two possible pathways. Firstly, the recombinant PR in MCF-7 cells 
enhances 17β-estradiol (E2) cellular uptake and thus E2 metabolism, which directly 
contributes to faster E2 depletion as well as more rapid accumulation of E2 
antiestrogenic metabolites (e.g. 2-methoxyestradiol). Accelerated depletion of E2 
causes faster abolishment of E2 growth stimulatory effects; and E2 antiestrogenic 
Summary 
xii 
metabolites inhibit MCF-7 cell proliferation. On the other hand, recombinant PR is 
found to suppress the estrogen-occupied ER binding to estrogen response element 
(ERE) which thereby represses estrogen-dependent ER transcription activity and 
further inhibits estrogen-mediated effect on MCF-7 cell cycle progression and 
proliferation. The ER/ERE binding interference may be induced by competition of 
recombinant PR with ER for transcription cofactors/co-regulators or for the binding 
with chaperone proteins. Moreover, the antiestrogenic potential of recombinant PR in 
MCF-7 cells is found to be ligand-independent, suggesting that recombinant PR might 
be activated via ligand-independent pathways. 
The findings in this study open up a new window for a hitherto unknown functional 
relationship between the PR and ER. Because PR-B is the critical PR isoform in 
exerting the antiestrogenic effects, the PR-B unique AF-3 domain is potentially 
important. The antiestrogenic effect of recombinant PR also provides a potential 
therapeutic strategy for estrogen-dependent but endocrine-resistant breast cancers. 
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1.1 Introduction of breast cancer 
1.1.1 Epidemiology of breast cancer 
Breast cancer is a global public health issue: it was reported that over 4.4 million 
women were suffering from breast cancer in 2002 (Ferlay et al., 2004). Also in 2002, 
there were over 1 million new breast cancer cases diagnosed and over 400,000 deaths 
were reported (Veronesi et al., 2005). 
Breast cancer incidence varies in different regions of the world. As reported by 
GLOBOCAN (a database setup by the Descriptive Epidemiology Group of 
International Agency for Research on Cancer, http://www-dep.iarc.fr/), the regions 
with highest breast cancer incidence were North America, West Europe and Australia, 
while Africa and most regions of Asia were the areas having the lowest incidence. In 
Singapore, breast cancer incidence reported in 2004 was 59 per 100,000 women, 
which is the highest in Southeast Asia (21.8 per 100,000 women in overall Southeast 
Asia countries). 
 
1.1.2 Risks of breast cancer 
According to population studies (Walker, 2000; Nogueira and Appling, 2000; Kelly, 
2002; Mitra et al., 2004; Veronesi et al., 2005), the most important breast cancer risk 
factors are: 
1) Gender: 99% of breast cancer cases happen in women, only 1% are male breast 
cancer. 
2) Age: Women over 60-year old have the greatest risk. As reported by American 
Introduction 
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Cancer Society (American Cancer Society, 2005), about 80% of new breast cases 
were diagnosed in the women over 50-year old in 2004. 
3) Previous history of diseases: Women with atypical duct hyperplasia have 8-11 
times higher risk developing breast cancer than normal women. Women who have 
had breast cancer in one breast have an increased chance of getting carcinoma in 
their other breast (Veronesi et al., 2005). 
4) Genetic alternations: Women carrying BRCA1, BRCA2 and other breast cancer 
related genes have increased risk of breast cancer (Kelly, 2002). 
5) Reproductive and menstrual history: Early age menstruation and late age 
menopause without children; women delivering their first child after 40-year old; 
women who took menopausal hormone therapy for over 5 years have more risk 
(National Cancer Institute, 2003; American Cancer Society, 2003). 
6) Breast density: loss of fat in older women induces dense breast, which increases 
risk of breast cancer (National Cancer Institute, 2003; American Cancer Society, 
2003). 
7) Other risks include: race, dietary, obesity, radiation therapy to the chest, etc. 
 
1.1.3 Classification of breast cancer 
Breast cancers can be classified into two main types, viz., carcinoma in situ and 
invasive carcinoma. 
Carcinoma in situ can be further classified according to the tumor foci into lobular 
carcinoma in situ and ductal carcinoma in situ. About 15% of all breast cancers are 
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carcinoma in situ. 
The other major type - invasive carcinoma covers over 80% of all breast cancers, 
which contains invasive ductal carcinoma (IDC) and invasive lobular carcinoma 
(ILC). Between them, IDC comprises 80-85% of all invasive carcinoma. 
 
1.1.4 Diagnosis of breast cancer 
Diagnostic methods mainly used to detect breast cancer are mammography, 
ultrasonography, magnetic resonance imaging (MRI) and positron emission 
tomography (PET). 
Mammography is the most important diagnostic method for screening women with 
breast tissue no dense. It is the best method to detect small and non-palpable lesions, 
but 11% of breast cancers are not detectable by mammography (Benson et al., 2004). 
On the other hand, ultrasonography is an effective tool to detect small tumors, 
especially in dense breasts (Helvie et al., 1994). MRI and PET are imaging screening 
tools for breast cancer tumor detection. MRI which is used to locate breast tumors and 
provide evidence for conservative surgery, is also subjective to high false-positive 
reports (Szabo et al., 2003). PET is used to discover undetected metastatic foci in 
distant organs, but it is not able to identify tumors less than 5mm in size (Wahl et al., 
2004). 
Apart from those mentioned above, breast biopsy, computerized tomography (CT), 
blood chemical and enzyme tests, and tumor maker tests are also the common clinical 
examination methods for breast cancer screening. They also help to determine 
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strategies for breast cancer treatment. 
 
1.1.5 Staging of breast cancer 
Staging of breast cancer is based on the TNM system, which uses size of tumor (T), 
nodes spreading (N) and metastasis (M) as parameters. Breast cancer is clarified 
according to the TNM system as Stage 0, I, IIA, IIB, IIIA, IIIB, IIIC and IV. 
 
1.1.6 Breast cancer therapy 
The three main types of treatments for breast cancer include: local therapy, systemic 
therapy and hormonal therapy. 
1.1.6.1 Local therapy 
Local therapy comprises surgery and radiation treatment. 
Surgical treatment includes lumpectomy, mastectomy and lymph node dissection. 
Lumpectomy is surgical removal of the breast lump and surrounding margins. Normal 
lumpectomy of invasive breast carcinoma is followed by 6-7 weeks radiation therapy. 
This combined breast cancer treatment, also known as breast conserving therapy, 
covers 75-85% of all breast cancer operations (Veronesi et al., 2005). It has been 
reported that this combined protocol has similar prognosis compared to those treated 
with mastectomy (Veronesi et al., 1995). Mastectomy is surgical removal of the entire 
breast. Simple mastectomy removes only the affected breast, but not breast lymph 
nodes under the arm or muscle tissue under the breast. This surgery is normally 
indicated for breast carcinoma in situ. Modified radical mastectomy removes not only 
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breast, but also the lymph nodes and surrounding muscles. Lymph node surgery is 
performed when cancer has spread to the lymph nodes and subsequently may develop 
distant metastasis. 
Radiation therapy is usually given after lumpectomy for breast conservation, and 
includes whole breast irradiation and partial breast irradiation. It is normally given 5 
days per week and lasts 6-7 weeks. As mentioned above, post-lumpectomy radiation 
therapy gives similar prognosis to mastectomy; and mastectomy followed by radiation 
therapy also showed beneficial effects on the overall survival of breast cancer 
(Overgaard et al., 1997; Overgaard et al., 1999). However, post-mastectomy radiation 
therapy remains controversial, since the radiation-related fibrosis raises risk of breast 
reconstruction (Chawla et al., 2002). On the other hand, radiotherapy is also used in 
prevention of breast cancer metastasis. 
1.1.6.2 Systemic therapy 
Systemic therapy is the main treatment for the breast cancer patients with known 
metastasis, as well as an important adjuvant therapy before and after surgery. 
Pre-surgery systemic therapy helps to shrink the tumor(s) as to make surgical removal 
easier; and post-surgery systemic therapy kills un-removed cancer cells that may have 
slightly metastasized. Chemotherapy is one of the most important systemic therapies, 
and other novel systemic therapies are also developed. Recombinant antibodies 
against the HER-2/neu (human epidermal growth factor receptor) receptor on the 
breast cancer cell surface, such as Trastuzumab and Pertuzumab, have been used 
currently in clinical trials (Agus et al., 2005; Piccart-Gebhart et al., 2005; Romond et 
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al., 2005). They may work alone or together with chemotherapy for those with cancer 
metastasis. Besides, tyrosine kinase, cyclin and proteasome inhibitors are also started 
to use in breast cancer therapy. Another newly developed strategy is anti-angiogenetic 
therapy by using recombinant anti-VEGF (vascular endothelial growth factor) 
monoclonal antibody to inhibit angiogenesis and thus prevent tumor growth (Ferrara, 
2005; Carmeliet, 2005). 
1.1.6.3 Hormonal therapy 
Hormonal status of women is critical for breast cancer development and 
differentiation. The strategy of hormonal therapy depends on the hormonal receptor 
status of the breast cancer tumors. Current strategies of hormonal therapy are mainly 
focused on repression of stimulatory effect of estrogen. Details of endocrine therapy 




1.2 Nuclear hormone receptors 
Small lipophilic molecules such as steroids, thyroid hormones, retinoids, and vitamin 
D play very important roles in human growth, differentiation, metabolism, 
reproduction, etc. The receptors of these lipophilic molecules generally locate at 
intracellular nucleus or cytoplasm, which belongs to a big superfamily known as 
nuclear receptor superfamily. 
1.2.1 Brief introduction to nuclear receptor superfamily 
Nomenclature of nuclear receptors is generally dependent on the ligand of the receptor. 
It is believed that one ligand is only able to bind to its specific receptor generally. 
However, some ligands such as oxysterols are able to bind to liver X receptor (LXR) 
as well as steroidogenic factor I (SF-1), which belong to two different subfamilies. 
The main ligands and their receptors are listed in Table 1. 
Based on evolutionary analysis, nuclear receptors are classified into 7 subfamilies 
(Table 1). Among all, types I and III subfamilies were mostly studied, which are 
generally called as non-steroidal lipophilic hormone receptors and steroid hormone 
receptors respectively. Well-known type I subfamily members include thyroid 
hormone receptor (TR), retinoic acid receptor (RAR) and vitamin D receptor (VDR). 
Type III nuclear receptors mainly contain estrogen receptor (ER), progesterone 
receptor (PR), androgen receptor (AR), glucocorticoid receptor (GR) and 
mineralocorticoid receptor (MR). The other 4 subfamilies are not well studied and 




Table 1. Subfamilies of mammalian nuclear receptors (modified from Nuclear 
Hormone Receptors and Gene Expression (Aranda and Pascual, 2001)) 
 
 Receptor Subtype Denomination Ligand 
TR α, β Thyroid hormone receptor Thyroid hormone 
RAR α, β, γ Retinoic acid receptor Retinoic acid 
VDR  Vitamin D receptor 1-25(OH)2 vitamin D3




PXR  Pregnane X receptor Pregnanes 
CAR α, β Constitutive androstane receptor Androstanes 
LXR α, β Liver X receptor Oxysterols 
FXR  Farnesoid X receptor Bile acids 
RevErb α, β Reverse ErbA Unknown 
RZR α, β, γ Retinoid Z receptor Unknown 
Class I 
UR  Ubiquitous receptor Unknown 
RXR α, β, γ Retinoid X receptor 9-Cis-retinoic acid 
COUP-TF α, β, γ Chicken ovalbumin upstream 
promoter transcription factor 
Unknown 
HNF-4 α, β, γ Hepatocyte nuclear factor 4 Fatty acyl-CoA 
thioesters 
TLX  Tailles-related receptor Unknown 




TR2 α, β Testis receptor Unknown 
GR  Glucocorticoid receptor Glucocorticoids 
AR  Androgen receptor Androgens 
PR  Progesterone receptor Progestins 
ER α, β Estrogen receptor Estradiol 
Class III 
ERR α, β, γ Estrogen-related receptor Unknown 
Class IV NGFI-B α, β, γ NGF-induced clone B Unknown 
Class V SF-1 α, β Steroidogenic factor 1 Oxysterols 
Class VI GCNF  Germ cell nuclear factor Unknown 
SHP  Small heterodimeric partner Unknown Class 0 










Thyroid hormone receptor (TR)
Retinoic acid receptor (RAR)
General Primary Structure of 














Fig.1. Structural organization of nuclear receptors 
One nuclear receptor may have different subtypes, and the specific ligands are able to 
bind to all subtypes, because the ligand-binding domain (LBD) of receptor is highly 
conserved among subtypes. A nuclear receptor may also have isoforms, such as 
progesterone receptor having isoform A and B. 
 
1.2.2 Molecular organization of nuclear receptors 
The general molecular structure of nuclear receptors is composed of a variable 
N-terminal region (region A/B), a conserved DNA binding domain (DBD, region C), 
a hinge region (region D) and a conserved ligand-binding domain (LBD, region E). 
Some receptors may also contain a small C-terminal region (region F) with 
controversial function. In estrogen receptors, region F may function for ligand 




Few activation domains are found in nuclear receptors. Activation factor-1 (AF-1) 
locates at the variable region, which relates to ligand-independent receptor 
transcription activation. Activation factor-2 (AF-2), locating at LBD, is related to 
ligand-dependent receptor activation. In progesterone receptor isoform B (PR-B), 
activation factor-3 (AF-3) is located at the N-terminus of the variable region, 
contributing to some PR-B specific functions. 
1.2.2.1 The variable region (A/B) 
The variable region of nuclear receptors differs both in size and coding sequence. This 
domain shows promoter- and cell-specific activities, suggesting that it plays important 
roles in the cross-talk of different isoforms as well as cell-type specific functions. The 
variable region-located AF-1 can be activated through phosphorylation and 
transcription co-factor binding, so that the domain is also critical for nuclear receptor 
ligand-independent activation (Rochette-Egly et al., 1992; Rochette-Egly et al., 1997; 
Taneja et al., 1997). 
1.2.2.2 The DNA binding domain (DBD) 
The DBD region is the most conserved domain in nuclear receptors, contributing to 
target DNA recognition and binding. It is made up of 70-80 amino acids, containing 
two zinc finger structures with ~60-70 amino acids in helix 1 and 2, and a C-terminal 
extension. The first zinc finger (P box) in helix 1 involves discrimination of the 
response element (Aranda and Pascual, 2001); the second zinc finger (D box) 
involves forming of nuclear receptor dimer. The helix 3, located at the C-terminal 
extension, contains T and A boxes, which are essential for DNA monomeric binding. 
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1.2.2.3 The hinge region 
This region acts as the hinge between the ligand-binding and DNA-binding domains. 
It contains nuclear localization signals (NLS) at the part near the DNA-binding 
domain; and also contains residues that the mutation of which abolishes interaction 
with nuclear receptor co-repressors (Aranda and Pascual, 2001). 
1.2.2.4 The ligand-binding domain (LBD) 
The LBD region is multifunctional. It basically contributes to the binding of the 
ligands. It also relates to homo- or hetero-dimerization of nuclear receptors, with the 
dimerization region composed of hydrophobic heptad repeats (Tanenbaum et al., 
1998). Generally, only dimerized hormone nuclear receptors can bind to the 
hormone-response element (HRE) sequence at the target gene. Hetero-dimerization of 
nuclear receptors include asymmetric dimerization of PPARγ/RXRα (Gampe, Jr. et al., 
2000) and symmetric dimerization of RAR/RXR (Bourguet et al., 2000). LBD region 
also interacts with heat-shock proteins (HSPs) and mediates ligand-dependent 
transcriptional functions. The AF2 domain at the C-terminus of LBD is responsive to 
the ligand-dependent transcriptional activation. 
 
1.2.3 Hormone response element (HRE) 
HRE is a special nuclear receptor regulatory sequence located at the up-stream of the 
target genes. It normally locates close to the core promoter, but is also found several 
kilobases upstream or downstream of the transcriptional initiation site in some case. 
Analyses of the HRE domain of numerable genes as well as synthetic HREs reveal 
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that a sequence of 6 base-pairs constitutes the core recognition motif. The sequence 
AGA (A/T) CA is recognized by steroid class III receptors (steroid hormone receptors) 
and AG (G/T) TCA is the recognition motif for other nuclear receptors (Beato et al., 
1995). The binding between HRE and nuclear receptor dimer is determined by the “P 
Box” at the DBD (Glass, 1994). 
 
1.2.4 Mechanisms of nuclear receptor action 
1.2.4.1 Pathways of nuclear receptor action 
Taking steroid hormone receptors (SR) as an example, inactivated and unliganded SR 
is associated with a protein complex, located in the cytoplasm. The chaperone 
proteins complex is commonly composed of heat-shock protein 70 (Hsp70), Hsp90, 
p23, FKBP52 (Hsp66), and probably other unknown small molecules. The chaperone 
protein complex binds to a certain region of SR LBD to maintain SR conformation 
and facilitate high affinity ligand binding. 
Once steroid hormone molecules pass through the cell membrane and bind to steroid 
receptors, the SRs dissociate with the chaperon protein complex and form homo- or 
hetero-dimers. Liganded receptor dimers thus enter into the cell nucleus and bind to 
the HRE sequence of the target gene. The ligand/receptor dimer/DNA complex works 
together with co-regulators to activate general transcriptional machinery (which 
contains TATA-binding protein, TATA-binding protein associated factor, RNA 
polymerase II and general transcription factors), and start mRNA transcription (Kraus 
et al., 1995; Katzenellenbogen, 2000). 
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After inactivation of steroid hormone receptors, the receptors are bound with p23 to 
release steroids. The dimers are then recycled to be monomers and bind to the 
chaperon protein complex again. The released steroids go into the endoplasm 
reticulum and are converted into their metabolites. The metabolic products are thereby 
transported to Golgi vesicles and finally sent out of the cell body. 
Steroid hormone receptors can also be activated by a steroid-independent pathway. 
The activation occurs via signaling cascades from membrane regulatory molecules 
such as cAMP, dopamine, growth factors, cytokines, and possibly other cellular 
regulators acting at the membrane (Mani et al., 1994). The cascades induced receptor 
phosphorylation is related to AF-1 at receptor variable region. 
Nuclear receptors are also reported to modulate gene expression with HRE binding 
independently (Gottlicher et al., 1998). The mechanism is based on protein-protein 
interaction and referred to as “transcriptional cross-talk” (Gottlicher et al., 1998). The 
nuclear receptor ER (estrogen receptor) and GR (glucocorticoid receptor) are able to 
bind to AP-1 complex, which is composed of dimers of Jun family proteins or Jun/Fos 
hetero-dimers, to play important roles in cell proliferation (Gaub et al., 1990; 
Gottlicher et al., 1998; Aranda and Pascual, 2001). 
Apart from steroid hormone receptors (subfamily III receptors), subfamily I receptors 
normally do not bind to chaperone protein complex and they are able to induce gene 





1.2.4.2 Nuclear receptor coactivators 
Steroid receptor coactivator-1 (SRC-1) is the first nuclear receptor coactivator 
discovered (Onate et al., 1995). SRC-1 interacts with human progesterone receptor 
and enhances PR’s transcriptional activity. This interaction is ligand- and AF-2 – 
dependent. The conserved LXXLL (L denotes leucine; and X, any amino acid) motif 
repeats several times and forms a domain called the NR box (nuclear receptor box) in 
SRC-1, contributing to coactivator and receptor binding. The coactivator family 
generally contains some proteins with molecular weigh of 160kD (p160, e.g. SRC-1) 
and 300kD (p300, e.g. CBP/p300). 
Recent reports showed some p160 coactivators can also interact with AF-1 region of 
nuclear receptors, such as androgen receptor (Onate et al., 1998; Alen et al., 1999; Ma 
et al., 1999). Binding of coactivators to AF-1 region does not involve LXXLL motif, 
but rather the glutamine-rich region of the coactivators (Bevan et al., 1999). 
1.2.4.3 Nuclear receptor corepressors 
Nuclear subfamily I receptors TR and VDR commonly form hetero-dimers with RXR. 
The dimers bind to HRE in a ligand-independent manner to repress basal transcription. 
Ligand binding to the receptors releases the transcriptional silencing and leads to gene 
activation. The corepressors normally work with the TR and VDR dimers 
ligand-independently. Recruitment of SMRT or NCoR to a promoter by fusion with a 
heterologous DBD results in a strong repression of basal promoter activity (Horlein et 
al., 1995; Chen and Evans, 1995). The NR box of corepressors is generally LXX (I/H) 
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Fig.2. Molecular organization and homology of estrogen receptor subtypes α and 
β (Homology derived from Enmark and Gustafsson, 1999) 
 
 
1.3 Estrogen receptor (ER) and progesterone receptor (PR) 
1.3.1 Introduction of estrogen receptor and progesterone receptor 
ER and PR are well-studied steroid hormone receptors, belonging to the subfamily III 
of nuclear receptors. 
1.3.1.1 Estrogen receptor 
Human estrogen receptor has two subtypes ERα and ERβ. ERα is the one 
well-studied and shows great importance in breast cancers. As members of nuclear 
receptor superfamily, the two subtypes share similar structure and functional domains, 
but are found to differ in many ways with respect to tissue distribution and 
transcriptional activities. 
ERα is mapped at the long arm of chromosome 6 (6q25.1), and contains 595-amino 
acid for the complete sequence. ERβ is a 530-amino acid protein mapped at q22-24 
region of chromosome 14. The molecular organization and homology comparison of 
the subtypes are shown in Fig. 2. As shown, the most conserved domain is the 
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DNA-binding domain with 97% homology between ERα and ERβ, and homology 
between ligand-binding domains is 55%. Homologies of other domains are all less 
than 30% (Enmark and Gustafsson, 1999). 
Both ER subtypes are distributed in human brain, breast, bone, cardiovascular system 
and urogenital tract. Only subtype α is found in human liver, and only subtype β is 
present in the gastrointestinal tract (Gustafsson, 1999). Liganded ERα is important to 
trigger ERα-target cell signaling cascades, inducing cell proliferation, differentiation, 
etc. Whereas, liganded ERβ has inhibitory effect in estrogen activated 
transcription (Pettersson and Gustafsson, 2001). Furthermore, ERβ has also been 
reported to contribute to reduce the risk of Alzheimer's disease, as ERβ is the major 
estrogen receptor subtype in human brain. (Enmark and Gustafsson, 1999). 
1.3.1.2 Progesterone receptor 
PR plays a central role in the reproductive events associated with the establishment 
and maintenance of pregnancy. Compared to ER, there is only one subtype of human 
PR currently found, which is mapped at chromosome 11q22. PR has two different 
isoforms A and B, coded by the same gene sequence but using different promoters and 
start codons. The shorter isoform A contains 768 amino acids, while the longer 
isoform B has 933 amino acids, containing an additional 164-aimno acid sequence at 
the N-terminal of PR isoform A. The additional sequence belongs to the variable 
region of PR and also named as activation factor-3 (AF-3). The molecular 
organization of PR is shown in Fig. 3.  
Introduction 
18 
1.3.1.3 Interactions between ER and PR 
PR is an estrogen-regulated protein. Treatment of some ER-positive breast cancer 
cells with estrogen can dramatically increase the expression of both isoforms of PR at 
transcription and protein levels (Druege et al., 1986; Kaneko et al., 1993; Graham et 
al., 1995). 
Liganded PRs also have repressive cross-talk with estrogen receptors (Chalbos and 
Galtier, 1994; Katzenellenbogen, 2000). It was found that suppression of 
estrogen-stimulated ER activity by agonist- and antagonist-occupied endogenous PR 
in primary rat uterine cells and 3T3 mouse fibroblasts has been ascribed to the 
effective inhibition of interaction of the ER/ERE complex with the transcriptional 
complex of the ER target gene after binding to PRE (Kraus et al., 1995; Kraus et al., 
1997). The magnitude of repression depends on several factors: the PR isoform (PR-A 
more effective than PR-B); the progestin ligand (antiprogestin more effective than 
progestin agonist); the promoter; and the cell type (Katzenellenbogen, 2000). It was 
also reported that liganded PR isoform B, rather than isoform A, suppressed 
estrogen-dependent transcription in breast cancer MCF-7 and MDA-MB-231 cell 
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lines transiently overexpressing PR isoform A or B (Chalbos and Galtier, 1994). 
 
1.3.2 Estrogen cellular uptake and metabolism 
1.3.2.1 Cellular uptake of steroid hormones 
The transport of steroids into cells is generally considered as simple diffusion of free 
steroid molecules across cell membranes (Giorgi, 1980). The permeability of cell 
membranes to steroid hormones depends on the physicochemical characteristics of the 
molecules and the composition of cell membranes. Therefore, great variation of 
membrane lipid composition affects the permeability of membrane to steroids. The 
selectivity of different organs to different steroids may be recognized as the cell 
sensitivity caused by the differences of cell membranes. Some proteins located in the 
cell membrane have affinity to steroids, and they may also play roles in mediating 
steroid diffusion. 
1.3.2.2 Metabolism of 17β-estradiol 
17β-estradiol (E2) is one of the important estrogens. After E2 dissociates from 
estrogen receptor, it enters the metabolic pathway. The main metabolic conversion 
happens in endoplasmic reticulum via the oxidative pathway (Mueck et al., 2002). 
The pathway in women and men is the same, thereby the metabolism pathway is not 
regulated by sex hormones (Lippert et al., 1999). The oxidative action is mainly 
performed by cytochrome P450 enzymes, including CYP 17, CYP 3As, CYP 1A1, 
CYP 1A2 and CYP 1B1 (Martucci and Fishman, 1993). 
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The metabolic pathways are shown in Fig. 4. The first metabolic step of conversion of 
E2 is believed to oxidize the C17 position to form estrone (E1). This step is reversible, 
but it is found that the conversion from estrone to estradiol is much slower than form 
estradiol to estrone (Fishman et al., 1960). Further conversion of estradiol metabolites 
is separated into two pathways, leading to A-ring or D-ring metabolites, via individual 
enzyme systems (Martucci and Fishman, 1993). The A-ring and D-ring metabolites 
can undergo an additional degradation step by conjugation, either by glucuronidation, 
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Fig. 4. Chemical structures of 17β-estradiol and its main A- and D-ring 




1.3.2.3 Metabolites of 17β−estradiol 
As mentioned above, E2 is converted into A-ring or D-ring metabolites. The main 
A-ring metabolites include 2-hydroxyestrone (2-OH-E1), 4-hydroxyesterone 
(4-OH-E1), 4-hydroxyestradiol (4-OH-E2) and 2-methoxyxyestradiol (2-ME-E2). The 
main D-ring metabolites include estriol (E3), and 16α-hydroxyestrone. 
The formation of A-ring or D-ring metabolites has been reported to relate to 
malignant diseases. Increased D-ring metabolism is found in patients with breast 
cancer (Schneider et al., 1982; Kabat et al., 1997), endometrial cancer (Fishman et al., 
1984), cervical cancer (Auborn et al., 1991; Sepkovic et al., 1995), and prostate 
cancer (Zumoff et al., 1980; Carruba et al., 1996). In breast cancers, the patients with 
BRCA1 and BRCA2 cancer-causing genes are confirmed have more D-ring 
metabolites than others (Hedenfalk et al., 2001); and this result was also confirmed in 
mice models (Bradlow et al., 1985). 
Some E2 metabolites are found to have tumor inhibitory effects in vitro. High dose of 
estriol has anti-proliferative effect on MCF-7, T47D and MDA-MB-330 breast cancer 
cells, which are either ER positive (MCF-7 and T47D) or negative (MDA-MB-330) 
(Reddel and Sutherland, 1987). Furthermore, in MCF-7 and MDA-MB-231 
(ER-negative) breast cancer cells, 2-methoxyestradiol (2-Me-E2), 2-methoxyestrone 
(2-Me-E1) and 4-hydroxyestrone (4-OH-E1) were found having similar inhibitory 
effect as antiestrogen tamoxifen (Seeger et al., 2004). The inhibitory effects of these 
metabolites were normally found in pharmacological dosages, which is commonly in 
the μM range (Reddel and Sutherland, 1987; Fotsis et al., 1994; Lippert TH et al., 
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1999; Mueck et al., 2002; Seeger et al., 2004). However, it is also reported that 
treating estrogen-starved MCF-7 cells with 10nM 2-Me-E2 and 0.1nM E2 for 8 days 
inhibited cell proliferation about 40% (Liu and Zhu, 2004). 
 
1.3.3 Significance of ER and PR in breast cancer 
1.3.3.1 Biological significance of ER and PR in breast cancer 
ERα is the most commonly studied estrogen receptor subtype in breast cancers. The 
expression level of ERα is increased during breast tumorigenesis (Leygue et al., 1998; 
Murphy and Watson, 2002). The effect of estrogen via ERα is generally to stimulate 
the growth of breast cancer tumors. Moreover, ERα may also play a pivotal role in the 
metastatic behavior of breast cancer. ERα expression was found much higher in breast 
carcinoma in situ (75%), atypical ductal hyperplasia (80%) and usual ductal 
hyperplasia (60%) than that in normal breast tissue (10-20%) (Ricketts et al., 1991; 
Pallis et al., 1992; Karayiannakis et al., 1996). Among these aforesaid diseases, 
atypical ductal hyperplasia and usual ductal hyperplasia have increased risk to 
develop into breast carcinoma in situ (Veronesi et al., 2005), and breast carcinoma in 
situ has a 10-fold increased risk of progression to invasive breast carcinoma (Page et 
al., 1995). The up-regulation of ERα expression and clonal selection of ERα mutants 
could be involved in the progression and metastasis of breast tumors (Fuqua, 2001). 
In contrast to ERα, ERβ is down-regulated during breast tumorigenesis (Leygue et al., 
1998; Roger et al., 2001). The function of ERβ independent to ERα is unknown, but 
ERβ has been reported having negative modulatory effects on ERα function when 
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both subtypes are co-expressed (Ogawa et al., 1998; Weihua et al., 2000; Peng et al., 
2003). It has been shown that ERβ knock-out mice had super-sensitivity to estrogen 
treatment (Weihua et al., 2000). 
The roles of progesterone receptor in breast cancers are controversial. Progesterone 
stimulated growth, had no effect, or inhibited growth depending on the experimental 
conditions and the status of hormone receptors (Sutherland et al., 1988; Jeng et al., 
1992; Groshong et al., 1997; Lin et al., 1999). It is also reported that high dose of 
progesterone (10μM) was able to induce apoptosis in PR-positive breast cancer T47D 
cell line (Formby and Wiley, 1998). Progesterone receptor has also been reported may 
play an important role in metastasis. Progesterone induced regulation of 
adhesion-related genes in T47D and PR-transfected MDA-MB-231 cells, which could 
be involved in metastasis (Lin et al., 2000; Sartorius et al., 2003; Leo et al., 2005). 
1.3.3.2 ER and PR status in breast cancer 
The estrogen and progesterone receptors are widely studied as breast cancer markers. 
The status of ER and PR in breast cancers by population study is variable depending 
on the detection method and hormonal status of the tumors. The proportion of 
ER-positive cases vary from 55 to 90% in all analyzed early breast cancers (Althuis et 
al., 2004). According to the Project Program database at Baylor College of Medicine 
(Houston, TX), about 80% of all detected early breast cancers were ER-positive, with 
70% of them (55% of total) were also PR-positive. In the other 20% of ER-negative 
breast cancer cases, 85% of them (~17% of total) were both ER and PR-negative. 
PR-positive, but ER-negative cases were very rare, which only covered 2.1% of total 
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early breast cancers in the database. (Bardou et al., 2003) 
ER and PR status is strongly related to the prognosis of early breast cancers, when 
given hormone therapy. Both ER and PR-positive (ER+/PR+) breast cancers are most 
responsive to endocrine therapy, ER-positive but PR-negative (ER+/PR-) breast 
cancers have intermediate sensitivity, whereas both ER and PR-negative (ER-/PR-) 
breast cancers are the most insensitive to the therapy. The reduction in relative risk 
was 25% for ER+/PR- patients and 53% for ER+/PR+ patients, compared with 
ER-/PR- patients. Patients with ER+/PR- tumors have a reduction in relative risk of 
death of 38%, while ER+/PR+ patients, 58%, compared with ER-/PR- patients 
(Bardou et al., 2003). 
1.3.3.3 Hormonal therapy for breast cancer 
Hormone replacement therapy is a valuable option for the treatment of 
postmenopausal women with ER-positive breast cancer due to its demonstrated 
efficacy and favorable safety profile. It is reported that only half of the patients with 
early breast cancer were treated with local surgery alone (Bardou et al., 2003). 
Current endocrine therapies are mainly based on targeting the ER signaling pathway 
by blocking the action of estrogen at its receptor or by reducing circulating levels of 
estrogen. 
Antiestrogen (estrogen antagonist) tamoxifen is the most widely used hormone 
replacement drug for advanced breast cancer in past 20 years. It is also classified as a 
selective ER modulator (SERM), which acts by blocking the action of estrogen and 
estrogen receptor. Tamoxifen is reported to reduce breast cancer recurrence rate by 
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47% and overall mortality by 26% (Nicholson and Johnston, 2005). It is also reported 
to reduce the risk of breast cancer development (Fisher et al., 1998). However, most 
patients are eventually resistant to tamoxifen, thereby sequential SERMs (e.g. 
reloxifene, megesterol and arzoxifene) are developed as further treatment options (Ali 
and Coombes, 2002). A pure ER antagonist fulvestrant was also developed, which has 
similar affinity (89%) to E2 but without any agonist effect (Osborne et al., 2004). 
The other strategy developed is the use of aromatase inhibitors, which suppress 
activity of P450 enzyme aromatase and thus reduce circulating estradiol levels. P450 
enzyme family is essential in estradiol synthesis and metabolism as mentioned in 
section 1.3.2.2. The newly developed third generation aromatase inhibitors have been 
shown to suppress plasma estradiol levels by 85-92% (Geisler et al., 1998; Geisler et 
al., 2002). 
1.3.3.4 Mechanisms of development of endocrine resistance 
Several different mechanisms have been hypothesized to be involved in the 
development of hormonal therapy resistance in breast cancers. The potential 
mechanisms include: reduced expression or altered function of ERα and PR, 
increased expression of ERβ, pharmacogenomic metabolisms of hormonal agents (e.g. 
CYP2D6 (a cytochrome P450 enzyme) variants for tamoxifen metabolism), altered 
expression of ER co-regulators (e.g. AIB1), estrogen hypersensitivity and 
supersensitivity and increased growth factor signaling (Johnston and Dowsett, 2003; 




The tamoxifen induced breast cancer endocrine therapy resistance could be based on 
the mechanism of ER and growth factor crosstalk. In breast cancer cells expressing 
high levels of the ER co-activator AIB1 and HER2/neu, tamoxifen has been shown to 
exert an increased estrogen agonist effects and induce de novo resistance mediated by 




1.4 Adenovirus-mediated protein expression in mammalian cells 
1.4.1 Brief introduction to adenovirus 
1.4.1.1 Pathology and taxonomy 
Adenovirus is a type of double-stranded DNA virus which frequently causes acute 
upper respiratory tract (URT) infections in infants. The pathology of adenovirus is 
fairly complicated as the virus not only causes respiratory and gastrointestinal tracts 
infections, but also relates to some eye diseases, such as conjunctivitis and 
keratoconjunctivitis. It is also an infectious source of acute haemorrhagic cystitis and 
hepatitis. Adenovirus is tumorgenic in rodents, but not in humans. 
More than 40 distinct serotypes and 93 different varieties of adenovirus have been 
identified to date. The taxonomy of adenovirus was based on their haemagglutination 
and oncogenic potential. As shown in Table 2, subgroup A adenoviruses have the 
Table 2. Taxonomy of adenoviruses (modified from AdenoVator Vector System 




A 12, 18, 31 
B 3, 7, 11, 14, 21, 34, 35 
C 1, 2, 5, 6 
D 8-10, 13, 15, 17, 19, 20, 22-30, 32, 33, 36-39 
E 4 
F - G 40, 41 
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strongest tumorgenic potential, and subgroup B has weak potential. Subgroups C - G 
have no oncogenic effect. Viruses from subgroup C (especially serotype 2, 5) cause 
various respiration infections; serotype 3 and 20 viruses cause conjunctivitis; serotype 
40 relates to gastrointestinal tracts infections. 
1.4.1.2 Morphology and structure of adenovirus 
All adeno-virions are non-enveloped and 60-90nm diameter particles. They have 
icosahedral symmetry and are composed of 252 capsomers: 240 "hexons" + 12 
"pentons" at vertices of icosahedron (2-3-5 symmetry). The hexons consist of a 
central pore and some associated minor polypeptides, being involved in stabilization 
and/or assembly of the particle. The pentons have a toxin-like activity - purified 
pentons causing CPE (cytopathic effect) in the absence of any other virus components 
(Prescott et al., 2004). A thin glycoprotein fiber, which protrudes form the centre of 
each penton, is responsive to haemagglutination. The hexon, penton base, and 
knobbed fiber are the most important capsid proteins for gene delivery (Russell, 
2000). 
1.4.1.3 Genome and gene transcription of adenovirus 
Adenoviruses contain a linear, double-stranded DNA genome, with a terminal protein 
(TP) attached covalently to the 5’ termini. The DNA, which has a length of 
approximately 30-38 kilo base pairs (vary from group to group), is wrapped in a 
histone-like protein and has inverted terminal repeats (ITRs) of 50-200 base pairs, 
which act as origins of replication. The whole genome has the theoretical capacity to 
encode 30-40 genes. 
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E1 gene is composed of E1A and E1B regions. E1A is a trans-acting transcriptional 
regulatory factor, which regulates other early expression regions, including E1B, E2, 
E3 and E4. E1 gene products are involved in the replication of the virus as well as 
primary cell transforming (especially adenovirus serotypes 5 and 12). E2 encoding 
proteins provide the machinery for viral DNA replication and the ensuing 
transcription of late genes. E3 region is involved in modulating the immune response 
of infected cells, and it is not essential for viral growth in vitro. E4 region contributes 
to the metabolism of virus messenger RNA and provides functions to promote virus 
DNA replication and shut-off host protein synthesis. E4 region products also prevent 
viral DNA concatenation. Furthermore, E1A is shown to bind to Rb gene, and E1B 
binds to p53 (Cowell, 1990; Frisch, 1996). 
Adenoviral genes are transcribed from both strands of its linear genome. The first 
transcribed region is E1A (about 1 hour after infection), which regulates transcription 
of other early transcribed regions, including E1B, E2, E3, E4 and some virion proteins. 
Most virion proteins are late transcribed. 
 
1.4.2 Adenovirus-mediated gene expression 
As a widely used viral gene delivery vector in gene therapy, adenovirus has been used 
to infect a wide variety of mammalian cells and mediate expression of various genes 
(Nasz and Adam, 2001; McConnell and Imperiale, 2004). Since they have the highest 
replication efficiency among viral vectors and they deliver their genome to the 
nucleus with extremely high efficiencies, they are excellent tools for functional 
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genomics applications as well as for the expression and delivery of therapeutic genes. 
1.4.2.1 Adenoviral expression vectors 
As mentioned above, E1 region is involved in the replication and primary cell 
transformation; while E3 region is not essential for viral growth in vitro. Therefore, 
most artificial adenoviral expression vectors are E1/E3-deleted adenovirus, which 
brings the capacity of about 8kb for inserting the gene of interest (GOI). However, 
E1-deletion is not able to fully inactivate the transcription of other viral assembly 
genes, which may cause cytopathic effect (CPE) and immuno-response especially in 
high titer. In a new generation of adenoviral vectors, an improvement of partial 
deletion of E2 and E4 region was introduced to minimize the CPE effect of 
adenoviruses. This improvement also increases the capacity for GOI to about 11kb 
(Raper et al., 1998; Amalfitano et al., 1998; Gorziglia et al., 1999). Current artificial 
adenoviral expression vectors are generally modified from adenovirus serotype 5 
(Ad5). 
1.4.2.2 Adenovirus-mediated protein expression 
The pathway by which an adenovirus enters a mammalian cell is mediated by a cell 
surface receptor called coxsackie/adenovirus receptor (CAR). CAR is a 
transmembrane protein with high affinity to the knob of subgroup C adenovirus (e.g. 
Ad5). After adenovirus binds to CAR, a specific RGD (arginine-glycine-aspartate) 
motif located at the penton base of virus interacts with αvβ3 or αvβ5 integrins on the 
cell surface, which mediates the internalization of adenovirus via endocytosis. 
Once inside the cell, the penton base mediates lysis of the endosomal membrane to 
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release viruses into the cytosol. The virion is then disassembled stepwise throughout 
the process of internalization and nuclear import. Transcription, replication and viral 
packaging all take place within the nucleus of infected cells. 
1.4.2.3 Pros and cons of adenovirus-mediated protein expression 
As a powerful tool for recombinant gene expression, adenovirus has been used in 
gene therapy clinically. In research labs, adenovirus-mediated protein expression is 
also widely used. Compared with other virus-mediated expression, such as retrovirus, 
adeno-associated virus, herpes simplex virus, etc, adenovirus has its advantages and 
disadvantages. 
Firstly, adenovirus mediates very high level of recombinant protein expression in 
either dividing or non-dividing cells. Secondly, because adenovirus does not integrate 
the GOI into target cell’s genome, the adenovirus-mediated gene delivery is not 
oncogenic. Thirdly, it is relatively easy to obtain high titer stocks of adenoviruses 
compared to retroviruses. 
On the other hand, the recombinant protein expression is transient because of no 
genome integration. The reported maximal recombinant protein expression in vivo 
was 2 years and commonly half a year. Furthermore, high immunogenicity may occur 







1.4.3 Brief introduction to gene therapy 
Gene therapy is to deliver recombinant gene into cells or animals. Some gene therapy 
strategies have been applied in clinical trials. Till 2004, over 1000 gene therapy 
clinical trials have been carried out, with about 2/3 of them in Phase I. Gene therapy 
strategy is considered as the ultimate treatment for immunodeficiency diseases, but 
two-thirds of approved clinical trials are conducted in cancers. The risk of gene 
therapy is a foremost consideration. Most of strategies use retrovirus as the gene 




1.5 Cell lines and biomarker genes used in this study 
1.5.1 Cell lines 
MCF-7 is a human breast adenocarcinoma epithelial cell line separated from 
mammary gland. When culturing in phenol red DMEM supplemented with 10% FCS, 
the doubling time of adherent MCF-7 cells is 29 hours, according to the datasheet 
provided by ATCC. In MCF-7 cells, both subtypes of estrogen receptors are naturally 
expressed; progesterone receptor expression is induced by treating with estrogen or 
estrogen agonists. 
MDA-MB-231 is a human breast cancer epithelial cell line. Compared with MCF-7, 
MDA-MB-231 is an ERα- and PR-negative cell line, but with ERβ expressed. 
MDA-MB-231 and its derived cell line ABC-28, which stably expresses recombinant 
progesterone receptor both isoforms, were used as control cell lines in some of studies 
described in this thesis. 
The QBI-HEK 293A cell line was generated by transformation of human embryonic 
kidney cell cultures (HEK) with sheared adenovirus 5 DNA (Graham et al., 1977). It 
contains left end sequences of Ad5 genome, and express the E1A and E1B genes of 
Ad5, which complement the deletion of the essential regions in the recombinant 
adenovirus (Louis et al., 1997). Therefore, QBI-HEK 293A cells are excellent for 









pS2 gene, with alternative names of gastrointestinal trefoil protein pS2 or Trefoil 
factor 1 (TFF1), is located at 21q22.3 and composed of 3 exons spanning less than 5 
kb (Jeltsch et al., 1987). The genes coding for the three trefoil proteins TFF1, TFF2, 
and TFF3 are clustered within a region spanning 55 kb (Jeltsch et al., 1987; Seib et al., 
1997). pS2 (TFF1) cDNA predicts a ~9 kD, 84-amino acid protein, and it is strongly 
expressed in normal gastric mucosa (Jakowlew et al., 1984; Ribieras et al., 1998). 
pS2 gene is also found to be up-regulated by estrogen treatment via ERα in MCF-7 
cells (Roberts et al., 1988). It is detected in approximately 50% of human breast 
tumors at either transcriptional or protein levels (Tomasetto et al., 1990). Therefore, 
pS2 has been an important biomarker for breast cancer diagnosis. 
1.5.2.2 GREB1 
GREB1 (gene regulated by estrogen in breast cancer protein) was first named by 
Ghosh et al. in 2000. It maps at 2p25.2, encoding a 947 amino acids protein. It is an 
early estrogen up-regulated (2 hours, ~7 folds) gene via ERα, but not responsive to 
antiestrogens tamoxifen and ICI 182,780 in MCF-7 cells (Ghosh et al., 2000; Rae et 
al., 2005). GREB1 may be critical to the growth of breast cancer tumors, because 
knocking-down of GREB1 using siRNA blocked estrogen induced growth in MCF-7 




1.6 Scope of study 
Estrogen has been well established to stimulate tumor growth in ER-positive breast 
cancers via ER-targeted signaling cascades. Antiestrogen has been used for clinical 
applications for decades; and new endocrine therapy drugs are mainly focused on 
ER-targeted signaling pathways. Nonetheless, antiestrogen-induced remissions are 
often followed by acquisition of antiestrogen resistance and ultimately disease relapse. 
The development of strategies for the effective treatment of tamoxifen-resistant breast 
cancer is one of the main challenges for breast cancer research. 
Compared with estrogen, the effects of progesterone on breast cancers are still 
controversial – it has been found to stimulate growth, have no effect, or inhibit growth 
depending on the experimental conditions and the status of hormone receptors 
(Sutherland et al., 1988; Jeng et al., 1992; Groshong et al., 1997; Lin et al., 1999). 
The controversies over the effect of progesterone in breast cancer are due to several 
complexities in the PR system: first, the PR expression is regulated by estrogen via 
ER; second, ligand-occupied PR has been demonstrated to suppress the 
estrogen-induced stimulatory effect of ER. Moreover, ER can also transmit signals 
received from the agonist-activated PR to the Src/Ras/ERK pathway (Migliaccio et al., 
1998), suggesting a synergistic interaction between the ER and PR. 
Previous work has shown that estrogen-independent expression of recombinant PR in 
the ER- and PR-negative breast cancer cells MDA-MB-231, facilitated a striking 
inhibition of cell growth by progesterone in vivo and in vitro (Lin et al., 1999; Lin et 
al., 2001).  Progesterone has also been demonstrated to induce remarkable focal 
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adhesions in the PR-transfected MDA-MB-231 cells (Lin et al., 2000). Studying the 
interactions between ER and PR may introduce a novel pathway for solving the 
SERM-induced endocrine therapy resistance for breast cancers. 
In this study, it is hypothesized that functional interactions between ER and PR will 
result in modulating ER-targeted estrogen stimulatory effects in ER- and PR-positive 
breast cancer MCF-7 cells. 
The objectives of this study are to: 
a) Establish MCF-7 cell lines overexpressing progesterone receptor via 
liposome or adenovirus-mediated methods 
b) Examine the effects of estrogen on cell proliferation and cell cycle 
distribution of the MCF-7 cells overexpressing PR 
c) Evaluate the effects of estrogen on cell proliferation and cell cycle 
distribution of the MCF-7 cells overexpressing PR when given progesterone 
or antiprogesterone simultaneously 
d) Investigate the mechanisms of action of exogenously expressed PR 
e) Assess possible factors which may cause estrogen cellular uptake change in 
MCF-7 cells overexpressing PR 
 
 



















Materials and Methods 
38 
2.1 Chemicals 
Bovine serum albumin (BSA), dextran, charcoal, propidium iodide (PI), RNase A, 
pepstatin A, leupeptin, aprotinin, Na3VO4, phenylmethylsulphonylfluoride (PMSF), 
CsCl, β-mercapthoethanol, ethidium bromide, formaldehyde, diethylpyrocarbonate 
(DEPC), NaF, 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), Tween 
20, MG132, cytochalasin D, colchicine, 17β-estradiol (E2), progesterone, RU486 
(mifepristone), ZK98299, estrone, estriol, 6α-hydroxyestradiol, 16α-hydroxyestrone, 
BSA-conjugated 17β-estradiol and FITC-conjugated phoilloidin were purchased from 
Sigma Chemical Co. (St. Louis, MO). Trichloroacetic acid (TCA) was purchased 
from Fisher Scientific (Hampton, NH). NP-40 was purchased from USB Corp. 
(Cleveland, OH). Proteinase K was purchased from Finnzymes (Espoo, Finland). [2, 4, 
6, 7, 16, 17-3H] estradiol-17β (~149Ci/mmol) was from Amersham Biosciences Inc. 
(Buckinghamshire, UK). Triton X-100 and All HPLC grade reagents (methanol, 
acetonitrile and acetone) were from Merck KGaA. (Darmstadt, Germany). Low 
melting point agarose was obtained from Invitrogen Inc. (Carlsbad, CA). 
 
2.2 Cell culture 
MCF-7 and MDA-MB-231 cells were obtained from American Type Culture 
Collection (ATCC, Manassas, VA) in 1995 at passage 147 and 28, respectively. 
HEK-293A cells were purchased from Qbiogen Inc. (Carlsbad, CA) at passage 1. 
MCF-7-PR cells are the MCF-7 cells stably transfected with PR expression vectors 
hPR1 and hPR2 plasmids, which contain human progesterone receptor (PR) cDNA 
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coding for PR isoform B and A respectively in pSG5 plasmid (Stratagene, La Jolla, 
CA). MCF-7-PR cells were also co-transfected with pBK-CMV (Stratagene) which 
contains the neomycin-resistant gene for transfectant selection. MCF-7-C control cells 
are the MCF-7 cells stably transfected with pSG5 and pBK-CMV empty plasmid 
vectors as experimental control for MCF-7-PR cells. MCF-7-Ad/Φ cells are the 
MCF-7 cells infected with adeno- control virus Ad/Φ. MCF-7-Ad/PRA and 
MCF-7-Ad/PRB cells are the MCF-7 cells infected with adenovirus Ad/PRA or 
Ad/PRB, which transiently express PR isoform A or isoform B, respectively. 
MDA-MB-231-C2 (clone 2) cells are the subcloned MDA-MB-231 cells. ABC-28 
cells are the MDA-MB-231-C2 cells stably transfected with plasmids hPR1, hPR2 
and pBK-CMV (Lin et al., 1999). 
MCF-7, MDA-MB-231 and their derived cell lines were routinely maintained in 
phenol red and high D-glucose-containing Dulbecco's Modified Eagle’s Medium 
(DMEM) supplemented with 7.5% fetal calf serum (FCS), 2 mM glutamine and 40 
mg/L gentamicin. HEK-293A cells were routinely maintained in phenol 
red-containing DMEM supplemented with 5% FCS, 2 mM glutamine, 1mM sodium 
pyruvate and 40 mg/L gentamicin. 
Since phenol red can act as weak estrogen, phenol red-free DMEM containing 5% 
dextran-coated charcoal-FCS (DCC-FCS), 2 mM glutamine and 40 mg/L gentamicin 
was used in some experiments involving cell culture. 
All cell culture reagents were from Invitrogen Inc. Fetal calf sera were from Hyclone 
(Logan, UT) or PromoCell GmbH (Heidelberg, Germany). All cell culture plastic 
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wares were purchased from Falcon (Becton Dickinson, San Jose, CA), NUNC (Nalge 
Nunc International, Rochester, NY), or Corning (Corning, NY). 
 
2.3 Transfection of MCF-7-C and MCF-7-PR cells 
MCF-7 cells were seeded in phenol red containing DMEM supplemented with 7.5% 
FCS and incubated in 37oC CO2 incubator until the confluence of cells reached 
60-70%. The transfection was carried out by Lipofectamine reagent (Invitrogen Inc.) 
in OPTI-MEM medium (Invitrogen Inc.). For MCF-7-C cells, MCF-7 cells were 
transfected with 5μg pSG5 and 1μg pBK-CMV plasmid vectors; for MCF-7-PR cells, 
MCF-7 cells were transfected with 5μg hPR1, 5μg hPR2 and 1μg pBK-CMV plasmid 
vectors. The transfection was performed according to the manufacturer’s instruction. 
The duration of transfection was about 16 hours. 
After transfection, the cells were continued to grow in normal growth media for 
another 48 hours. Cells were then subcultured and the neomycin-resistant 
transfectants were selected by culturing in DMEM supplemented with 7.5% FCS and 
500μg/ml Geneticin (G418, Invitrogen Inc.). The neomycin-resistant colonies formed 
about 2 – 3 weeks later; the single colonies were picked and transferred into 24-well 
plates with Geneticin-containing medium. The cells continued growing in selective 
medium and transferred to 6-well plates, 10-cm Petri-dishes when reached 
confluence. 
To verify positive MCF-7-C transfectants, cells were firstly typsinized and pelleted by 
centrifuge. Cells were then resuspended with the lysis buffer (200 μg/ml proteinase K 
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and 0.5% Tween 20 in Tris-EDTA buffer (pH 8.0)) and incubated at 56oC for 1 hour 
to release genomic DNA. The lysed products were used as DNA templates for PCR. 
The primers were designed to flank the regions of pSG5 plasmid 182-405 bp: 
Forward, 5'-AGTCAGCAACCATAGTCCCGC-3'; and Reverse, 
5'-CCAAACTCACCCTGAAGTTCTCA-3'. The primers have little sequence 
homology to the vector pBK-CMV, so that the PCR products of expected size were 
further confirmed by digestion with restriction endonuclease Nco I (New England 
Biolabs, Ipswich, MA). 
Screening of MCF-7-PR positive clones was performed by quantifying PR expression 
levels by using PR-EIA (enzyme immunoassay) kit from Abbott Laboratories (Abbott 




2.4.1 Cell lysate preparation and protein concentration quantification 
The cell lysates were prepared by 2 methods. 
Method I: Cells were pelleted by centrifuge at ~150 x g, 20oC for 5 min, and 
immediately resuspended with a buffer containing 0.2M Tris-HCl (pH6.8), 4% SDS, 
20% glycerol and 2% β-mercapthoethanol by vortex. Resuspended cells were 
subjected to three cycles of freezing (liquid nitrogen) and thawing (37oC water bath), 
and homogenized by going through 29# gauge for at least 6 times. Cells were boiled at 
100oC for 8-10 min and store at -20oC until needed. 
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Method II: Cells were lysed in a buffer containing 100mM NaF, 50mM HEPES 
(pH7.5), 150mM NaCl, 1% Triton X-100, 1mM PMSF and the cocktail of proteinase 
inhibitors (5μg/ml pepstatin A, 5μg/ml leupeptin, 2μg/ml aprotinin and 1mM Na3VO4) 
on ice. The cell debris was discarded by centrifuge at ~20,000 x g, 4oC for 12 min. 
The supernatants were immediately added immunoblotting sample buffer (0.625M 
Tris-HCl (pH6.8), 10% SDS, 50% glycerol and 5% β-mercapthoethanol) and boiled at 
100oC for 8-10 min. Samples may store at -20oC until use. 
Method I is to prepare samples for progesterone receptor (PR) immunoblotting, while 
Method II is suitable for other proteins. Protein concentration quantification was 
performed by BCA protein assay kit (Pierce, Rockford, IL) 
2.4.2 Immunoblotting 
Lysates containing equal amounts of total proteins were separated on SDS-PAGE and 
transferred to nitrocellulose membranes (Amersham Biosciences Inc.). Membranes 
were blocked by 5% non-fat milk, and the antibodies used are listed as follows: 
Primary antibodies: 
a) anti-human progesterone receptor (PR) antibody (for both isoforms A and B): 
Ab-8 from NeoMarkers (Fremont, CA). 
b) anti-human estrogen receptor isoform α (ERα): Ab-15 from NeoMarkers 
c) anti-human glyceraldehyde-3-phosphate dehydrogenase (GAPDH): from 
Ambion Inc. (Austin, TX) 
Secondary antibody: 
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HRP (horseradish peroxidase)-conjugated anti-mouse IgG: from Amersham 
Biosciences Inc. 
Signal detection was carried out by using enhanced chemiluminescence (ECL, 
Amersham Biosciences Inc.) system and exposing to X-ray films (Eastman Kodak Co. 
New Haven, CT). The analysis of immunoblotting results was performed with a 
spectrodensitometer (Bio-Rad Laboratories, Hercules, CA). 
 
2.5 Immunocytochemistry 
Cells were seeded onto 6-well plates equipped with sterile glass cover-slips. Treated 
cells were firstly fixed with 4% formaldehyde in PBS on a rocker shaker, and then 
permeablised with 0.1% Triton X-100 in PBS. 2% FCS in PBS was used for blocking. 
Cells were incubated with primary and secondary antibody in a humid dark box at 
37oC. Alternatively, incubation of primary antibody could also be carried out at 4oC 
for over night (~16 hours). Cover-slips were finally mounted onto slides with 
fluorescent mounting media (DakoCytomation Corp., Carpinteria, CA). Examination 
of slides was performed on a LSM6 Meta confocal microscope (Carl Zeiss, 
Oberkochen, Germany) equipped with digital imaging system. The primary antibody 
used in this study was anti-human PR isoform A and B antibody Ab-8 (NeoMarkers); 
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2.6 Cell cycle distribution analysis 
Cells were harvested by trypsinization, and pelleted by centrifuge at 150 x g at room 
temperature for 5 min. Cells were then stained with propidium iodide (PI) in 
Vindelov’s cocktail (10mM Tris-HCl, pH 8.0, 10mM NaCl, 50mg/L PI, 10mg/L 
RNase A and 0.1% NP-40) for 1 hour in the dark at 4oC. The stained cells were 
analyzed in FACS Caliber flow cytometer (Becton Dickinson, Franklin Lakes, NJ) 
with excitation wavelength of 488 nm. The resulting histograms were analyzed by the 
software MODFIT (Becton Dickinson). 
 
2.7 Cell proliferation assay 
Cells were seeded onto 6-well plates in phenol red-free DMEM supplemented with 
5% DCC-FCS. Two days later, the cells were treated with 10-9M E2 in fresh medium 
from 1000-fold stock in ethanol, which gave a final concentration of ethanol of 0.1%. 
Treatment controls received 0.1% ethanol only. The media with the test compounds 
were replaced with fresh every two days. Counting of the cells was performed on a 
hemocytometer. 
 
2.8 Quantitative real-time RT-PCR 
Total RNA was harvested by using Trizol reagent (Invitrogen Inc.) following the 
manufacturer’s instruction. Pelleted RNA was dissolved with 0.2% DEPC pretreated 
sterile double distilled water. Quantification was performed on a spectrophotometer 
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(Beckman Coulter Inc., Fullerton, CA) at the wavelength of 260nm. The ratio of 
260nm/280nm greater than 1.70 was considered as acceptable. 
cDNAs were synthesized from 5μg of total RNA using Superscriptase II reverse 
transcriptase and random primers (Invitrogen Inc.) according to the manufacturer’s 
instruction. Quality of the synthesized cDNAs was tested by PCR using human acidic 
ribosomal phosphoprotein (36B4) as primers at the annealing temperature at 57oC. 
Real-time PCR was performed with SYBR Green Mater Mix (Applied Biosystems, 
Foster City, CA) on an ABI Prism 7700 Sequence Detection System (Applied 
Biosystems). The total reaction volume was 25μl. Reaction of each gene fragment 
was performed in triplicates and each experiment was repeated twice.  





































57 oC 102bp 
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The relative amount of PCR products generated from each primer set was determined 
on the basis of threshold (Ct). The 2-ΔΔCt method was adopted to analyze the data. ΔCt 
is equal to the difference in threshold cycles for target and reference genes (Ct of 
target gene - Ct of 36B4). Subsequently, the ΔΔCt values were calculated by 
subtracting the ΔCt values of the controls from the ΔCt values of the samples. 
Changes in gene expression were reported as fold increases (2-ΔΔCt) relative to 
controls. 
 
2.9 Promoter interference assay 
Transient transfection of the promoter interference constructs with reporter gene into 
MCF-7 cells were carried out in 6-well plates in OPTI-MEM by Lipofectamine regent 
as mentioned in section 2.3. The quantity of the DNA used were: CMV-TATA-CAT 
(cytomegalovirus-TATA-chloramphenicol acetyltransferase), 2μg/well; and 
CMV-TATA-ERE2-CAT (cytomegalovirus-estrogen response element- 
chloramphenicol acetyltransferase), 2μg/well. The duration of transfection was ~16 
hours. 
Treated cells were harvested by using the lysis buffer and following the protocol 
provided by CAT-ELISA kit (Roche Applied Sciences, Indianapolis, IN). Protein 
concentration was determined by BCA protein assay kit (Pierce). Quantification of 
CAT reporter protein expression was carried out by CAT-ELISA kit according to the 
users’ manual provided by the manufacturer. 
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2.10 Whole cell ligand-binding assay for E2 cellular uptake 
Cells were grown on 12-well plates in phenol red-free DMEM supplemented with 5% 
DCC-FCS for 48 hours before they were incubated with [3H]-E2 at 37oC. 
Non-specific uptake was determined by incubating cells with [3H]-E2 in the presence 
of 200-fold excess of unlabeled E2.  Following incubation, the cells were washed 
with cold Mg2+- and Ca2+-free DBPS three times, and cellular [3H]-E2 was extracted 
with 100% absolute ethanol at room temperature for 30 min. The radioactivity was 
measured by a Microbeta liquid scintillation counter (Perkin Elmer, Inc., Wellesley, 
MA). 
 
2.11 HPLC analysis for E2 metabolism 
Cells were seeded onto 6-well plates and grown in phenol red-free DMEM 
supplemented with 5% DCC-FCS for 48 hours before they were treated with 10-9M 
[3H]-E2. The conditioned media were harvested following 3h, 6h and 24h treatment. 
Cell-free media incubated with 10-9M [3H]-E2 were used as controls for each time 
point. 
The proteins in the media were precipitated with 10% trichloroacetic acid followed by 
washing with 0.2 volume of acetone twice. The pH value of the deproteinated media 
was adjusted to ~5.0 with 10M NaOH. The samples were filtered with 0.22μ syringe 
driven filter (Millipore Co, Ireland) and store at -80oC until use. 
HPLC was performed on a HPLC system (Waters Corp. Milford, MA) equipped with 
UV detector and auto sample collector at room temperature (20-25oC). The analytical 
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HPLC column used was Supercosil LC-18-DB column (5μm, 25cm x 4.6mm, 
Supelco Bellefonte, PA) The mobile phase A contains 21% acetonitrile/22% 
methanol/57% water/0.1% acetic acid; B contains 40% acetonitrile/60% water/0.33% 
acetic acid. The gradient was as follows: 0-15 min, 100% solvent A; 15-25 min, a 
linear increase to 19% solvent B; 25-30 min, a linear increase to 20% solvent B; 
30-53 min, a linear increase to 100% solvent B; 53-60 min, 100% solvent B. The flow 
rate was 1.5ml/min. 0.5 min flow fractions were collected and the radioactivity was 
measured on a Microbeta liquid scintillation counter. Unlabeled E2 and E2 
metabolites standards were detected by UV absorbance at the wavelength of 280nm. 
 
2.12 Preparation of adenoviruses for protein expression 
2.12.1 Transpose-AdTM adenoviral expression system 
Transpose-AdTM is a commercially available adenoviral expression system from 
Qbiogene, Inc. (Carlsbad, CA). The adenoviral expression vector Transpose-AdTM 
294 is an Ad5 genome plasmid vector, with full E1 and 60% E3 regions deletion (E1 
deletion: 356-3533; E3 deletion: 28599-30469). A transpose 7 (Tn7) sequence is 
located in the deleted E1 region of Transpose-AdTM 294 plasmid for homologous 
recombination with GOI. A β-galactosidase gene (LacZ) was also cloned between Tn7 
attachments for white/blue screening of positive clones. The capacity of 
Transpose-AdTM 294 is about 5.8 kb for complete expression cassette, in which 4.1 kb 
for the GOI. 
 























Transform HighQ-1 Transpose-AdTM 294
Linearize with Pac I and Transfect 
in QBI-HEK 293 cells






Fig. 5. Generation of recombinant adenovirus using Transpose-AdTM system
(modified from Transpose-AdTM Adenoviral Vector System Applications Manual Ver
1.1 (QBIOgene Inc., 2001)) 
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The strategy of Transpose-AdTM adenoviral expression system (Fig. 5) is to firstly 
clone GOI into the shuttle vector, where it is flanked by two Tn7 inverted repeats. 
This creates a mini Tn7 transposable element, containing Tn7 attachments, gene 
expression promoter (CMV promoter), intron, GOI and polyA sequence. After 
transforming the cloned shuttle vector into Transpose-AdTM 294 plasmid containing E. 
Coli. Cells (HighQ-1 Transpose-AdTM 294), the helper plasmid expresses transposase 
to recombine the mini Tn7 transposable element into Transpose-AdTM 294 plasmid. 
The recombinant adenoviral construct is subsequently cleaved with Pac I to expose its 
ITR (inverted terminal repeats) and transfected into QBI-HEK 293A cells to produce 
viral particles. The QBI-HEK 293A cells express the E1A and E1B genes of Ad5, 
which complement the deletion of the essential regions in the recombinant adenovirus. 
Therefore, the recombinant adenovirus is only assembled in QBI-HEK 293A cells. 
GOI expresses in other cell lines, where recombinant adenoviruses are not assembled 
as short of E1 region. 
2.12.2 Cloning of adenoviral transferring vectors 
To obtain PR-B encoding sequence (~3.8kb, contains PR-B cDNA and a non-coding 
fragment at C-terminus), the hPR1 plasmid vector was firstly digested with restriction 
endonucleases EcoR I and Pvu I (New England Biolabs). Pvu I digested the pSG5 
backbone into small fragments for easier separation. The digested product was 
separated by electrophoresis and the band containing PR-B was extracted by Gel 
Extraction Kit (Qiagen GmBH, Germany). The coding sequence of PR-B was thus 
cloned into the EcoR I site of pCR259 shuttle vector (from Transpose-AdTM 
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adenoviral expression kit, Qbiogene Inc.) by T4 ligase (New England Biolabs) at 
16oC for over night (~16 hours). The positive clones (pCR259/PRB) with correct 
inserting direction were selected and verified by restriction endonuclease digestion. 
The shuttle vector containing PR isoform A (PR-A) coding sequence (pCR259/PRA) 
was modified from pCR259/PRB plasmid. The pCR259/PRB plasmid was digested 
with Xho I and BstE II to remove a 492bp fragment, which included the start codon of 
PR-B. The linear pCR259/PRA was purified by electrophoresis and gel extraction. T4 
ligase-mediated self ligation was carried out after Klenow DNA polymerase reaction, 
which made the sticky ends of linear pCR259/PRA to be blunt ends. Positive clones 
were verified by restriction endonuclease digestion. 
2.12.3 Preparation of adenoviral expression plasmids 
Three shuttle vectors were used to prepare adenoviral expression plasmids: pCR259 
for control adenovirus (pAd/Φ), pCR259/PRA for adenovirus carrying PR-A gene 
(pAd/PRA) and pCR259/PRB for adenovirus carrying PR-B gene (pAd/PRB). The 
shuttle vectors were chemically transformed into HighQ-1 Transpose-AdTM 294 
competent cells. The transformed cells were incubated at 37oC, 225 rpm for 4 hours to 
allow homologous recombination. The cells thus grew on LB agar plate containing 
ampicillin (100μg/ml), chloramphenicol (20μg/ml), tetracycline (15μg/ml), IPTG 
(40μg/ml) and Bluo-gal (300μg/ml) at 37oC for at least 24 hours. 100% white 
colonies were picked and amplified in LB media with chloramphenicol (20μg/ml). 
The plasmids were extracted by MiniPrep Spin Kit (Qiagen GmBH). 
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A further purification by transformation was carried out, because the plasmids 
prepared at last step might be a mixture of pAd/GOI, pCR259/GOI and the Tn7 
transposease encoding helper plasmids. Therefore, the plasmids were re-transformed 
into chemical competent cells and 100% positive clones were selected on LB agar 
plate containing chloramphenicol (20μg/ml), IPTG (40μg/ml) and Bluo-gal 
(300μg/ml). The positive cells were further confirmed by growing cells on LB agar 
plates which contained ampicillin or chloramphenicol or tetracycline together with 
IPTG and Bluo-gal at 37oC for over 24 hours. Positive clones were 100% white 
ampicillin sensitive, tetracycline sensitive and chloramphenicol resistant colonies. 
Positive clones were verified by restriction endonuclease digestion and then amplified 
in a large scale. The plasmids were linealized with Pac I digestion and purified by 
ethanol precipitation. Purified plasmids were dissolved in sterile double distilled 
water and quantified on a spectrophotometer at the wavelength of 260nm. 
2.12.4 Generation of adenoviruses 
8μg of linealized pAd/Φ, pAd/PR-A or pAd/PR-B plasmids were transfected into 
about 60% confluent QBI-HEK 293A cells by Lipofectamine reagent using the 
protocol mentioned in section 2.3. The duration of transfection was 16 hours. After 
transfection, the cells were subcultured into few 10-cm Petri dishes at different 
dilutions and grew at 37oC for 24 hours. The cells were then overlaid with 1.25% of 
low melting point agarose gel and continued to grow in 37oC CO2 incubator until 
plaques occurred, which took 16-20 days. 
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Plaques were picked and virions were eluted in 0.5ml DMEM supplemented with 5% 
FCS for 24 hours at 37oC in 24-well plates. The eluted virions were applied to infect 
QBI-HEK 293A cells seeded in 24-well plates to make small scale of viral stocks. 
The cells were harvested when completed CPE achieved; and the viral particles were 
released by freezing/thawing (-20oC ethanol bath/37oC water bath) cells for three 
times. The cell debris was removed by centrifuging at 2000 x g, room temperature for 
10 minutes. The virion-containing supernatants were stored at -80oC until use. The 
resulting solution containing viruses was called “the viral stock of the first 
amplification”. 
2.12.5 Verification of positive adenoviral clones 
The eluted viral stocks of Ad/PRA and Ad/PRB clones were verified as positive by 
expressing recombinant PR-A or PR-B in ER- and PR-negative MDA-MB-231 cells. 
The MDA-MB-231 cells were infected with eluted viruses; and the expressed proteins 
were analyzed by immunoblotting using anti-PR antibody Ab-8 as probe. 
Verification of positive Ad/Φ virus was performed by infecting MCF-7 cells. 
Transpose-AdTM 294 plasmid codes β-galactosidase protein and successful 
homologous recombination reaction should replace the β-galactosidase coding 
sequence with the Tn7 transposable element from pCR259/GOI, so that MCF-7 cells 
infected with positive Ad/Φ viruses do not express β-galactosidase. β-galactosidase 
expression was detected by β-gal staining kit (Invitrogen Inc.) by following 
manufacturer’s instruction. Commercial Ad/LacZ virus, which mediates 
β-galactosidase expression in mammalian cells, was used as positive control. 
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2.12.6 Amplification of large scale adenoviral stocks 
Large scale of adenoviral stocks were amplified from the verified positive “viral stock 
of the first amplification” via repeating infection of QBI-HEK 293A cells. 
The infection was carried out by incubating plated QBI-HEK 293A cells with small 
volume of virion-containing media for 90 minutes at 37oC. The media were then 
topped-up and cells were cultured until completed CPE. Harvest of cells and release 
of viral particles followed the same protocol as mentioned in section 2.12.3. 4 
passages of infection were carried out and the last passage of amplification was to 
infect about 1 x 108 QBI-HEK 293A cells. Released viruses may be stored at -80oC 
until needed. 
2.12.7 Purification of adenoviruses 
To fully remove the cell debris and other contaminants, purification of the final 
passage of adenoviruses was performed by discontinuous CsCl gradient 
ultracentrifuge and continuous CsCl gradient ultracentrifuge sequentially. 
The purified virions were dialyzed at 4oC with a cellulose ester membrane having a 
molecular weight cut-off (MWCO) of 10kD to remove the CsCl. The formula of the 
dialysis buffer was 20mM Tris-HCl (pH 8.0), 25mM NaCl and 2.5% glycerol in 
double distilled water. The viral stocks were dialyzed in at least 200-times volume of 
the samples and the dialysis buffer was replaced with the fresh every hour, 3 times 
totally. 
The dialyzed virus was stored as small aliquots in cryotubes at -80oC for long-term 
storage. 
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2.12.8 Titration test of viral stocks 
The titrations of the purified viral stocks were determined with the TCID50 (tissue 
culture infectious doses) biological method, which is based on the development of 
CPE in QBI-HEK 293A cells using end-point dilutions to estimate the titer. 
1 x 104 cells/well were seeded onto 96-well plates and infected with 100μl of serial 
diluted virus stocks (normally used dilution 10-6 to 10-13). To improve the infection 
efficiency, cells were centrifuged at 4oC, 1,400 x g for 90min. Cells were continued to 
culture in a 37oC CO2 incubator for 10 days to allow CPE fully developed. CPE 
statuses of each well were carefully observed - a well was counted as positive even if 
only a small spot or a few cells showed CPE. The ratios of the positive wells to all 
wells infected with the same dilution of virus were determined. 
TCID50 of the viral stock was calculated by following formula: 
T=10 1 + d (S-0.5) TCID50/100μl = 10 2 + d (S-0.5) TCID50/100ml 
Where, S = the duplicate average of the sum of the ratios. Count starting from the 
10-1 to 10-13, the ratio of 10-1~10-5 were considered as 1.0. d = Log10 of the 
dilution, which equals to 1.0 in this assay 
 
2.13 Statistical Analysis 
Differences among treatment groups with regard to cell proliferation and growth were 
analyzed by ANOVA followed by least significant difference (LSD) test.  
Differences of gene expression, reporter gene activity, E2 concentration between 
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3.1 MCF-7 transfected cell lines stably overexpress both progesterone receptor 
(PR) isoform A and isoform B 
3.1.1 Selection of MCF-7 transfectants 
To test the PR levels in MCF-7 clones, the MCF-7 parental, MCF-7 cells transfected 
with pSG5 empty vector and MCF-7 cells transfected with PR expression vectors 
were starved in phenol red-free DMEM supplemented with 5% DCC-FCS for 72 
hours. This step was to minimize the expression of endogenous PR. Phenol red in 
normal DMEM has been known to have weak estrogenic effect to induce endogenous 
PR expression via estrogen receptor (ER)-targeted pathway (Berthois et al., 1986; 
Adams et al., 1989). Meanwhile, the serum factors in FCS could also affect natural 
PR expression (Cho et al., 1994; Stoica et al., 2000). Pretreatment of FCS with 
dextran-coated charcoal removes majority of serum factors and steroids, so that the 
aforesaid effects of serum were also minimized. Cells were harvested and PR amounts 
in each cell line were precisely measured by the PR-EIA kit from Abott Laboratories 
as mentioned in the Materials and Methods. 
The parental MCF-7 clone contained 24 fmol PR/mg protein after 3-day starvation. 
The vector-transfected MCF-7 control clone 8 and 14 contained 27 and 68 fmol 
PR/mg protein respectively. The PR-transfected MCF-7 clone 3, 6, 8, 11, 15, 16, 19, 
21 and 26 contained 88, 74, 220, 52, 70, 84, 99, 60 and 167 fmol PR/mg protein. For 
reference, estradiol-treated MCF-7 cells express 136 – 326 fmol PR/mg protein 
(Clarke and Sutherland, 1990; Kalkhoven et al., 1994; Botella et al., 1994). 
The vector-transfected MCF-7 clone 8 was selected as control cell line, since it 
Results 
59 
contained similar PR level as MCF-7 parental cells. The PR-transfected MCF-7 cells 
clone 8 and 26, which contained obviously higher amounts of transfected PR 
compared with other transfected clones and control clones, were selected in this study. 
In some studies, only the clone 8 was used, since it contains relatively a higher 
amount of the transfected PR compared to the clone 26. 
 
3.1.2 Expression of ERα, PR in MCF-7 parental, control and PR-transfected cells 
detected by immunoblotting 
The expression of estrogen receptor subtype α in MCF-7 and its derived cell lines 
were detected by immunoblotting to investigate whether overexpression of PR 
influenced ERα expression in the presence and absence of estrogen. The cells were 
seeded into phenol red-free DMEM supplemented with 5% DCC-FCS for 48 hours, 
and treated with 10-9 M E2 or 0.1% ethanol as vehicle control. Total proteins were 
harvested at 24 and 72 hours after the treatment; ERα expression levels were detected 
by immunoblotting using anti-ERα antibody Ab-15. 
Fig. 6 shows that the ERα in all tested cell lines were down-regulated about 20% 
when given 10-9M E2, compared with their own vehicle-treated controls regardless of 
the time point examined. It has been known that binding of E2 to ERα induces quick 
(4-6 hours) degradation of ERα via ubiquitin – proteasome pathway (Pakdel et al., 
1993). The degradation rate is variable among cell lines. 
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The PR levels in MCF-7 and its derived cell lines were also measured using the same 
batch of cell lysates. The PR expression in MCF-7-PR cells was obviously higher than 
that in the parental and control cell lines. After 72-hour starvation in phenol red-free 
DMEM supplemented with 5% DCC-FCS, the PR-transfected MCF-7 clone 8 
(MCF-7-PR8) expressed 3.7-fold PR-A and 4.7-fold PR-B of the parental clone, while 
MCF-7-PR26 cells, 2.5-fold PR-A and 1.6-fold PR-B. After 96-hour incubation, the 
PR expression in MCF-7-PR8 cells decreased to 1.7 and 2.2-fold of the parental clone 
PR-B
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Fig. 6. Expression of PR and ERα in MCF-7 cells, vector transfected MCF-7 cells 
and PR-transfected MCF-7 cells. Cell lysates were collected from the cells treated 
with 0.1% ethanol (-) or 10-9M E2 (+) for 24 or 72 hours. 50μg of total proteins were 
separated with 8.5% SDS-PAGE and transferred to nitrocellulose membranes. The 
antibodies used to probe were: anti-human PR isoform A and B antibody Ab-8 and 
anti-human ERα antibody Ab-15. Human glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) probed by anti-GAPDH antibody was used as loading control. ER- and 
PR-negative breast cancer cell line MDA-MB-231 (50μg) and ABC28 cells (5μg, 
MDA-MB-231 cells stably transfected with PR-A and PR-B) were used as negative 
and positive controls, respectively. The protein level of the ethanol-treated samples 
was defined as 1; the numbers below the E2-treated samples represent the levels 
compared with the ethanol-treated control at the same time point. 
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in PR isoform A and B respectively. However, the PR protein levels in MCF-7-PR26 
were relatively stable compared with that at 24-hour time point. This might be due to 
clone to clone difference. 
E2 treatment was able to dramatically increase the expression of PR in all cell lines. 
In MCF-7 parental cells, 24-hour E2 treatment enabled natural PR to be expressed 6.1 
times higher than vehicle control in isoform B and 3.8 times in isoform A. In 
MCF-7-C8 cells, they were 7.9 times and 3.8 times. In the PR-transfected cell lines, 
the increments of PR expression after E2 treatment were not as obvious as that in the 
control cell lines, because of the presence of transfected PR. At 24 hours after E2 
treatment, MCF-7-PR8 expressed only 1.5-fold PR-B and 2.7-fold PR-A, compared 
with its vehicle control cells. In MCF-7-PR26 cells, they were 4.3 and 2.8-fold, 
respectively. 
In summary, PR transfection led to moderate levels of PR comparable to that 
following E2 treatment in MCF-7 cells. This allows the study of PR-mediated effect 
in the absence of estrogen induction. It is also noticed that overexpression of PR in 
MCF-7 cells was much less than that in MDA-MB-231 cells, which are both 
endogenous ER- and PR-negative. PR-transfected MDA-MB-231 cells (ABC-28) 





3.2 Proliferation of MCF-7 parental, vector-transfected, and PR-transfected cells 
in the presence or absence of 17β-estradiol 
Estrogen is known to stimulate the growth of ER-positive cells via its receptor - 
estrogen receptor (ER). It has been shown that 1 pulse of E2 (1nM, 1 min) was able to 
continuously promote MCF-7 cell growth for 5 days (Otto, 1995). This section was 
designed to investigate whether PR transfection modulated MCF-7 proliferation in the 
presence or absence of estrogen. 
Phenol red can act as weak E2, which is not only able to enhance endogenous PR 
expression but also stimulate MCF-7 cell proliferation (Berthois et al., 1986). In order 
to reduce the effect, all tested cell lines were grown in phenol red-free DMEM 
supplemented with 5% DCC-FCS for the proliferation assay. The culture duration was 
8 days, and the treating media (containing 0.1% ethanol as vehicle control or 10-9M 
E2) was replaced with fresh media every 2 days. It is known that the doubling time of 
parental MCF-7 when growing in normal phenol red and high D-glucose containing 
DMEM supplemented with 10% FCS is about 29 hours (http://www.atcc.org/). 
It was found that the doubling time of parental MCF-7 cells given control vehicle 
treatment was 36.12 ± 1.89 hours (Table 3). The doubling times of the MCF-7-C8, 
MCF-7-PR8 and MCF-PR-26 cells were 35.86 ± 2.52, 34.86 ± 0.69 and 35.32 ± 1.64 




When the cells were continuously treated with 10-9M of E2, the doubling times of 
parental and control cells decreased to 30.34 ± 0.82 and 29.46 ± 0.89 hours, which 
were similar to the cells growing in normal DMEM with 10% FCS 
(http://www.atcc.org/). Whereas the doubling times of PR-transfected cells clone 8 
and 26 remained to be 35.16 ± 2.09 and 34.28 ± 1.67 hours, which were fairly similar 
to their ethanol-treated controls (p<0.01). 
Table 3. The growth stimulatory effect of E2 was inhibited in PR-transfected 

















0 2.33±0.13 2.33±0.13 
2 7.69±0.48 11.10±0.53 
4 16.47±0.84 28.39±1.21 







0 2.49±0.31 2.49±0.31 
2 8.86±0.37 12.15±0.22 
4 23.40±2.89 37.42±0.55 






0 3.90±0.14 3.90±0.14 
2 9.24±0.85 9.32±0.85 
4 20.80±2.74 21.17±2.19 






0 2.97±0.17 2.97±0.17 
2 7.83±0.82 7.68±0.65 
4 21.54±1.14 22.82±0.88 







The doubling times of MCF-7 parental and its derived cell lines were calculated based 
on the results shown in Fig. 7. Cell numbers and doubling time are expressed as mean 
± SD, n = 4. 
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Cell numbers of the PR-transfected clones were similar to their vehicle controls after 
8-day treatment (Fig. 7 and Table 3). In contrast, the cell numbers of the E2-treated 
MCF-7 parental and vector-transfected cells were double that of vehicle-treated 
controls after 8 days. 
This finding suggested that the E2-stimulated cell proliferation was abolished in the 
PR-transfected MCF-7 cells, and this inhibitory effect was PR ligand-independent. 















































































Fig. 7. The growth stimulatory effect of E2 was inhibited in PR-transfected
MCF-7 cells. 1 x 104 MCF-7, MCF-7-C8, MCF-7-PR8 and PR26 cells were seeded
onto 6-well plates and starved in phenol red-free DMEM supplemented with 5%
DCC-FCS for 48 hours. Cells were then treated with 10-9M E2 or 0.1% ethanol
(control vehicle) for various periods of time. Treating media were replaced with fresh
every two days. The cell numbers were determined by counting on a hemocytometer
at 0, 2, 4, 6 and 8 days after the initial treatment. Results are expressed as mean ± SD,
n = 4. 
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3.3 PR transfection modified MCF-7 cell cycle distribution 
As shown above, PR transfection inhibited E2-stimulated MCF-7 cell growth. One of 
important events involved in E2 proliferative effect is the E2 promoted cell cycle 
progression via ER-targeted cell signaling cascades. Therefore, effects of PR 
transfection on MCF-7 cell cycle distribution were studied. 
 
3.3.1 The transfection of PR abolished E2 stimulatory effect on MCF-7 cell cycle 
progression 
In Fig. 8, MCF-7 parental, vector-transfected clone 8, PR-transfected clone 8 and 26 
cells were given 10-9M 17β-estradiol treatment up to 72 hours. Their cell cycle 
distributions at 0, 24, 36, 48, 60 and 72-hour post-treatment were recorded by flow 
cytometry cell cycle analysis. It showed that the control vehicle (0.1% ethanol) 
treatment decreased the S phase fractions after 24-hour, compared with the cells 
before treatment (0-hour) in all tested cell lines (p<0.05). This was due to the 
continuous starvation effect of the testing medium (phenol-red free DMEM 
supplemented with 5% DCC-FCS). Correspondingly, G2/M phase fractions were also 
decreased at the same time (p<0.01), with an accompanying increase of G0/G1 phase 
fraction (p<0.01). After 24-hour, the vehicle control-treated cells exhibited similar cell 


































































































































Fig. 8. The stimulatory effect of E2 on cell cycle progression as a function of time.
1 x 105 MCF-7, MCF-7-C8, MCF-7-PR8 and PR26 cells were seeded onto 6-well 
plates and starved in phenol red-free DMEM supplemented with 5% DCC-FCS for 48 
hours. Cells were then treated with 10-9M E2 or 0.1% ethanol as control vehicle in 
fresh media before they were harvested at the time points indicated. Harvested cells 
were thus stained with PI cocktail and analyzed for cell cycle distribution by flow 
cytometer. Results are expressed as mean ± SD, n = 3. 
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As expected, the 17β-estradiol increased the S and G2-M phase fractions after 24-hour 
treatment in all tested cell lines (p<0.01). The effect reached a peak at the 24-hour 
time point by increasing S phase fraction about 30-40% compared with the 0-hour 
time point. This stimulatory effect slightly decreased and sustained at a level which 
was higher than the vehicle-treated control in the parental and vector-transfected 
control cells till the 72-hour time point (p<0.05). However, it only sustained up to 60 
hours in the PR-transfected cells. At 72h following E2 treatment, the S phase fractions 




































































Fig. 9. Effect of replacement of fresh E2 on cell cycle progression. 1 x 105
MCF-7-C8 and PR8 cells were seeded onto 6-well plates and starved in phenol
red-free DMEM supplemented with 5% DCC-FCS for 48 hours. Cells were then 
treated with 10-9M E2 or 0.1% ethanol as control vehicle in fresh media. Treating 
media were replaced with fresh at 72h and 120h after the initial treatment. Cells were 
harvested and stained for cell cycle distribution analysis at the time points indicated. 
Results are expressed as mean ± SD, n = 3. 
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of MCF-7-PR cells decreased by ~50-60% compared with that at 60-hour (p<0.01). 
Correspondingly, their G0/G1 phase fraction increased, while the G2/M phase fraction 
remained as no change. 
The growth stimulatory effect of E2 in MCF-7-PR cells seemed short-lived. In this 
scenario, a second dose of E2 should still be growth stimulatory initially. To prove 
this hypothesis, MCF-7-C8 and PR8 cells were treated with E2 for 168 hours (Fig. 9). 
The treating media were replaced with fresh media at the 72 and 120-hour time points. 
In MCF-7-C8 cell, E2 enabled cells to enter S phase and this effect sustained till 
72-hour, which was similar to what shown in Fig. 8. After adding fresh treating 
medium at 72 and 120-hour, the S phase fraction increased and then dropped to a 
certain level higher than vehicle control. On the other hand, E2 showed the same trend 
as shown in Fig. 8 in MCF-7-PR8 cells during the first 72 hours. Replacement of 
fresh E2-containing medium also enabled promotion of cells into S phase. However, 
this re-stimulation can only last for less than 48 hours, since the S phase fractions at 
120 and 168-hour were less than that in the vehicle-treated control cells (p<0.01). 
 
3.3.2 Progesterone agonist and antagonists modulated MCF-7 cell cycle 
distribution 
3.3.2.1 Progesterone stimulated the growth of MCF-7 parental, vector- 
transfected, and PR-transfected cells in a manner of dose-dependence 
As the results shown in Figs. 7-9, PR-transfection was found to inhibit E2-induced 
cell proliferation and cell cycle progression PR ligand-independently following 
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72-hour treatment. To study the effect of progesterone on the PR-transfected MCF-7 
cells, cell cycle distribution of the MCF-7-PR cells as well as the control cell lines by 
giving serial doses of progesterone was examined in the presence or absence of E2. 
In Fig. 10, the cells were treated with 10-9M E2 and serially diluted progesterone at 
10-12, 10-9 and 10-6M. It was observed that progesterone slightly promoted all tested 
cell lines into S phase in the absence of E2 at the highest 10-6M dosage (p<0.01). 
When the cells were pretreated with 10-9M E2, which enabled the cells to express PR 
protein before given progesterone treatment, the S phase fractions of the MCF-7 
parental and vector-transfected cells were higher than that without E2 treatment  
(p<0.01). It meant that the stimulatory effect of E2 sustained for at least 72 hours. 
However, the E2-treated PR-transfected cell lines had fewer cells at S phase compared 
with the non-E2 treated controls. This confirmed the findings shown in Figs. 8 and 9. 
Moreover, progesterone was shown to have no effect on MCF-7 cell cycle distribution 
at all tested concentrations, when the cells were given 10-9M E2 treatment. 
To further investigate whether the effect of progesterone was time-dependent, 
MCF-7-C8 and MCF-7-PR8 cells were starved and treated with 10-9M E2 or 0.1% 
ethanol in the presence or absence of 10-7M progesterone. Treating media were 
replaced with fresh media at 72h and 120h after the initial treatment (Fig. 11). The 
determination of the progesterone dosage applied in this experiment was according to 
the previous studies in the laboratory on MDA-MB-231 and its derived cell lines (Lin 




































































































































Fig. 10. Effects of progesterone on MCF-7 cell cycle distribution in the presence 
or absence of E2. 1 x 105 cells were first starved in phenol-red free DMEM 
supplemented with 5% DCC-FCS for 48 hours. Cells were then treated with 0.05%
ethanol or 10-9M E2 for 24 hours before they were treated with vehicle (0.05%
ethanol) or serially diluted progesterone at 10-12, 10-9 and 10-6M for another 48 hours. 
The cells were harvested and analyzed for cell cycle distribution by flow cytometry.
Results are expressed as mean ± SD, n = 3. 
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Cell cycle analysis by flow cytometry showed that progesterone slightly increased 
MCF-7-C8 S phase fraction after 24-hour treatment (p<0.01), while it was not found 
in MCF-7-PR8 cells. Furthermore, the effect of 10-7M progesterone on MCF-7-C8 
cells was short-lived, it was only observed at 24-hour. On the other hand, when the 
cells were given E2 simultaneously, the effect of progesterone was fully surpassed by 
E2 as shown in Fig. 10. 
Summarizing the results of Figs. 10 and 11, MCF-7 and its derived cell lines were not 
 







































































Fig. 11. Progesterone did not modify antiestrogenic effect of PR transfection 
when given repeated E2 treatment. 1 x 105 MCF-7-C8 and PR8 cells were seeded 
onto 6-well plates and starved in phenol red-free DMEM supplemented with 5% 
DCC-FCS for 48 hours. Cells were then treated with 10-9M E2 or ethanol (as control 
vehicle) in the presence or absence of 10-7M progesterone in fresh media. The final 
concentration of vehicle was adjusted to 0.1%. Treating media were replaced with 
fresh at 72h and 120h after the initial treatment. Cells were harvested and stained for 
cell cycle distribution analysis at the time points indicated. Results are expressed as 
mean ± SD, n = 3. 
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well responsive to progesterone in cell growth, especially the PR-transfected cell lines. 
This result confirmed that the antiestrogenic function of overexpressed PR was 
progesterone independent. It also revealed something, which might be plausible, that 
cells with more progesterone receptors were less responsive to progesterone. It might 
be speculated that recombinant PR is not as responsive as natural PR to progesterone; 
and recombinant PR might also have suppressive function on natural PR. 
 
3.3.2.2 The effects of progesterone antagonists RU486 and ZK98299 on the cell 
cycle distributions of MCF-7-C8 and MCF-7-PR8 cells 
Fig. 12a and 12b shows the effects of antiprogestins RU486 and ZK98299 on 
MCF-7-C8 and PR8 cell cycle distributions. The dosages of the progesterone 
antagonists used in this experiment were determined by previous studies on 
MDA-MB-231 and its derived cell lines (Lin et al., 1999; Lin et al., 2001; Leo et al., 
2004). Cells treated with control vehicle (0.1% ethanol) or 10-9M E2 were used as 
controls. 
Similar to progesterone, antiprogestins RU486 and ZK98299 showed no effect on 
MCF-7 cell cycle distribution when the cells were treated with E2 simultaneously. 
In the absence of E2, ZK98299 showed no effect on cell cycle distribution, compared 
with the cells treated with control vehicle. However, antiprogestin RU486 showed 
long-term stimulatory growth effect on both cell lines up to 72 hours. This effect 
induced a relative ~25% increment in the S phase fraction of both cell lines, compared 
with the vehicle control treated cells (p<0.01). This was associated with decrements in 
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the G0/G1 phase (p<0.01). 
Therefore, progesterone antagonists RU486 and ZK98299 had opposite effect on 
MCF-7-C8 and MCF-7-PR8 cell cycle distributions. RU486 is able to slightly induce 
a long-term cell cycle progression onto S phase, but ZK98299 is not. The difference is 
due to the features of these two antagonists, which will be discussed in Chapter 4 in 
detail. Furthermore, the overexpressed PR seemed not to affect the effect of RU486 in 
cell cycle progression. It supported the speculation made in section 3.3.2.1 that 
recombinant PR may not be well responsive to progesterone agonists or antagonists in 














































































































































Fig. 12. Progesterone antagonists did not modify antiestrogenic effect of PR 
transfection. 1 x 105 MCF-7-C8 and PR8 cells were seeded onto 6-well plates and 
starved in phenol red-free DMEM supplemented with 5% DCC-FCS for 48 hours. 
Cells were then treated with 10-9M E2 or ethanol (as control vehicle) with the 
presence or absence of 10-7M progesterone antagonist in fresh media. The final 
concentration of vehicle was adjusted to 0.1%. Cells were harvested and stained for 
cell cycle distribution analysis at the time points indicated. Results are expressed as 




3.4 Transfection of PR into MCF-7 cells suppressed ER-target gene expression at 
transcription level 
Two well-known ER-target genes pS2 and GREB1 were selected for this study. Both 
of them have been reported to be highly induced by E2 treatment in MCF-7 parental 
cells (Jakowlew et al., 1984; Rae et al., 2005). The MCF-7 parental, 
vector-transfected and PR-transfected cell lines were treated with E2 at the 
concentration of 10-9M for up to 72 hours. The total RNAs were harvested at 24, 48 
and 72 hours post-treatment. 
Fig. 13A and 13B show the relative pS2 and GREB1 genes transcription levels in 
MCF-7 and its derived cells lines given E2 treatment compared to those given vehicle. 
The pS2 gene expression increased by 8-10 fold in MCF-7 parental cell line after E2 
treatment, and 6-8 fold in MCF-7-C8 cells. The fold of increase in MCF-7 and 
MCF-7-C8 cells were similar at all 3 time points investigated. However, in the 
PR-transfected clone 8 cells, the fold of induction of pS2 gene expression by E2 at 
24-hour was about 6-fold; it dropped to only about 1.5-fold at 48 and 72-hour. In 
MCF-7-PR26 cells, the pS2 expression level was decreased from ~10-fold at 24-hour 
to 4.5 and 2.5-fold at 48-hour and 72-hour respectively. The pS2 levels at 48 and 
72-hour were significantly less (p<0.01) than that at 24-hour in these PR-transfected 
cell lines. 
Similar results were also found in E2-induced GREB1 gene expression. In MCF-7 
parental and vector-transfected control cells, the GREB1 expression levels were 
similar at all 3 time points examined. In contrast, the GREB1 expression at 48 and 
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72-hour in PR-transfected cells was significantly less than the levels at 24-hour within 
the same cell line. 
These results firstly confirmed that E2 can stimulate the ER-target gene expression in 
the parental and vector-transfected control cell lines for at least 72 hours. It suggests 
that the ER-targeted signal transduction may also last for >72 hours in these two cell 
lines. Secondly, the results also revealed that the transfection of PR into MCF-7 cells 
suppressed the ER-mediated signaling only at the late time points 48 and 72-hour, 
while no suppression effect was found at 24-hour. 
It is also noticed that the expression levels of both genes among cell lines varied, 
especially GREB1. The expression levels of GREB1 at 24h in PR-transfected cells 
were much less than those in control cell lines. This could be the results of clonal 
variation, or that recombinant PR had ligand-independent inhibitory effect on GREB1 

































































































Fig. 13. Induction of the gene expression of pS2 and GREB1 by E2 was repressed
in PR-transfected MCF-7 cells. Cells were seeded onto 6-well plates and starved in 
phenol red-free DMEM supplemented with 5% DCC-FCS for 48 hours before treated 
with 0.1% ethanol (vehicle) or 10-9M E2 in 0.1% ethanol. Total RNAs were extracted 
from the cells at 24, 48 and 72 hours after treatments. cDNAs synthesis using the total 
RNAs as templates was performed by the method described in the Materials and 
Methods. The transcription expression levels of ER-targeted early expression genes 
pS2 (A) and GREB1 (B) were analyzed by real-time RT-PCR. The expression of each 
gene is expressed relative to vehicle-treated controls which is given the value of 1. 
Results are expressed as mean ± SD, n = 3. * indicates that the gene expression at 48h 




3.5 The suppression of ER-target gene expression in MCF-7-PR cells was caused 
by the interference of liganded ER binding to ERE 
As described in the Introduction, the activated ER dimer/estrogen complex binds to 
the ERE sequence located at the upstream of the target gene, and this procedure is 











































Fig. 14. Effect of PR transfection in MCF-7 cells on ER/ERE binding in promoter
interference assay. MCF-7 parental and derived cell lines were firstly starved in
phenol red-free DMEM supplemented with 5% DCC-FCS for 48 hours. Cells were
then transiently transfected with CMV-TATA-ERE2-CAT or CMV-TATA-CAT
constructs for 16 hours before they were treated with 0.1% ethanol or 10-9M E2. Cells
were harvested at 16, 24 and 48 hours after E2 treatment. The CAT protein expression
level was measured by CAT-ELISA assay. The CAT activity in
CMV-TATA-ERE2-CAT –transfected cells was calculated as the percentages of that in
cells transfected with CMV-TATA-CAT.  Results are expressed as mean ± SE, n = 3.
* indicates that CMV-driven CAT activity in E2 treated cells is significantly (p<0.01)
less than that in vehicle-treated control cells. 
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binding could impair the transcription of target gene. To perform the promoter 
interference assay, the MCF-7, MCF-7-C8, PR8 and PR26 cells were transiently 
transfected with reporter gene-equipped promoter interference plasmid vector 
CMV-TATA-ERE2-CAT. It is a CMV (cytomegalovirus) promoter driven CAT 
(chloramphenicol acetyltransferase) reporting plasmid vector inserted with double 
repeating sequence of ERE. The binding of ERE and ER causes reduced expression of 
CAT. Cells transfected with control plasmid vector CMV-TATA-CAT were used as 
control. The expression levels of CAT were detected by CAT ELISA kit as mentioned 
in the Materials and Methods. 
Fig. 14 shows the result of CAT relative expression levels at 16, 24, and 48 hours after 
addition of E2 (also post-transfection). It was found that the CAT protein activity in 
the CMV-TATA-ERE2-CAT transfected cells after 0.1% ethanol (vehicle control) 
treatment were mostly about 50-60% of that in the CMV-TATA-CAT transfected cells 
treated with ethanol at all time points. This decrease of CAT expression might be 
caused by the difference in the promoter activities between the two constructs. It 
might be also due to ligand-independent binding of ER to ERE. 10-9M E2 treatment 
decreased CAT expression levels by 40-60% in the MCF-7 and MCF-7-C8 cells 
compared with the cells given 0.1% ethanol as vehicle control. It meant that liganded 
ER was able to bind to ERE; and this binding interfered with the expression of CAT. 
However, no significant difference was found between the ethanol and E2 treatments 
in the PR-transfected cells at 16 and 24-hour time point. At 48-hour, the differences 
between vehicle and E2 treatment in MCF-7-PR cells were statistically significant, 
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but the decreases were only ~10%. Nevertheless, the ER/ERE binding in MCF-7-PR 
cells were still markedly inhibited when comparing with the MCF-7 parental and 
vector-transfected cells. It suggested that transfection of PR dramatically impaired the 
ER/ERE binding in MCF-7 cells up to 48 hours. 
Hence, transfection of PR into MCF-7 cells interfered with the binding of liganded 
ER to ERE, which could further suppress the transcription of ER-target genes as the 
results shown in section 3.4. It is also noted that the promoter interference happened 
at as early as 16 hours post-treatment of E2, but ER-target gene transcription 
suppression only occurred after 24-hour. This time delay phenomenon will be 
discussed in Chapter 4 in detail. 
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3.6 Transfection of PR into MCF-7 cells enhanced metabolism of E2 
To further elucidate the mechanisms which impaired estrogenic effect of E2 in 
PR-transfected MCF-7 cells, the metabolism of E2 was analyzed by HPLC using 
MCF-7-C8 and MCF-7-PR8 as cell models. As mentioned in section 3.3.1, the 
stimulatory effect of E2 was present in MCF-7-PR cells within the first 36 hours, and 
quickly dropped from 48-hour, and was eventually abolished at 72-hour. The 
difference of E2 effects in control and PR overexpressing cell lines was that the effect 
of E2 was short-lived in MCF-7-PR cells, rather than had an immediate inhibitory 
effect at the beginning of the treatment. Therefore, E2 metabolism could be critical for 
these events. 
 
3.6.1 The retention time of 17β-estradiol and some E2 metabolites 
17β-estradiol and its common metabolites estrone, 6α-hydroxyestradiol, 
16α-hydroxyestrone and estriol were analyzed for their retention times by analytical 
HPLC. The gradient mobile phases and flow settings were mentioned in the Materials 
and Methods. The histograms of the elution profiles of the standards were shown in 
































































































































































































Fig. 15. HPLC analysis of unlabeled E2 and E2 metabolite standards. About 20 x 
10-15 molar of E2 and E2 metabolites were analyzed by reversed-phase HPLC C-18 
column. The mobile phases used were mentioned in the Materials and Methods. 
Samples were detected by UV absorbance at the wavelength of 280nm, and the
average retention times of the compounds were labeled on the top of the peaks. The 
results are the means of 3 replicates. The compounds applied for analysis were: A, 




3.6.2 17β-estradiol metabolic profile in the MCF-7-C8 and PR8 cells 
In order to study the metabolism of E2, MCF-7-C8 and PR8 cells were treated with 
10-9M [3H]-labeled E2 for 3, 6 and 24 hours. The whole conditioned media were 
harvested and analyzed without solvent extraction by analytical HPLC for E2 and E2 
metabolites. The conditioned media were not solvent extracted so that metabolites of 
both hydrophobic and hydrophilic nature were present in the sample. The protein 
components were removed by 10% TCA precipitation to prevent interference in 
separation. The protein bound [3H] were extracted by washing the precipitated protein 
with 100% acetone for twice. The samples were analyzed on a C-18 analytical HPLC 
column and radioactivity of the 0.5min flow fractions was counted on a Microbeta 
scintillation counter. 














Fig. 16 shows the histograms of the HPLC separated [3H]-E2 and its metabolites as 
the [3H] radioactivity in the tested cell lines. Table 5 summarizes the percentage 
distributions of the peaks present in Fig. 16. Peak y was considered as E2 because it 









































































































































Fig. 16. E2 metabolic profiles in MCF-7-C8 and PR8 cells. MCF-7-C8 and PR8
cells were first starved in phenol red-free DMEM supplemented with 5% DCC-FCS 
for 48 hours. Cells were then incubated with 10-9M [3H]-E2 for 3, 6 or 24 hours. The 
conditioned media were harvested, deproteinated and analyzed by reverse-phase 
HPLC as described in the Materials and methods. The radioactivity in 0.5 min flow 
fractions were counted on a liquid scintillation counter. The data are presented as
counts per minute (cpm) in each fraction versus the retention time. Peak x is a mixture 
of [3H]-E2 metabolites and [3H]-E2 was eluted in peak y. 
Results 
85 
only peak found in the cell-free media. Peak x was considered as the mixture of some 
E2 metabolites, since it was absent from the cell-free media control and hydrophilic 
compounds were the first to be eluted on C-18 column. Some other trace amounts of 
E2 metabolites may have occurred and been eluted at the retention times other than 
peaks x and y. They were not detected due to the sensitivity of the assay, and the 
methods of sample collection and radioactivity counting. A progressive decrease of 
peak y and increase of peak x, which indicates the metabolism of estradiol, was found 
in both tested cell lines. However, the metabolic speed of E2 in MCF-7-PR8 cells was 
much faster than that in MCF-7-C8 cells. 3 hours after the addition of [3H]-E2, only 
about one quarter of E2 was metabolized in MCF-7-C8 cells, but ~60% in 
MCF-7-PR8 cells. At 6 hours post-treatment, 40% E2 in MCF-7-C8 and 77% in 
Table 5. The percentage of radioactivity in peaks x and peak y for the histogram 
















The percent radioactivity is calculated as the sum of the counts of all the fractions in
each peak in percentage to the total counts detected.
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MCF-7-PR8 cells had been converted into metabolites. It showed that the metabolic 
speed of E2 in MCF-7-PR8 cells was almost double of that in MCF-7-C8 cells at the 
first 6 hours. With the depletion of the substrate (E2), the metabolic speeds in both 
cell lines slowed down. Percentages of the metabolites peaks were 80% and 93% at 
24-hour in MCF-7-C8 and PR8 cells, respectively. It meant that the E2 in MCF-7-PR8 
cells was almost fully metabolized within first 24 hours. 
As shown in Fig. 15 and Table 4, the retention time of some major E2 metabolites, 
6α-hydroxyestradiol (4.3 min), estriol (5.1 min) and 16α-hydroxyestrone (7.9 min) 
overlapped the retention time of peak x. There is insufficient evidence to confirm the 
composition of peak x, even though these three compounds have been reported to be 
the main hydroxyl- metabolites of estradiol. Glucuronidation or sulfation of the A-ring 
or D-ring E2 metabolites may also enable them to be eluted out at early time in C-18 
HPLC column (Adams et al., 1989; Wild et al., 1991; Cavalieri et al., 2001). 
Estrone (30.2 min), an important intermediate metabolite of E2 (Mueck et al., 2002), 
was not detected in the E2 metabolites profiling. The possible reason could be that 
estrone was quickly converted into other final metabolites, which were eluted out in 
peak x, so that only trace amounts of estrone remained in conditioned media and 
could not be detected. The other possibility might be that most estrone was not 
expelled out of cells as it is an intermediate metabolite, so that it was not detectable in 
conditioned media. Even though some metabolites remained inside the cell, the scale 
was very small: only ~5% of [3H]-labeled compounds were found in the cells by 
counting the radioactivity of cytosolic ethanol extracts (data not shown). 
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3.7 Cellular uptake of E2 in MCF-7 and its derived cell lines 
One important factor which may affect E2 metabolism in MCF-7 cells is the cellular 
uptake of E2. Cellular uptake analysis (whole-cell binding assay) was performed to 
detect how much E2 was bound in MCF-7 and its derived cell lines after incubating 
for certain duration. The assay is based on the principal that the ligands enter the cells 
and bind to their receptors. After a certain equilibrium time, all available receptors are 
supposed to be occupied by the ligands. 







































Fig. 17. 17β-estradiol cellular uptake in MCF-7 cells was saturable. MCF-7 cells 
were plated into 12-well plates and starved in phenol red-free DMEM supplemented
with 5% DCC-FCS for 48 hours. The E2 cellular uptake assay was performed by
treating cells with 0.1, 0.2, 0.5, 1.0, 2.0, 5.0, 10.0 and 20.0 x 10-9M of [3H]-E2 in 37oC 
CO2 incubator for 1 hour. Cells treated with [3H]-E2 and 200-fold molar excess of 
unlabelled E2 simultaneously were used as non-specific binding controls. [3H]-E2 in 
the cells was extracted and its radioactivity was determined by counting in a liquid
scintillation counter. Specific uptake of [3H]-E2 was determined by subtracting the 
[3H]-E2 bound to the cells in the presence of unlabeled E2 from the total [3H]-E2 
bound (in the absence of unlabelled E2). The radioactivity in figure is presented as 
counts per minute (cpm). Results are expressed as mean ± SD, n = 3. 
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3.7.1 Cellular uptake of E2 in MCF-7 cells was saturable 
A saturation curve of 17β-eatradiol cellular uptake in MCF-7 is shown in Fig. 17. It 
was carried out by treating MCF-7 parental cells with serial diluted tritium labeled 
17β-eatradiol ([3H]-E2). 
Fig. 17 shows that the linear increment of MCF-7 [3H]-E2 cellular uptake occurred at 
0.1 – 2.0 x 10-9M concentrations. The [3H]-E2 binding showed saturation at the 
concentration more than 5 x 10-9M, since the detected radioactivity from 5.0 to 20.0 x 
10-9M was at the similar level. 










































































































Fig. 18. 17β-estradiol cellular uptake in MCF-7-C8 and PR8 cells by time. Cells
were plated into 12-well plates and starved in phenol red-free DMEM supplemented
with 5% DCC-FCS for 48 hours. The assay was carried out by incubating cells with
10-9M [3H]-E2 in the presence or absence of 200-fold molar excess of unlabelled E2 
for various durations as indicated. [3H]-E2 in the cells was extracted and its 
radioactivity was determined by counting in a liquid scintillation counter. Specific
uptake of [3H]-E2 was determined by subtracting the [3H]-E2 bound to the cells in the 
presence of unlabeled E2 from the total [3H]-E2 bound (in the absence of unlabelled 
E2). The radioactivity at each time point was presented as percentages of that at 1min.
Results are means ± SD, n = 3.
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3.7.2 Time-dependent cellular uptake of [3H]-E2 in MCF-7 cells 
MCF-7-C8 and PR-8 cells were given 1 x 10-9M of [3H]-E2 for 1 min - 6 hours (Fig. 
18). MCF-7-C8 and PR8 cells showed similar time course curve of [3H]-E2 cellular 
uptake. The peak of uptake occurred when the cells were incubated with [3H]-E2 for 
15 minutes: a dramatic increase was found during 1min to 15min, and gradual 
decrease was found after the 30-minute time point. It is noticed that the rate of 
decrease from 30-min to 1-hour was about 10%; from 1-hour to 3-hour, the decrease 
was also about 10%. This result indicated that the cellular uptake of [3H]-E2 in 






















































Fig. 19. 17β-estradiol cellular uptake in MDA-MB-231 cells. Cells were plated into 
12-well plates and starved in phenol red-free DMEM supplemented with 5% 
DCC-FCS for 48 hours. The assay was carried out by incubating cells with 10-9M 
[3H]-E2 in the presence or absence of 200-fold molar excess of unlabelled E2 for 
various durations as indicated. [3H]-E2 in the cells was extracted and its radioactivity 
was determined by counting in a liquid scintillation counter. Specific uptake of
[3H]-E2 was determined by subtracting the [3H]-E2 bound to the cells in the presence 
of unlabeled E2 from the total [3H]-E2 bound (in the absence of unlabelled E2). The 
radioactivity at each time point was presented as percentages of that at 5min. Results 
are means ± SD, n = 3. 
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MCF-7 cells was relatively stable during 1 - 3-hour. From 3-hour to 6-hour, the rate of 
decrease escalated to about 30%. In the following experiments, 1-hour incubation was 
used for studying [3H]-E2 cellular uptake. 
The time-dependent [3H]-E2 cellular uptake in ER-negative breast cancer cell line 
MDA-MB-231 (Fig. 19) showed that the [3H]-E2 amount inside the cells did not 
significantly change with time. Moreover, the actual radioactivity of the ethanol 
extracts from MDA-MB-231 was fairly similar to the background. It meant that E2 
was not taken up by MDA-MB-231 cell. This finding could suggest that the presence 
of ER is essential to mediate E2 cellular uptake. 
 
3.7.3 PR transfection enhanced MCF-7 cells cellular uptake 
To investigate the effects of PR exogenous expression on E2 cellular uptake in MCF-7 
cells, whole cell ligand binding assay was performed by incubating the cells with 
10-9M of [3H]-E2 for 1 hour in MCF-7 parental, MCF-7-C8, PR8 and PR26 cells. 
Fig. 20 shows that MCF-7 parental and vector-transfected clone 8 cells had similar 
level of [3H]-E2 uptake, but PR-transfected clones 8 and 26 had ~ 30% more cellular 
uptake of [3H]-E2 than the two control cell lines. It suggested that the transfection of 
PR was able to enhance MCF-7 cells cellular uptake of E2. It might be one of main 





















































Fig. 20. Transfection of PR increased cellular uptake of E2 in MCF-7 cells. 
MCF-7 parental and deviant cell lines were incubated with 10-9M [3H]-E2 in the 
presence or absence of 200-fold molar excess of unlabelled E2 for 1 hour. [3H]-E2 in 
the cells was extracted and its radioactivity was determined by counting in a liquid 
scintillation counter. Specific uptake of [3H]-E2 was determined by subtracting the 
[3H]-E2 bound to the cells in the presence of unlabeled E2 from the total [3H]-E2 
bound (in the absence of unlabelled E2). Results are expressed as mean ± SE, n = 3. * 
indicates that the [3H]-E2 uptakes in PR-transfected cells are significantly greater than 






3.7.4 Modulation of cellular uptake of E2 in MCF-7 and its derived cell lines 
3.7.4.1 Estrogen receptor (ER) protein expression level in MCF-7 cells was 
essential to E2 cellular uptake 
As shown in Fig. 19, the ER-negative cell line MDA-MB-231 did not take up E2. 
Therefore, the ER expression level in MCF-7 cells may be a key factor to regulate E2 
cellular uptake. MG132 is a widely-used proteasome inhibitor, which effectively 
inhibits the ubiquitin-proteasome pathway in cells. Treating MCF-7 cells with 1μM of 
MG132 for 24 hours knocked down >95% of ER protein expression. In Fig. 21A, the 
total proteins from MCF-7 cells were harvested and analyzed by immunoblotting after 
treating with 1nM of E2, 1μM of MG132 or 1μM MG132 + 1nM E2 at 37oC for 24 
hours. Similar to what shown in Fig. 6, E2 reduced the ER protein level about 20% 
compared with the vehicle-treated control cells. Treatment of 1μM MG132 reduced 
~96% protein level of ER when compared with vehicle control cells. When cells 
treated with 1μM MG132 together 1nM E2, ~92% ER was knocked down. 
Furthermore, Fig. 21B shows that 24-hour 1μM MG132 treatment reduced ERα in 




























































Fig. 21. Proteasome inhibitor MG132 knocked-down expression of ERα in 
MCF-7 cells in both protein and transcription levels. MCF-7 cells were seeded and 
starved in phenol red-free DMEM supplemented with 5% DCC-FCS for 48 hours. In 
A, cells were thus treated with 0.1% ethanol (lane 1), 10-9M E2 (lane 2), 10-6M 
MG132 (lane 3) or10-9M E2 together with 10-6M MG132 (lane 4) for 24 hours at 
37oC. The cells were harvested and the lysates were separated with 8.5% SDS-PAGE 
and transferred to nitrocellulose membranes. ERα protein expression levels were 
detected by probing with anti-human ERα antibody Ab-15. Human 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probed by anti-GAPDH 
antibody was used as loading control. The ER level of the ethanol-treated samples 
was defined as 1; the numbers below are the ER levels compared with the
ethanol-treated control. In B, cells were treated with 0.1% DMSO as the vehicle 
control or 10-6M MG132 for 24 hours. Total RNAs were extracted from the cells and 
the transcription expression level of ERα was analyzed by real-time RT-PCR. The 
expression of ERα is expressed relative to vehicle-treated control which is given the 
value of 1. Results are expressed as mean ± SD, n = 3. * indicates that the ERα
transcription level is significantly (p<0.01) less than that of vehicle control. 
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Knock-down of ER by MG132 induced dramatic decrease of E2 cellular uptake in 
MCF-7 cells. As shown in Fig. 22, using MCF-7 cells treated with 1μM MG132 
(24-hour) as the sample cells, the [3H]-E2 cellular uptake level decreased to only ~8% 
of the vehicle control cells after incubating with 10-9M [3H]-E2 for 1 hour. Therefore, 
it could be concluded that E2 cellular uptake in MCF-7 cells was largely dependent on 















































Fig. 22. Proteasome inhibitor MG132 suppressed E2 cellular uptake in MCF-7 
cells. MCF-7 parental cells were seeded and starved in phenol red-free DMEM 
supplemented with 5% DCC-FCS for 48 hours. Cells were thus treated with 10-6M 
MG132 or 0.1% DMSO as vehicle control for 24 hours. The E2 cellular uptake assay
was carried out by incubating cells with 10-9M [3H]-E2 in the presence or absence of 
200-fold molar excess of unlabelled E2 for 1 hour. [3H]-E2 in the cells was extracted 
and its radioactivity was determined by counting in a liquid scintillation counter.
Specific uptake of [3H]-E2 was determined by subtracting the [3H]-E2 bound to the 
cells in the presence of unlabeled E2 from the total [3H]-E2 bound (in the absence of
unlabelled E2). Results are means ± SD, n = 3. * indicates that the E2 cellular uptake 
in the MG132-treated cells is significantly (p<0.01) less than that of vehicle control. 
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3.7.4.2 Cytoskeleton disruption decreased E2 cellular uptake in MCF-7 cells 
Cytoskeleton disruption was found to be another possible factor which may affect E2 
cellular uptake in MCF-7 cells. MCF-7 cells were treated with cytoskeleton disruption 
drugs cytochalasin D and colchicine for 3 hours at 37oC before proceeding to carry 
out the cellular uptake assay. Cytochalasin D and colchicine disrupt actin filaments 



















































Fig. 23. Cytoskeleton disruption drugs cytochalasin D and colchicine suppressed
E2 cellular uptake in MCF-7 cells. MCF-7 parental cells were seeded and starved in 
phenol red-free DMEM supplemented with 5% DCC-FCS for 48 hours. Cells were 
thus treated with 10μM cytochalasin D, or 100μM colchicine, or 0.1% DMSO as 
vehicle control for 3 hours. The E2 cellular uptake assay was carried out by
incubating cells with 10-9M [3H]-E2 in the presence or absence of 200-fold molar 
excess of unlabelled E2 for 1 hour. [3H]-E2 in the cells was extracted and its 
radioactivity was determined by counting in a liquid scintillation counter. Specific 
uptake of [3H]-E2 was determined by subtracting the [3H]-E2 bound to the cells in the 
presence of unlabeled E2 from the total [3H]-E2 bound (in the absence of unlabelled 
E2). Results are means ± SD, n = 3. * indicates that the E2 cellular uptake in the 




In Fig. 23, 10μM Cytochalasin D was shown to decrease E2 cellular uptake by ~20%; 
and 100μM colchicine, ~10%. This result suggested that actin filaments and 
microtubules related to E2 cellular uptake, and actin filaments may play more 
significant effects.  
 
3.7.4.3 BSA-conjugated E2 reversed the increased E2 cellular uptake in 
PR-transfected MCF-7 cells 
In order to study the mechanisms which cause the enhanced E2 cellular uptake in 
PR-transfected MCF-7 cells, it is speculated that some cytoplasm membrane 
components with E2-affinity ability might mediate E2 uptake. To confirm this 
assumption, MCF-7-C8 and PR8 cells were incubated with 10-9M [3H]-E2, 10-9M 
[3H]-E2 + 50-fold excessive BSA, or 10-9M [3H]-E2 + 50-fold excessive 
BSA-conjugated E2. 66kD BSA can not enter cytoplasm (Morales et al., 2003), so 
that any BSA-conjugated E2 binding to other molecules only happens on cell 
membrane. 
It was found that the addition of 50-fold excessive BSA or BSA-conjugated E2 did 
not affect the cellular uptake of [3H]-E2 in MCF-7-C8 cells (Fig. 24). In MCF-7-PR8 
cells, similar to the results shown in Fig 20, ~30% more [3H]-E2 cellular uptake was 
induced by PR transfection compared with MCF-7-C8 cells. Addition of 50-fold 
excessive BSA to [3H]-E2 did not induce significant change. The significant 
difference was observed when the MCF-7-PR8 cells were given 50-fold excessive 
BSA-conjugated E2 - the [3H]-E2 cellular uptake decreased to the similar level to that 
Results 
97 
in MCF-7-C8 cells. It implied that 50-fold excessive BSA-conjugated E2 was able to 
block the increased [3H]-E2 cellular uptake caused by PR-transfection. Because 
BSA-conjugated E2 can not get across the cell membrane, this result may suggest that 
some E2 binding proteins in the cellular membrane were involved in the increment of 
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Fig. 24. BSA-conjugated 17β-estradiol reversed the increased E2 uptake in 
MCF-7-PR cells. Cells were plated into 12-well plates and starved in phenol red-free 
DMEM supplemented with 5% DCC-FCS for 48 hours. Cells were incubated with 
10-9M [3H]-E2, or 10-9M [3H]-E2 with 50-fold molar excess of BSA, or 10-9M 
[3H]-E2 with 50-fold molar excess of BSA-conjugated E2 for 1 hour at 37oC. Cells 
given above treatments and 200-fold molar excess of unlabelled E2 coinstantaneously
were used as non-specific binding controls. [3H]-E2 in the cells was extracted and its 
radioactivity was determined by counting in a liquid scintillation counter. Specific 
uptake of [3H]-E2 was determined by subtracting the [3H]-E2 bound to the cells in the 
presence of unlabeled E2 from the total [3H]-E2 bound (in the absence of unlabelled 
E2). Results are expressed as mean ± SD, n = 3. * indicates that the [3H]-E2 uptakes 
in PR-transfected cells are significantly greater than that in control cells (p<0.01). 
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3.8 Adenovirus-mediated progesterone receptor (PR) expression in MCF-7 cells 
Adenovirus mediates high level of recombinant protein expression in either dividing 
or non-dividing mammalian cells. Therefore, expressing PR in MCF-7 cells by 
adenovirus can bring following advantages: (a) accurately control the overexpression 
level of recombinant PR, or overexpression ratio of PR-A and PR-B in MCF-7 cells 
by infecting with calculated dosages. (b) because adenovirus can be easily injected 
into animal models compared with liposome-mediated protein overexpression, this 
also makes in vivo PR overexpression possible, which may finally contribute to the 
PR-related gene therapy strategies. 
 
3.8.1 Features of recombinant adenoviruses 
Four types of adenoviruses were prepared in this study. They were the adenovirus 
carrying the multi-cloning site (MCS) of viral shuttle vector (no recombinant protein 
expressed, Ad/Φ), the adenovirus carrying β-galactosidase gene (Ad/LacZ), the 
adenovirus carrying progesterone receptor isoform A gene (Ad/PRA) and the 
adenovirus carrying progesterone receptor isoform B gene (Ad/PRB). 
The titrations of these purified viruses were determined by the biological assay 
TCID50 (tissue culture infectious doses). Titration of Ad/Φ was 8.0 x 1011 TCID50/ml; 
Ad/LacZ was 4.0 x 1011 TCID50/ml; Ad/PRA was 4.0 x 1010 TCID50/ml; and Ad/PRB 











Fig. 25. Dose-dependent adenovirus-mediated β-galactosidase expression in 
MCF-7 cells. MCF-7 parental cells were plated on 6-well plates in DMEM 
supplemented with 7.5% FCS. After the cells attached to plate wells, cells were
infected with serial diluted doses of adenovirus carrying β-galactosidase encoding
sequence (Ad/LacZ) at MOI = 0 (A), 200 (B), 500 (C), 1000 (D), 2000 (E) and 5000 
(F) at 37oC for 48 hours. Detection of β-galactosidase expression was performed by 
β-gal stain kit. Bar, 100μm. 
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3.8.2 Adenovirus-mediated protein expression in MCF-7 cells 
3.8.2.1 Ad/LacZ mediated β-galactosidase expression in MCF-7 cells 
The LacZ gene encodes β-galactosidase, which catalyzes the hydrolysis of 
β-galactosides (i.e. X-gal), producing a blue color that can be visualized under a 
microscope. It is a powerful tool for studying the adenovirus-mediated expression of 
recombinant protein in mammalian cells. In Fig. 25, MCF-7 cells were infected with 
different doses of Ad/LacZ virus as the MOI (multiplicity of infection) of 0, 200, 500, 
1000, 2000 and 5000 for 48 hours. 
The expression of β-galactosidase in MCF-7 cells was dose-dependent. Higher dose 
of Ad/LacZ infection obviously increased the number of cells which expressed 
β-galactosidase as well as the β-galactosidase expression level in a single cell. At the 
highest dose (MOI = 5000), >95% of MCF-7 cells were infected and expressed 
detectable amount of β-galactosidase. It was also concerned that the expression of 
β-galactosidase had “hot-spot”, which meant that some of MCF-7 cells were able to 
express much higher amount of β-galactosidase than the others. The distribution of 
these “hot-spot” cells was random and the cause remained unknown. 
 
3.8.2.2 Ad/PRA and Ad/PRB mediated PR expression in MCF-7 cells 
In this section, adenoviruses encoding PR isoform A or B were used to infect MCF-7 
cells, which provided transient and high level of progesterone receptor overexpression. 
It helps to study the interactions between ER and individual PR isoform with 
controlled expression level. Successful in vitro study on adenovirus-mediated PR 
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expression in MCF-7 cells may also support future in vivo study in ER-positive breast 
cancers and finally open a window for foreseeable PR-based gene therapies. 
3.8.2.2.1 Dosage-dependent overexpression of PR in MCF-7 cells mediated by 
Ad/PRA or Ad/PRB 
To select proper viral infection doses for further experiments, MCF-7 cells were 
infected with adenovirus at different dosages to investigate the expression levels of 
progesterone receptors. MCF-7 cells were infected with either Ad/PRA or Ad/PRB 






Fig. 26. Dose-dependent adenovirus-mediated PR isoform A or B expression in 
MCF-7 cells. MCF-7 parental cells were seeded in phenol red-free DMEM 
supplemented with 5% DCC-FCS. After the cells attached, they were infected with 
serial diluted doses of adenoviruses carrying PR isoform A or B gene at 37oC for 16 
hours. The infection media were then replaced with fresh phenol red-free DMEM 
supplemented with 5% DCC-FCS, and the cells were continuously cultured in 37oC 
CO2 incubator for another 48 hours. The cells were harvested and the lysates were
separated with 8.5% SDS-PAGE and transferred to nitrocellulose membranes. PR-A 
and PR-B protein expression levels were detected by anti-human PR antibody Ab-8. 
Human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probed by
anti-GAPDH antibody was used as loading control. The layout of the blot is: lane 1, 
MCF-7 parental (negative control); lane 2, MCF-7-Ad/Φ (MOI = 1000, negative 
control); lanes 3~8, MCF-7-Ad/PRA (MOI = 20, 50, 100, 200, 500 and 1000); lanes




cells infected with Ad/Φ control virus at the MOI = 1000 were used as the controls. 
The infection media was made by diluting the viral stock into a small volume (2.5ml 
for 60-mm Petri-dish) of phenol red-free DMEM supplemented with 5% DCC-FCS. 
After 16-hour infection at 37oC, the infection media were replaced with fresh 
non-infection medium and cultured for another 48 hours. Total proteins were 
harvested and 25μg of them were analyzed by immunoblotting. 
Fig. 26 shows the PR immunoblotting result of the adenovirus-infected MCF-7 cells. 
Lanes 1 and 2 are the control MCF-7 parental and MCF-7- Ad/Φ cells. The expression 
of PR in these two cell lines was too low to be detected compared with the 
adenovirus-mediated PR expression under the condition used, showing that 
expression level of natural PR in MCF-7 cells was much less than the 
adenovirus-mediated recombinant PR. Lanes 3 - 8 show the PR expression in Ad/PRA 
infected MCF-7 cells with infection doses from 20 to 1000. The unique band matches 
the molecular weight of PR isoform A and the minimal visible dose in the figure was 
MOI = 50. The expression level of PR-A gradually increased with the increased 
dosage of Ad/PRA virus. It implied that the expression of PR-A in MCF-7-Ad/PRA 
cells was viral dose-dependent. 
Similarly, the expression level of PR-B in MCF-7-Ad/PRB cells (lanes 9 – 14) also 
showed dose-dependent pattern. It is noticed that there are not only PR-B, but also 
PR-A and a protein with the molecular weight between PR-A and PR-B (~100kD) 
were found in MCF-7-Ad/PRB cells. It is known that the expressions of PR isoform A 
and B originate from the same gene sequence but using different promoters and start 
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codons. The expressed ~100kD protein might be an expression product which uses an 
unusual start codon “GTG”, located between the PR-B and PR-A start codons. The 
expressions of PR-A and the ~100kD protein were also shown as Ad/PRB 
dose-dependent, but had relative less expression level compared with PR-B. 
Surprisingly, the expression of PR-A and the ~100kD protein was cell line 
context-specific. Fig. 27 shows the Ad/PRB mediated PR-B expression in 
MDA-MB-231 cells, which is a well-known ER and PR-negative breast cancer cell 
line. After infected with Ad/PRB at MOI = 1000 for 48 hours, MDA-MB-231 cells 








Fig. 27. Adenovirus-mediated PR isoform B expression in MDA-MB-231 cells.
MDA-MB-231 cells were seeded in phenol red-free DMEM supplemented with 5% 
DCC-FCS. After the cells attached, they were infected with serial diluted doses of 
adenoviruses carrying PR isoform B gene at 37oC for 16 hours. The infection media 
were then replaced with fresh phenol red-free DMEM supplemented with 5% 
DCC-FCS, and the cells were continuously cultured in 37oC CO2 incubator for 
another 48 hours. The detection of PR-B protein expression was carried out by the 
same method as mentioned in Fig. 26. The layout is: lane 1, MDA-MB-231 (negative 




non-infected (lane 1) and control virus-infected (lane 3) cells. Expression of Ad/PRB 
induced PR-A in lane 2 was only occurring as a faint band, and the ~100kD protein 
mentioned above was not found. It suggested that expressions of these two proteins 
were well suppressed in MDA-MB-231, but not in MCF-7 cells. 
Fig. 26 also shows the expression level of PR-A and PR-B in the ABC-28 
(MDA-MB-231 cells stably overexpressing PR isoform A and B) cells, which has 
been well studied in previous research in the laboratory (Lin et al., 1999; Lin et al., 
2000; Lin et al., 2001; Lin et al., 2001; Lin et al., 2003). Dosages of Ad/PRA and 
Ad/PRB, which induced similar expression level of PR-A and PR-B in MCF-7 to that 
in ABC-28 cells, were selected for subsequent study. Because the effects of 
overexpressed PR in ABC-28 cells have been well studied, MCF-7 PR overexpression 
comparable to that in ABC-28 cells enables ABC-28 to serve as a useful control. The 
doses were Ad/PRA, 200 TCID50/cell and Ad/PRB, 500 TCID50/cell. Correspondingly, 
Ad/Φ at the higher dose of 500 TCID50/cell was chosen as control for future work. 
3.8.2.2.2 Time-dependent overexpression of PR in MCF-7 cells mediated by 
Ad/PRA or Ad/PRB 
As mentioned in the Introduction chapter, adenovirus-mediated protein expression is 
transient, since adenovirus does not incorporate the carried gene into the genome of 
target cells. Knowledge of the expression duration of the Ad/PRA and Ad/PRB 
induced PR in MCF-7 is critical for future study. 
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In Fig. 28, lane 1 and 2 are the MCF-7 parental and MCF-7-Ad/Φ cells, which served 
as negative controls. Lanes 3-7 are the MCF-7 cells infected with Ad/PRA for 0-8 
days and Lanes 8-12 are those infected with Ad/PRB. In the Ad/PRA-infected cells, 
adenovirus-induced PR-A started as a high level expression immediately from the 
time when removed the infection media. The expression level stably increased to the 
maximal amount at Day 1 and Day 2. At Day 5, the PR-A expression level decreased 
to a level similar to that on Day 0, and there was only a small mount of PR-A 
expressed on day 8. It suggests that expression of the Ad/PRA mediated PR-A 
expression lasted less than 8 days in MCF-7 cells; and strongest expression occurred 
at first 48 hours after removal of infection media. Ad/PRB infected MCF-7 cells 







Fig. 28. Time-dependent adenovirus-mediated PR isoform A or B expression in 
MCF-7 cells. MCF-7 cells were infected with Ad/PRA (MOI = 200) or Ad/PRB 
(MOI = 500) for 16 hours at 37oC, followed by culturing in fresh medium for another 
48 hours. Cells were harvested and 25μg of total proteins were analyzed by 
immunoblotting as mentioned in Fig. 26. The layout is: lane 1, MCF-7 parental 
(negative control); lane 2: MCF-7-Ad/Φ (MOI = 500, negative control); lanes 3~7, 
MCF-7-Ad/PRA cells harvested at 0, 1, 2, 5 or 8 days after removal of infection 
media; lanes 8~12, MCF-7-Ad/PRB cells harvested at 0, 1, 2, 5 or 8 days after 
removal of infection media; lane 13, ABC-28 cells (positive control). 
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than 8 days and the maximal expression peak was during the first 48 hours. However, 
Ad/PRB virus did not mediate significant PR-B expression at Day 0 which is the time 
point immediately after the infection media removal, as no detectable PR-B was 
found by immunoblotting. Besides, similar to what has mentioned in section 3.8.2.2.1, 
Ad/PRB mediated not only PR-B, but PR-A and another unexpected ~100kD protein 
expression according to the immunoblotting result (Fig. 28). 
 
3.8.2.3 Immunocytochemistry of PRs in the MCF-7 cells infected with Ad/PRA or 
Ad/PRB 
Investigation of the immunocytochemistry of the adenovirus-mediated PR expression 
demonstrates the expression level of recombinant PR in individual MCF-7 cells and 
location of recombinant PR. 
1 x 105 MCF-7 cells were plated onto 6-well plate quipped with sterile cover-slips and 
infected with Ad/PRA at MOI = 200 or Ad/PRB at MOI = 500. Cells without 
infection or infected with Ad/Φ control virus at MOI = 500 were used as controls. 
After 16-hour infection, cells were cultured in normal growth medium for another 48 
hours. Cells were then probed with anti-human PR (Ab-8, from NeoMarkers) as the 
primary antibody and Cy5-conjugated anti-mouse IgG as the secondary antibody. 
Cells were also probed with FITC-conjugated phoilloidin, which specifically bound to 
F-actin filaments, for showing the cell morphology. Stained cells were examined on a 
confocal microscope using excitation lasers at the wavelength of 488nm (for 
FITC-conjugated phoilloidin) and 635nm (for Cy5) as multi-track scanning. The 
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stained cells were initially scanned at 10x objective lens to study the expression 
efficiency of recombinant PR in MCF-7 cells. Cells were then observed at 63x oil 
objective lens for location study of recombinant PR. Green color is the 
FITC-conjugated phoilloidin, which shows cell morphology in the presence or 
absence of adenovirus infection. Because >99% cells were stained with the 
FITC-conjugated phoilloidin, it also shows the full image of all the plated MCF-7 
cells. Red color is Cy5, which indicates both endogenous and recombinant 
progesterone receptors. The pinhole and gain amplifier parameters were fixed when 
all the pictures were scanned. 
Fig. 29 shows the pictures of the combined green and red channels. According to the 
immunoblotting result shown in Figs. 26 and 28, natural PR in MCF-7 were expressed 
at very low level, and adenovirus mediated much higher PR expression at the selected 
infection dosages. The cells indicating red (or yellow) and green colors were those 
expressing high level of recombinant PR, while the cells indicating green color only 
were the ones uninfected or expressing relative less amount of recombinant PR. 
Firstly, it is observed that MCF-7 parental (Fig. 29A, B) and Ad/Φ-infected MCF-7 
cells (Fig. 29C, D) only showed green color under both 10x and 63x objective lenses. 
It suggested that the natural PR expression in these two cell lines was too low to be 
detected by immunocytochemistry. In contrast, MCF-7-Ad/PRA (Fig. 29E, F) and 
MCF-7-Ad/PRB (Fig. 29G, H) cells expressed much higher PR, showing that the cells 




Fig. 29. Immunocytochemistry of adenovirus-mediated PR-A or B expression in 
MCF-7 cells. MCF-7 were infected with Ad/PRA (MOI = 200) or Ad/PRB (MOI = 
500). MCF-7 parental and cells infected with Ad/Φ at MOI = 500 were used as 
negative controls. Immunocytochemistry analysis was performed by probing cells 
with anti-PR Ab-8 for PR location (red) and FITC-conjugated phoilloidin for showing 

















It is also noticed that some Ad/PRA or Ad/PRB infected MCF-7 cells expressed 
detectable high level of PR and some almost not expressed, which confirmed the 
results shown in Fig. 25 that viral infection was not even, although the virions in the 
infection media were distributed evenly. Besides, the MCF-7-Ad/PRB cells expressed 
more PR than MCF-7-Ad/PRA cells by showing that those cells indicated brighter red 
color, but MCF-7-Ad/PRA cells showed more yellow color instead. It might be 
because of non-specific staining in MCF-7-Ad/PRB cells. 
Secondly, there was no obvious morphological change after adenovirus infection by 
comparing with the non-infected and control virus-infected MCF-7 cells. 
Overexpression of PR-A (Fig. 29E, F) induced some MCF-7 cells in round shape, 
which might be because Ad/PRA infection promoted MCF-7 cells into S and G2/M 
phases (Fig. 31). The kinases involved in S and G2/M phases may influence the 
cytoskeleton and lead to changes in the cell shape (Huang and Ingber, 1999). 
Overexpression of PR-B (Fig. 29G, H) caused some cells to be spindle-like. Similarly, 
significant cell spreading has been reported in the MDA-MB-231 cells overexpressing 
PR-A and PR-B in the presence of progesterone (Lin et al., 2000; Sumida et al., 2004). 
Since the morphological change in Ad/PRB infected MCF-7 cells was induced 
ligand-independently, it suggested that recombinant PR-B in MCF-7-Ad/PRB cells 
may be activated ligand-independently, so that it induced similar effect as the 
progesterone-treated PR-transfected MDA-MB-231. 
Thirdly, all cell lines observed on 63x oil objective lens showed faint red color 
background in both cytoplasm and nucleus. It might be caused by the expression of 
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natural PR or the nonspecific binding of the Cy5-conjugated secondary antibody. In 
Fig. 29F, highly expressed recombinant PR-A mostly locates at cell nucleus; while 
MCF-7-Ad/PRB cells (Fig. 29H), which expressed both PR-A and PR-B, showed PR 
location (red) in both cytoplasm and nucleus. 
 
3.8.3 Cellular uptake of E2 in adenovirus-infected MCF-7 cells 
Fig. 20 shows that stable transfection of PR into MCF-7 cells increased cellular 
uptake of E2. MCF-7-Ad/PRA and MCF-7-Ad/PRB were the cell lines which 
transiently expressed much higher level of PR than MCF-7-PR8 and PR26 cells. 
Study of E2 cellular uptake in those two MCF-7-Ad cell lines may help to further 
understand the mechanism of the PR-enhanced E2 uptake. 
Fig. 30 shows that infection of adenoviruses reduced MCF-7 E2 cellular uptake. The 
[3H]-E2 in MCF-7-Ad/Φ (6.7fmol/104) cells was ~15% less than that in the uninfected 
MCF-7 cells (7.9 fmol/104 cells). Infection of Ad/PR-A and Ad/PR-B significantly 
increased MCF-7 cells [3H]-E2 cellular uptake about 10% (p<0.05) and 30% (p<0.01), 
compared with the MCF-7-Ad/Φ cells. Fig. 20 showed liposome-mediated PR stable 
transfection increased E2 cellular uptake by 35% in MCF-7-PR8 and 21% in 
MCF-7-PR26, compared with MCF-7-C8 cells. Fig. 6 also showed that MCF-7-PR8 
expressed more PR-B than PR-A, while MCF-7-PR26 expressed more PR-A than 
PR-B. Therefore, it might suggest that overexpression of PR-B had stronger effect on 
MCF-7 E2 cellular uptake than PR-A. 
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Fig. 30. Adenovirus-mediated PR overexpression in MCF-7 cells enhanced E2 
cellular uptake. MCF-7 parental cells were infected with Ad/PRA (MOI = 200) or 
Ad/PRB (MOI = 500) for 16 hours at 37oC followed by culturing in fresh DMEM 
supplemented with 5% DCC-FCS for another 48 hours. MCF-7 parental cells and 
cells infected with Ad/Φ at MOI = 500 were used as negative controls. Cells were 
incubated with 10-9M [3H]-E2 in the presence or absence of 200-fold molar excess 
of unlabelled E2 for 1 hour. [3H]-E2 in the cells was extracted and its radioactivity 
was determined by counting in a liquid scintillation counter. Specific uptake of 
[3H]-E2 was determined by subtracting the [3H]-E2 bound to the cells in the 
presence of unlabeled E2 from the total [3H]-E2 bound (in the absence of 
unlabelled E2). Results are means ± SD, n = 3. * indicates that the E2 cellular 
uptakes in PR overexpressing cells are significantly higher than that in 
MCF-7-Ad/Φ cells: 1, p<0.05; 2, p<0.01. 
 
3.8.4 Cell cycle distribution of adenovirus-infected MCF-7 cells 
To investigate cell cycle distributions of adenovirus-infected MCF-7 cells, MCF-7 
cells were infected with Ad/PRA at MOI = 200 or Ad/PRB at MOI = 500. After 
infection, cells were cultured in normal fresh medium for another 24 hours, which 
allowed stable expression of recombinant PR. Cells were then treated with 10-9M E2 
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or 0.1% ethanol (control vehicle), and cells were harvested and analyzed by flow 
cytometry at 0, 24 and 72 hours after the treatment. 
In Fig. 31, uninfected and Ad/Φ-infected MCF-7 cells showed the same trend as the 
MCF-7 parental and vector-transfected cells shown in Fig. 8. After given 10-9M of E2 
for 24 hours, S phase fraction in both cell lines increased about 60% compared with 
the vehicle-treated control cells; 72 hours later, the increment of uninfected cells was 
~25%, and ~20% in MCF-7-Ad/Φ cells. On the other hand, infection of adenovirus 
affected the absolute percentages of cells in cell cycle distribution. 24 hours after the 
treatment, control vehicle-treated uninfected MCF-7 cells had 17.7% cells in S phase, 
while only 15.9% of MCF-7-Ad/Φ cells were in S phase. Both cell lines had similar 
percentages of cells in G0/G1 phase, suggesting that adenovirus infection may promote 
MCF-7 cells from S phase into G2/M phase (p<0.05). 
Expression of recombinant PR-A promoted MCF-7 cells into S phase in a 
ligand-independent manner. Compared with the MCF-7-Ad/Φ cells, MCF-7-Ad/PRA 
cells had ~5% (in absolute S phase fraction; ~25% in relative proportion, p<0.01) 
more cells in S phase at 0 and 24-hour time points, which were 24 and 48 hours after 
removal of infection media. This ~5% increment was also observed when the cells 
simultaneously given E2 treatment. However, the effect lasted not more than 96 hours 
after infection, since the S phase fraction of MCF-7-Ad/PRA decreased to be the same 
as the MCF-7-Ad/Φ cells at 72-hour time point. The adenovirus-mediated PR-A 
overexpression was to promote MCF-7 cells from G0/G1 phase into S phase and arrest 
cells in S phase rather than stimulate cell cycle progression. This is because the cell 
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Fig. 31. Modulations of adenovirus-mediated PR-A or PR-B overexpression on 
cell cycle distribution of MCF-7 cells. MCF-7 parental cells were infected with 
Ad/PRA (MOI = 200) or Ad/PRB (MOI = 500) for 16 hours at 37oC, followed by 
culturing in fresh DMEM supplemented with 5% DCC-FCS for another 24 hours.
Cells were then treated with 10-9M E2 or 0.1% ethanol as vehicle control for 0, 24 or
72 hours. MCF-7 parental cells and cells infected with Ad/Φ at MOI = 500 were used 
as negative controls. Harvested cells were forwarded to PI staining and flow
cytometry for cell cycle analysis. Results are expressed as mean ± SD, n = 3. 
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number of MCF-7-Ad/PRA cells at 48 hours after removal of infection media was 
counted ~30% less than the MCF-7-Ad/Φ cells (Fig. 32). Furthermore, the S phase 
inhibitory effect of PR transfection shown in Fig. 8 was not observed in the 
MCF-7-Ad/PRA cells after 72-hour 10-9M E2 treatment. It meant that PR-A might not 
contribute to this antiestrogenic effect in MCF-7 cells. 
On the other hand, adenovirus-mediated PR-B overexpression in MCF-7 cells did not 
have any S phase promotion effect as PR-A in the presence or absence of E2. The 



































Fig. 32. Cell proliferation of the adenovirus-infected MCF-7 cells. MCF-7 parental 
cells were infected with Ad/PRA (MOI = 200) or Ad/PRB (MOI = 500) for 16 hours
at 37oC, followed by culturing in fresh DMEM supplemented with 5% DCC-FCS for 
another 48 hours. MCF-7 parental cells and cells infected with Ad/Φ at MOI = 500 
were used as negative controls. The cell numbers were determined by counting on a
hemocytometer and results are expressed as mean ± SD, n = 3. * indicates that the cell 
numbers of Ad/PRA or Ad/PRB infected MCF-7 cells were significantly (p<0.01) less 
than that of MCF-7-Ad/Φ cells. 
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cells in Fig. 31. Whereas, the S phase fraction of the E2-treated MCF-7-PRB cells 
dramatically decreased ~50% at the 72-hour time point, compared with the control 
virus infected cells. It was the same as the PR-transfected MCF-7 cell cycle 
distribution shown in Fig. 8. Moreover, it is observed that the cell number of 
MCF-7-Ad/PRB decreased ~30% compared with the MCF-7-Ad/Φ cells in the 
absence of E2 (Fig. 32). Because Fig. 31 shows no difference between these two cell 
lines in cell cycle distribution within 96 hours after removal of infection media (i.e. 72 
hours after ethanol treatment), it possibly suggest that PR-B was also able to arrest 
MCF-7 cells ligand independently. 
Adenovirus infection slightly inhibited MCF-7 cell cycle progression, which resulted 
in a slight cell proliferation decrement about 10% compared with the uninfected cells 
at 48 hours after infection (Fig. 32). High level of adenovirus-mediated recombinant 
PR-A expression, instead of PR-B, arrested cells at S phase ligand-independently. The 
similar antiestrogenic effect of recombinant PR in MCF-7-PR cells was only found in 
the MCF-7-Ad/PRB cells, suggesting that PR-B played critical role in exerting 






















4.1 Expression of progesterone receptor (PR) and estrogen receptor (ER) in 
MCF-7 cells 
4.1.1 Expression of endogenous PR in MCF-7 cells 
MCF-7 cells expressed both PR isoforms at low level, which was only about 24 fmol 
PR/mg protein after 3-day starvation in phenol red-free DMEM supplemented with 
5% DCC-FCS. Expression of PR isoforms A and B were both up-regulated by 
17β-estradiol treatment. The up-regulation lasted for at least 72 hours. 
Estrogen-dependent up-regulation of PR expression is known to act through ER 
signaling cascades. Estrogen agonists and other cytokines or growth factors, such as 
EGF and insulin, are also able to stimulate the expression of PR via ER-targeted 
signaling pathways (Druege et al., 1986; Kaneko et al., 1993; Graham et al., 1995). 
Besides, phenol red in DMEM medium and the serum factors in FCS can also induce 
PR expression (Berthois et al., 1986) 
 
4.1.2 Stably transfected recombinant PR expression in MCF-7 cells 
Stable transfection of PR into MCF-7 cells enabled both progesterone receptor 
isoforms to be expressed constitutively. PR isoform A and isoform B expressed at 
different levels, because these two isoforms were encoded by two individual plasmids 
– hPR2 and hPR1. Although equal amounts of the two plasmids were used for 
transfection, the difference could arise due to transfection efficiency in MCF-7 
subclones as clone to clone difference. It could be also caused by the difference in the 
stability of PR isoforms. As a result, there was imbalanced expression of PR in 
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MCF-7-PR clone 8 and 26 cells, with more isoform B in clone 8 and more isoform A 
in clone 26. Moreover, it is reported that transfection of hPR1 (PR-B expression 
vector) could also induce PR-A expression (Dai et al., 2001). It is expected, because 
the entire coding sequence of PR-A is contained within the PR-B coding sequence. 
The possibility of this hPR1-induced PR-A expression is difficult to be eliminated. 
Nevertheless, the hPR1-induced PR-A expression would not affect the findings in this 
present study, because the objective is to investigate the function of both PR-A and 
PR-B together. 
It was also noticed that the expression of recombinant PR in the estrogen-starved 
MCF-7-PR cells was about 5 times higher than that in estrogen-starved MCF-7 
parental cells. However, PR-transfected MDA-MB-231 cells (ABC-28) expressed PR 
about 20 times higher than that in MCF-7-PR cells. The possible reason for this 
differential PR expression could be the endogenous PR status in cells: MCF-7 is an 
ERα- and PR-positive cell line; but MDA-MB-231 is an ERα- and PR-negative cell 
line. It is hypothesized that the presence of natural PR may impair the expression of 
recombinant PR. Possible suppression of exogenous ERα expression by endogenous 
ERα was previously reported by Zajchowski et al. (1993) in MCF-7 cells. It was 
found that recombinant ER was highly expressed in MDA-MB-231 cells, but weakly 
expressed in MCF-7 cells, although the mRNA level of recombinant ERα in MCF-7 
cells was high. In this present study, the PR transcription levels of MCF-7-PR clone 8 
and 26 were 41- and 36-fold higher than that in MCF-7 parental cells respectively. 
The mechanism of the possible suppression effect of endogenous PR on exogenous 
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PR expression in MCF-7 cells remains unknown. 
 
4.1.3 Adenovirus-mediated recombinant PR expression in MCF-7 cells 
4.1.3.1 Adenovirus-mediated recombinant PR protein expression 
Firstly, the Ad/PRA infected MCF-7 cells expressed only PR isoform A. However, 
MCF-7-Ad/PRB mediated both PR isoforms A and B expression in MCF-7 cells in a 
dose-dependent manner. It is known that the PR isoform A encoding sequence is 
contained within isoform B coding sequence. PR-A and PR-B share the same 
encoding DNA sequence and reading frame, but use different promoters and start 
codons. As a result, isoform A is short of 164 amino acids at the N-terminus of PR-B. 
When exogenous PR expression was mediated by Ad/PRB in MCF-7 cells, both PR-B 
and PR-A start codons were recognized, even though there is a Kozak sequence 
immediately located at the upstream of the PR-B start codon. The transcription started 
from the PR-A start codon caused expression of PR-A protein in MCF-7 cells. A 
similar result was reported by Dai et al. (2001). However, this Ad/PRB-induced PR-A 
expression seems cell line dependent as only trace amount of PR-A was expressed in 
MDA-MB-231 cells infected with Ad/PRB virus. 
It is also found that there was an unexpected protein expressed in MCF-7-Ad/PRB 
cells with the molecular weight between PR isoform A and B, and its expression level 
was adenoviral infection dose-dependent. This protein was absent from the Ad/PRB 
infected MDA-MB-231. Two reasons are speculated: (a) degradation of PR-B; (b) 
expression of a new protein. Based on the sequence analysis of PR-B gene, there is a 
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‘GTG’ start codon located between PR-B and PR-A ‘ATG’ start codons in the same 
reading frame. It has been known that there are approximately 8% of prokaryotic and 
some eukaryotic gene products are initiated with a ‘GTG’ start codon rather than the 
usual ‘ATG’ (Kozak, 1983; Kozak, 1989; Gualerzi and Pon, 1990). The ‘GTG’ codon 
initiates the expression of a protein with 851 amino acids (~100 kD theoretically). 
This protein is detectable by the anti-PR antibody Ab-8 against its C-terminal epitope; 
and it also has the similar molecular weight as the ~100kD protein found in 
MCF-7-Ad/PRB cells by immunoblotting. 
Secondly, the adenovirus-mediated transient expression of recombinant PR in MCF-7 
cells lasted less than 8 days. Both PR isoforms reached the expression peak at 24 and 
48 hours after removal of infection media, and it then sharply decreased from 5-day 
and almost undetectable at 8-day. Since the PR-A or PR-B genes carried in adenovirus 
do not integrate into MCF-7 genome due to the characteristics of adenovirus, 
adenovirus-mediated PR expressions are transient. This provided guidelines for 
subsequent studies using the MCF-7-Ad cells, as PR overexpression model should be 
planned within ~8 days. 
Thirdly, the expression of recombinant PR is dosage-dependent, showing that the 
higher infection dose, the more recombinant PR expressed. It is also noticed that 
infection of Ad/PRA and Ad/PRB at the same dose (e.g. MOI = 500) induced similar 
protein expression of PR isoform A and isoform B, but the total protein they 
expressed were actually different because MCF-7-Ad/PRB cells also expressed the 
PR-A and ~100kD protein. The reason for the unequal expression could be the 
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variation of TCID50 viral titration test. As a biological function assay, results of 
TCID50 assay can be affected by many factors, such as the volume of virus stock used, 
the type of vessel, the incubation time, the number of cells and the medium 
(QBIOgene Inc., 2001). Even though replication tests were performed for the same 
viral stock to reduce variations, TCID50 test may give 2-5 folds difference upon the 
performed experiments. Therefore, titrations of replicates at the same power grade 
were considered as acceptable. 
Finally, some infection dosages adenovirus mediated PR transient expression 
comparable to that in ABC-28 cells, which was much higher than the 
liposome-mediated PR stable expression in MCF-7 cells. Two possibilities should be 
taken into consideration: transient expression and adenoviral characteristics. Transient 
transfection can induce higher expression level, whether the expression is mediated by 
adenovirus or liposome. The reason is that not only the genome integrated gene of 
interests (GOI) but also non-integrated GOI encodes protein for transient expression, 
whereas only genome integrated GOI expresses recombinant protein in the stably 
transfected cell lines. Only a small part of DNA is integrated into genome. The other 
depends on the characteristics of adenoviruses – they are able to enter cell bodies by 
receptor-mediated infection and deliver their genome/GOI to the nucleus with high 






4.1.3.2 Location of PR in adenovirus-infected MCF-7 cells 
Immunocytochemistry of the adenovirus-infected MCF-7 cells revealed recombinant 
PR location. The protein level of PR in MCF-7-PR cells was too low to be detected by 
immunocytochemistry. Whereas, high expression level of recombinant PR mediated 
by adenovirus infection enabled easy detection. It is found that PR in MCF-7-Ad/PRA 
cells was mostly observed in cell nucleus, but PR in MCF-7-Ad/PRB cells was found 
in both nucleus and cytoplasm. Since MCF-7-Ad/PRB cells expressed recombinant 
PR-B as well as PR-A and the ~100kD protein, and all of them can be probed by the 
anti-PR antibody, it is difficult to tell whether recombinant PR-B was only located in 
cytoplasm or in both cytoplasm and nucleus. It is also unlikely that PR-B and PR-A 
only located at nucleus, but the ~100kD protein only located at cytoplasm, since all of 
them contain the NLS (nuclear localization signal) motif, which is essential for PR 
nuclear localization. Lim et al. (1999) reported localization of transfected PR isoform 
A or B in Hela, Cos-1, 1471.1 and 3134 cell lines: 82% of unliganded PR-A was 
found in nucleus, while only 56% of unliganded PR-B in nucleus. The location of 
unliganded PR-A and PR-B in these four cell lines presented similar pattern, 
suggesting that their localization did not change with cell line. Size of the two 
isoforms is unlikely the reason of the different localization patterns, since PR-A 
(~90kD) and PR-B (~110kD) are both above the exclusion size of approximately 
45kD for free diffusion across the nuclear pore complex (Jans, 1995). The possible 
reason causing the different localization pattern of PR-A and PR-B may be due to the 
presence of PR-B unique AF-3 domain. Less effective NLS has been shown to lead an 
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increased residency time of PR-B in cytoplasm (Guiochon-Mantel et al., 1991). The 
AF-3 may affect efficiency of NLS and further enhance PR-B localization in 
cytoplasm. Another possible reason is the formation of heterodimers (Lim et al., 
1999). Steroid hormone receptors can form dimers in the absence of ligand (Chen et 
al., 1999). Since MCF-7-Ad/PRB cells expressed not only PR-B, but also PR-A and 
the ~100kD protein. Heterodimerization between PR-B and PR-A, or PR-B and the 
~100kD protein may affect the PR nuclear localization. This hypothesis remains to be 
investigated. 
 
4.1.3.3 Proposed improvements in adenovirus-mediated PR expression 
Improvements of adenovirus-mediated PR expression are mainly focused on the 
following: (a) reduction of PR-A and the ~100kD protein expression in 
MCF-7-Ad/PRB cells; (b) minimization of adenoviral dosage. 
As discussed above, expression of PR-A and the ~100kD protein in MCF-7-Ad/PRB 
is possibly caused by the misrecognition of the PR-B start codon. Two strategies 
could be used to improve expression. The first is to use mutation to replace the 
unnecessary start codons with other genetic codes which code the same amino acid. 
Mutating the ‘GTG’ start codon (codes Valine) with ‘GTT’, ‘GTC’ or ‘GTA’ is able to 
stop the transcription of the ~100kD protein, but keep the amino acid unchanged. 
Obviously this strategy is not suitable for removing PR-A, because the genetic code 
for methionine (ATG) is unique. Therefore, cloning the PR-B specific promoter to the 
upstream of PR-B sequence may help, since the expression of human PR isoforms are 
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controlled by two distinct promoters (Kastner et al., 1990; Graham and Clarke, 2002). 
In Transpose-AdTM expression system, the GOI protein transcription is controlled by 
the general mammalian expression CMV promoter. Replacing the CMV promoter 
with PR-B promoter could reduce the nonspecific PR-A expression in 
MCF-7-Ad/PRB cells. 
Infection of adenovirus may cause cytotoxicity to target cells, especially at high 
dosage. In order to minimize this side-effect, using doses as low as possible is 
recommended. Both physical and biological methods can be used for this purpose. 
The physical methods are performed at the incubation step. The first method is to use 
small volume and rocking movement during adsorption of the virus. Incubating cells 
on 6-well plate (35-mm well) with virus-containing fluid 0.5ml on a rocker shaker in 
37oC CO2 incubator for 16 hours enables maximal infection efficiency >97% 
(Mittereder et al., 1996). The second method is to centrifuge plates with cells and 
viruses at 1000 x g for 90min (Nyberg-Hoffman et al., 1997), which has been 
evaluated as having similar result as the former rocking method. 
The biological method is based on the theory of adenovirus CAR receptor-mediated 
infection. Treating cells with HDAC (histone deacetylase) inhibitor enhanced 
adenovirus mediated gene expression by increase CAR receptor protein expression 
(Kitazono et al., 2001; Kitazono et al., 2002; Goldsmith et al., 2003). However, other 





4.1.4 The expression of ER in MCF-7 cells 
It was shown in this current study that the ER expression level was not affected by 
transfection of PR, but down-regulated by E2 treatment by 20%. Previous studies 
have demonstrated that the half-life of ER is ~5 days without estrogen, but only 3 - 4 
hours with the presence of estrogen (Pakdel et al., 1993; Nirmala and Thampan, 1995). 
The binding of ER ligands to ER enables ER degradation via the ubiquitin – 
proteasome pathway (Pakdel et al., 1993). However, not all steroid hormone receptors 
are similarly regulated. Progesterone receptor (PR) and glucocorticoid receptor (GR) 
are reported to have longer half-lives (~20 – 25 hours) regardless of the presence of 
ligands (Nardulli et al., 1988; Burnstein and Cidlowski, 1992). 
The finding that the 24-hour proteasome inhibitor MG132 treatment greatly inhibited 
the expression of ER in MCF-7 cells at the concentration of 1μM, was similar to that 
reported by Fan et al. (2004). However, in Hela cells stably expressing recombinant 
ERα, MG132 has no effect on reduction of ER expression (Nawaz et al., 1999). The 





4.2 Modulation of MCF-7 proliferation and cell cycle distribution by 
recombinant PR overexpression 
4.2.1 Overexpression of PR modulated MCF-7 cell cycle distribution 
The low expression of recombinant PR in MCF-7 cells without E2 treatment did not 
modulate cell cycle distribution. MCF-7 parental, vector-transfected and 
PR-transfected cells were demonstrated to have very similar trends with time when 
given vehicle treatment. 
High level of recombinant PR-A other than PR-B promoted entries of MCF-7 cells 
from G0/G1 phase into S phase in MCF-7-Ad/PRA cells. However, this did not 
stimulate cell proliferation, but rather caused cell cycle arrest in S phase. The 
experimental evidence suggested that this S phase arrest effect was time-dependent 
that the effect diminished in MCF-7-Ad/PRA cells at late time point. Furthermore, 
this S phase arrest was not observed in the MCF-7-Ad/PRB cells, where both 
isoforms of PR were expressed and PR-B was the predominant. It has been reported 
that progesterone agonist-bound PR-A only dramatically impacted transcription in the 
T47D cells expressing excessive transfected PR-A over PR-B, whereas the PR-A 
transcriptional activity was suppressed in the T47D cells where PR-B was 
predominant (McGowan and Clarke, 1999). Therefore, the PR-A induced S phase 
arrest may be repressed by higher PR-B expression in MCF-7-Ad/PRB cells. 
However, it is also noticed that the aforesaid PR-B suppression effect on PR-A was 
PR ligand-dependent, while the effect was PR ligand-independent in this present study. 





4.2.2 PR overexpression modulated effects of estrogen in MCF-7 proliferation 
and cell cycle distribution ligand-independently 
It has been established that estrogen promotes ER-positive cells from G0/G1 phase 
into S and G2/M phases, and stimulates cell proliferation. It is reported that estrogen is 
able to stimulate the proliferation of MCF-7 cells for 5 days when given only one 
pulse at 10-9M dosage for 1 minute (Otto, 1995). The results in the present study also 
showed that 10-9M of 17β-estradiol (E2) continuously stimulated S phase promotion 
of MCF-7 parental and vector-transfected cells for 72 hours. Cell proliferation assay 
revealed that treating MCF-7 parental cells with 10-9M E2 for 8 days doubled cell 
growth when compared with the vehicle-treated control cells. 
However, the transfection of PR abolished the S phase promotion effect of E2 in 
MCF-7 cells ligand-independently. Cell proliferation assay also showed that E2 
stimulated cell growth was inhibited in MCF-7-PR cells. It is interesting that 
E2-induced cell cycle promotion into S phase was also observed in the MCF-7-PR 
cells at early time points but diminished after 60-hour of treatment, rather than 
inhibited the S phase promotion effect all the time. The possible mechanisms involved 
may include the PR transfection induced ER/ERE binding interference, ER-targeted 
signaling cascade suppression, and increased depletion of E2 in MCF-7-PR cells. The 
details will be discussed in section 4.3. 
Studies on adenovirus-infected MCF-7 cells revealed that recombinant PR-B could 
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function alone, or together with recombinant PR-A to exert antiestrogenic effects; but 
recombinant PR-A alone is not antiestrogenic. Therefore, PR-B is the critical PR 
isoform with antiestrogenic potential. MCF-7-Ad/PRB cells treated with 10-9M E2 
showed similar inhibitory effect on S phase progression at late time-points as that in 
MCF-7-PR cells; whereas MCF-7-Ad/PRA and MCF-7-Ad/Φ cells did not show 
modulation of E2 stimulatory effect similar to MCF-7 parental cells. Whole cell 
ligand-binding assay also showed that E2 cellular uptake was dramatically enhanced 
in MCF-7-Ad/PRB rather than in MCF-7-Ad/PRA cells. This finding is partially 
supported by a ligand-dependent study in MCF-7 cells (Chalbos and Galtier, 1994) 
that ligand-bound PR isoform B not A suppressed ER-target gene transcription in 
MCF-7 cells. 
It was observed that the recombinant PR in MCF-7-PR and MCF-7-Ad/PRB cells 
functioned antiestrogenically without PR ligand-binding. MCF-7-PR cells treated 
with progesterone or anti-progesterone simultaneously with E2 was also demonstrated 
to have the same cell cycle distribution as the cells treated with E2 alone. These 
findings may suggest that the antiestrogenic potential of recombinant PR in MCF-7 
cells is ligand-independent. Similar ligand-independent antiestrogenic effect of 
recombinant PR has been recently reported in an in vivo study: breast cancer cells 
T47D over-expressing PR grew into smaller estrogen-dependent tumors in nude mice 
than PR-negative T47D cells and this phenomenon was independent of PR ligand 
(Sartorius et al., 2003). The PR may be activated by the ligand-independent pathways 
by cAMP, growth factors, cytokines and other possible cellular regulators acting at the 
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membrane (Mani et al., 1994; Osborne and Schiff, 2005), but the exact activation 
pathway in MCF-7-PR and MCF-7-Ad/PRB cells remains to be investigated. 
 
4.2.3 Effects of progesterone and anti-progesterone in MCF-7-PR cell cycle 
distribution 
Although MCF-7 cells showed antiestrogenic potential of recombinant PR in a ligand 
independent manner, PR in MCF-7, MCF-7-C and MCF-7-PR remained responsive to 
progesterone and anti-progesterone treatment in the absence of estrogen. 
It is observed that progesterone stimulated cell proliferation in parental MCF-7, 
vector-transfected and PR-transfected MCF-7 cells without the concurrent 
administration of E2 at a high pharmacological dosage (10-6M). A similar result in 
MCF-7 cells was reported by van der Burg et al. (1992). Overexpression of PR 
seemed not to affect this effect, because there was no significant difference of 
proliferation between the control (parental and vector-transfected) and PR-transfected 
cells when they were given the same dosage of progesterone. Moreover, progesterone 
did not have any significant effect on cell cycle distribution in the presence of E2. 
This suggested that the slight growth stimulation of progesterone was masked by the 
stronger growth effect of estrogen. 
Similar to progesterone, the effects of anti-progestins RU486 and ZK98299 were also 
masked by estrogen. Without treatment of E2, RU486 was observed to continuously 
promote MCF-7-C8 and MCF-7-PR8 cells into S phase fraction for up to 72 hours. 
This estrogenic action of RU486 has been reported: RU486 was able to exert the 
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estrogen-like effect through ER to stimulate cell growth and ER-target gene 
expression (including PR) in MCF-7 cells; and this effect can be inhibited by estrogen 
antagonists 4-hydroxytamoxifen and ICI 164,384 (Jeng et al., 1993). However, 
ZK98299 was found having no effect on MCF-7 cell cycle distribution. The 
difference is caused by the mechanisms of action of RU486 and ZK98299. ZK98299 
is previously believed to be a Type I anti-progesterone that failed to promote binding 
of PR to PREs. In contrast, RU486 increases the binding of PR to PREs and thus have 
been considered as a Type II antagonist (el-Ashry et al., 1989; Klein-Hitpass et al., 
1991; Takimoto et al., 1992; Beck et al., 1993). A new mechanism believes that Type 
I anti-progesterones bind to PREs but promote different conformational changes from 
that induced by Type II anti-progesterones (Gass et al., 1998; Spitz, 2003). Therefore, 
ZK98299 might not able to exert progesterone-like effects on MCF-7 and its derived 





4.3 Possible mechanisms of the antiestrogenic effects of overexpressed PR in 
MCF-7 cells 
4.3.1 ER-target gene expression was suppressed by PR overexpression in MCF-7 
cells ligand-independently 
This study demonstrated that E2 triggered transcription of ER-target genes pS2 and 
GREB1 was inhibited at late time points (48 and 72-hour after treatment) in 
MCF-7-PR cells. Moreover, the interference of ER and ERE binding by PR 
overexpression was found as early as 16 hours after E2 treatment. 
As mentioned in the Introduction, the activation of estrogen receptor induces liganded 
ER dimer binding to ERE DNA sequence, which is essential for the transcription of 
ER-target genes. It was reported that agonist- and antagonist-occupied endogenous 
PR in primary rat uterine cells and 3T3 mouse fibroblasts contributed to the effective 
inhibition of interaction of the ER/ERE complex with the transcriptional complex of 
the ER target gene after binding to PRE (Kraus et al., 1995; Kraus et al., 1997). The 
magnitude of repression depends on the PR isoform (PR-A more effective than PR-B), 
the progestin ligand (progesterone antagonists more effective than agonists), the 
promoter and the cell type (Katzenellenbogen, 2000). In their studies, cells were 
transiently transfected with ERE-PRE-pS2 promoter-CAT construct, so that liganded 
PR binding to PRE exerted inhibitory effect on ER/ERE induced and pS2 promoter 
driven CAT protein expression. However, in this present study, the construct 
transiently transfected was CMV-TATA-ERE2-CAT, which does not contain the PRE 
binding sequence for PR. ERE motif between CMV and CAT gene interferes CAT 
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protein expression. Therefore, the interference found in MCF-7-PR cells was not 
because of the suppression of ER/ERE complex binding to transcription co-regulators, 
but that ligand-independent PR repressed liganded ER binding to ERE. Since ERE 
and PRE motifs are not sequentially located at the upstream of ER-target genes in cell 
as that in the construct of ERE-PRE-pS2 promoter-CAT, promoter interference 
construct CMV-TATA-ERE2-CAT is more suitable for studying the interactions 
between PR and ER. 
The suppression of liganded ER binding to ERE would directly affect ER-target genes 
expression in MCF-7-PR cells. This may explain the impaired effect of E2 on the 
stimulation of ER-target genes GREB1 and pS2. Because no ER protein level 
difference was found between MCF-7 and its derived cell lines, the loss of ER 
activities could be caused by impaired ER/ERE binding. 
One possible mechanism that has been reported is that transcriptional activity of ER 
was inhibited in HeLa cells by co-expressing ER and PR in a ligand-dependent 
manner (Meyer et al., 1989).  This appears to suggest that PR may compete with ER 
for transcription cofactors or co-regulators so as to impair ER’s transcriptional activity. 
Another possibility is that recombinant PR compete for the binding with chaperone 
proteins such as heat shock protein 90 and various immunophilins that are required to 






4.3.2 17β-estradiol metabolism in MCF-7 cells 
After E2 dissociates with ER, it enters the estradiol metabolic pathway in 
endoplasmic reticulum, where E2 is converted into A-ring or D-ring final metabolites 
(Martucci and Fishman, 1993; Mueck et al., 2002). The speed of E2 metabolism in 
MCF-7-PR8 cells was twice as fast as that in MCF-7-C8 cells. Only 3 hours after 
10-9M E2 treatment, 57.9% of E2 had been converted in MCF-7-PR8 cells, while only 
25.8% in MCF-7-C8 cells. The metabolized E2 at 6-hour was 77.0% in MCF-7-PR8, 
but only 40% in MCF-7-C8. Enhanced E2 metabolism in MCF-7-PR cells may have 
two consequences: faster depletion of E2 and generation of E2 metabolites which may 
be inhibitory to cell growth. 
Otto (1995) reported that one pulse of E2 treatment (10-9M and 1min) was enough to 
stimulate MCF-7 cell proliferation for 5 days. Therefore, the E2-stimulated cell 
growth might be regulated by the events which happen at very early time points. Even 
though it is postulated that competition of recombinant PR with ER for transcription 
cofactors or co-regulators and for the binding with ER chaperone proteins were the 
two possible reasons for promoter interference, this study provided direct evidence 
that depletion of E2 possibly contributed to the antiestrogenic effects. 
Generation of inhibitory metabolites could be another reason. Because of the faster 
depletion of E2 in MCF-7-PR cells, accumulation of E2 metabolites was also much 
faster than MCF-7-C cells. By the HPLC analysis of E2 metabolites, most metabolites 
were eluted out at early retention time. With reference to running of metabolite 
standards, the retention time of 6α-hydroxyestradiol, estriol and 16α-hydroxyestrone 
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matched that of the metabolites peak, but the true identities of the metabolites in the 
mixture remains to be determined. It has been suggested that estriol and 
6α-hydroxyestradiol are among the major end products of follicular metabolism 
(Dehennin et al., 1984). On the other hand, studies in MCF-7 cells suggested estrone, 
2-hydroxyestrone, and estradiol 3 sulphate as the main metabolites of E2 
(Brueggemeier et al., 1989; Wild et al., 1991; Brueggemeier et al., 2001; Lavigne et 
al., 2001). However, all three compounds were not detectable in this study based on 
their retention time (Wild et al., 1991; Wilson and Reed, 2001). The discrepancies 
may be due to many differences in experimental conditions such as the position and 
the number of tritium labeling in E2, the concentration of E2 used and the method of 
extraction. 
Among E2 metabolites, some of them have been reported as potential cell growth 
inhibitors: estriol, 2-methoxyestradiol (2-Me-E2), 2-methoxyestrone (2-Me-E1) and 
4-hydroxyestrone (4-OH-E1). Estriol was reported to exert anti-proliferative effect on 
MCF-7, T47D and MDA-MB-330 breast cancer cell, which are either ER positive 
(MCF-7 and T47D) or negative (MDA-MB-330) (Reddel and Sutherland, 1987). 
2-Me-E2, 2-Me-E1 and 4-OH-E1 were also found to have similar inhibitory effect as 
tamoxifen (Fotsis et al., 1994; Seeger et al., 2004). 2-Me-E2 was also found to have 
antiangiogenic action, for 2-Me-E2 is able to act as a microtubule disrupter (Fotsis et 
al., 1994; Klauber et al., 1997). The growth inhibitory effects of the metabolites were 
normally found in pharmacological dosages, which is commonly in the μM range 
(Fotsis et al., 1994; Lippert et al., 1999; Mueck et al., 2002; Reddel and Sutherland, 
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1987; Seeger et al., 2004; Seeger et al., 2004). It is also reported that treating 
estrogen-starved MCF-7 cells with 0.01μM 2-Me-E2 and 0.1nM E2 simultaneously 
for 8 days inhibited cell proliferation about 40%, compared with the cell treated with 
0.1nM E2 alone. The drugs were given freshly every two days (Liu and Zhu, 2004). 
This may explain why in this present study that 10-9M E2-treated MCF-7-PR8 and 
MCF-7-PR26 had the same cell numbers as the vehicle-treated control cells after 
8-day treatment. It is possible that the growth-stimulatory effect of E2 was cancelled 
by the growth inhibitory effect of its inhibitory metabolites. The retention time of 
2-Me-E2 was reported immediately after E2 when separated by C-18 HPLC column 
(Lavigne et al., 2001). According to the HPLC analysis in this present study, 98% of 
E2 was metabolized within 24 hours in MCF-7-PR8, which may enable generation of 
small amounts of 2-Me-E2, which was not detectable probably because of the 
limitation of detection method. Even though this small amount of 2-Me-E2 had the 
concentration much less than the reported 0.01μM, it may play similar 
anti-proliferative effects by considering the difference between the metabolites 
generated in the cells and the dose added to the medium. Therefore, when MCF-7-PR 
cells were treated with 1nM of fresh estradiol every two days, it was possible to 
mimic the similar effect as that reported by Liu and Zhu (2004). 
 
4.3.3 Enhanced E2 metabolism in MCF-7-PR cells was possibly caused by 
increased cellular uptake 
It has been investigated that the E2 cellular uptake increased about 30% in MCF-7-PR 
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cells, compared with MCF-7 parental and vector-transfected cells. In 
adenovirus-infected MCF-7-Ad/PRA and MCF-7-Ad/PRB cells, only 
MCF-7-Ad/PRB showed similar increased E2 cellular uptake as MCF-7-PR cells. 
There were ~30% more E2 cellular uptake in MCF-7-Ad/PRB cells, while only ~10% 
in MCF-7-Ad/PRA. It suggested that PR isoform B rather than isoform A plays a 
critical role in enhancing estradiol cellular uptake. This result agrees with the cell 
cycle distribution result, where only MCF-7-Ad/PRB showed similar E2-induced S 
phase promotion inhibitory effect as that in MCF-7-PR cells. 
 
4.3.4 Factors which regulate MCF-7 E2 cellular uptake 
4.3.4.1 E2-bound membrane components 
It was shown that the increased cellular uptake of E2 in MCF-7-PR cells can be fully 
reversed by treating cells together with a 50-fold excess of BSA-conjugated E2. The 
66kD protein BSA does not go through cellular membrane, so that BSA-conjugated 
E2 does not enter cell body. It suggests that the regulation may be mediated via some 
membrane components which are possibly regulated by PR overexpression. 
The hypothesis is based on the presence of cell membrane estrogen receptors (mERs). 
mERs are estrogen plasma membrane binding proteins frequently localized to plasma 
membrane subdomains rich in caveolin, especially in endothelial cells (Zhu and Smart, 
2003). Controversies continue over whether mERs are completely indistinguishable 
from nuclear ERs except by localization (Singh et al., 2002), or whether they are 
novel ER receptors (Toran-Allerand et al., 2002). 
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In this current study, the result of BSA-conjugated E2 cellular uptake suggested a 
possible mechanism that expression of recombinant PR may affect expression or 
conformational change of E2-bound membrane components, which mediated the 
enhanced E2 cellular uptake and metabolism in MCF-7 cells; and thus resulted in 
faster depletion of E2 and accumulation of E2 inhibitory metabolites, which 
eventually inhibited MCF-7 cell proliferation. Most likely E2-bound membrane 
component in this study is mER, because BSA-conjugated E2 is believed only 
binding to mER (Stevis et al., 1999; Fiorini et al., 2003; Taguchi et al., 2004). 
Increased expression level of mER has been shown to inhibit estrogen stimulated cell 
growth. Cell proliferation study was performed in the MCF-7 subcloned cells, 
containing high level or low level of mERα. It is found that a 5-day E2 (1nM) 
treatment only stimulated proliferation of MCF-7 cells with high level of mERα for 
about 10%, compared with cells treated with vehicle control. However, cell number of 
MCF-7 with low level of mERα increased about 30% (Zivadinovic et al., 2005). One 
possible mechanism of mERα-mediated antiestrogenic effect is believed not to relate 
to E2 cellular uptake and metabolism, but to exert a negative feedback effect of 
estrogen-activated cAMP-PKA pathway on the estrogen-activated Ras-Raf-MAPK 
pathway of cell proliferation (Zivadinovic et al., 2005; Zivadinovic and Watson, 
2005).  
4.3.4.2 Other factors regulating MCF-7 E2 cellular uptake 
There are two other factors which could regulate E2 cellular uptake. 
One is the expression level of ERα. By knocking-out >95% ERα protein expression 
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with proteasome inhibitor MG132, cellular uptake of E2 reduced >90% in MCF-7 
cells. Because the whole cell binding assay examines both the bound and free E2 in 
cell body, this result suggested that most E2 in cell body were bound to ER. Thereby, 
the cellular uptake can be greatly regulated by ER protein level. 
The other is the intracellular cytoskeleton. Treating MCF-7 cells with 10mM 
cytochalasin D decreased cellular uptake by ~25%, while colchicine reduced that for 
~10%. As cytoskeleton disruption drugs, cytochalasin D disrupts microfilaments 
(actin filament) and colchicine works on disassembling microtubules. It meant that the 
intracellular cytoskeleton might play an important role in cellular uptake. It is 
reported that actin-mediated trafficking was involved in sterol uptake in Arabidopsis 
(Grebe et al., 2003). Even though there is no report on actin function of sterol uptake 
in mammalian cells or animal models, this in vivo work in plant may provide a clue to 
explain the function of actin filaments on E2 cellular uptake: actins might be 
important for allowing E2 to go through cell membrane cortex into cell body. 
Compared with actin filaments, function of microtubule in E2 cellular uptake seems 
irrelevant – it might relate to expulsion of E2 metabolites. The whole cell 
ligand-binding assay only tests the ligands in cell body, but expulsion of the 
metabolites should also be considered. The classic steroid secretion pathway involves 
steroid conversion from cholesterol at rough endoplasmic reticulum, modification at 
smooth endoplasmic reticulum and Golgi apparatus, and expulsion out of cell via 
vesicles. Among this, microtubules act as transporters to deliver steroids from smooth 
endoplasmic reticulum to Golgi apparatus. P450 enzyme mediated E2 metabolic 
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conversion also happens at rough endoplasmic reticulum, and the metabolites are 
expelled via the same pathway as steroid secretion. Therefore, disruption of 
microtubules by colchicine disabled transportation of metabolites between smooth 
endoplasmic reticulum and Golgi apparatus, which eventually affected removal of 
metabolites. Since the presence of non-specific lipid transfer proteins (sterol carrier 
proteins), expulsion of E2 metabolites were not fully blocked by microtubule 
disruption (Liscum and Munn, 1999). Therefore, cellular uptake reduction by 
colchicine was not as significant as that by cytochalasin D. 
However, the aforesaid intracellular cytoskeleton changes were unlikely induced by 
PR transfection in MCF-7 cells. It has been reported that PR was able to induce 
cytoskeleton remodeling in the dependence of progesterone or anti-progesterone in 
PR-positive breast cancer cells, which resulted in morphological changes of the cells 
(Perrot-Applanat et al., 1992; Lin et al., 2000; McGowan et al., 2003; Sumida et al., 
2004). In this present study, there was no morphologically change observed between 





In this study, two MCF-7 cell models with exogenous PR expression were established 
via distinct methods: stable transfection and adenovirus infection. 
Transfection of both PR isoforms into MCF-7 cells abolished the stimulatory effects 
of E2 on cell proliferation and cell cycle progression ligand-independently. Similar 
antiestrogenic effects were also observed in MCF-7-Ad/PRB cells, but not in 
MCF-7-Ad/PRA cells. It suggests that PR-B is the PR isoform which plays critical 
role in exerting the antiestrogenic effects of PR. PR-B may work solely or together 
with PR-A. The PR-B unique AF-3 domain may be crucial for the antiestrogenic 
potential of PR. 
Activated PR possibly exerts antiestrogenic effects via two pathways: increased E2 
metabolism and suppressed ER-targeted signaling cascades. Ligand-unoccupied 
recombinant PR is found to enhance E2 cellular uptake about 30% in MCF-7 cells, 
which possibly relates to some E2-bound cell membrane components. This is because 
the increased E2 cellular uptake can be reversed by treating MCF-7 cells with 
excessive dose of BSA-conjugated E2 which is cell membrane impermeable. Enhance 
E2 cellular uptake could directly contribute to increased E2 metabolism, causing 
faster depletion of E2 and accumulation of E2 growth inhibitory metabolites. The E2 
metabolism in the PR-transfected MCF-7 was found twice as fast as that in the 
vector-transfected control cells. Accelerated depletion of E2 induces quicker 
abolishment of E2 growth stimulatory effects; and E2 antiestrogenic metabolites 
inhibit MCF-7 cell proliferation. 2-methoxyestradiol could be the key E2 metabolite 
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which functions antiestrogenically in MCF-7 cell growth. On the other hand, 
ligand-unoccupied recombinant PR could also compete with ER for transcription 
cofactors/co-regulators or for the binding with ER chaperone proteins to repress 
liganded ER binding to ERE. Impaired binding between ER and ERE dramatically 
suppresses estrogen-dependent ER transcription activity with eventual inhibition of 
estrogen-stimulated MCF-7 cell cycle progression and proliferation. 
The study provided evidence of the functional interactions of ER and PR, thus 
verifying the hypothesis that overexpression of PR modulates ER-targeted estrogen 
stimulatory effects in MCF-7 cells. 
The foresaid two possible pathways of the antiestrogenic effects of the recombinant 



































































































































































































































































































































































Fig. 33. Possible pathways of the antiestrogenic effect of recombinant PR 
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4.5 Future studies 
In the present study, pathways which contribute to the antiestrogenic potential of 
recombinant PR are investigated. However, some mechanisms remain unknown. 
Recombinant PR in MCF-7 cells is possibly activated ligand-independently. Although 
the ligand-independent PR activation pathway has been reported, the pathway 
contributing to exogenous PR activation in this study remains elusive. Elucidating this 
pathway could help in understanding the interactions between PR and ER or other 
molecules such as growth factors and cytokines. 
mER is speculated as the key protein mediating increased E2 cellular uptake in PR 
overexpressing cells, but there is insufficient evidence. Comparison of the mER 
expression levels between control and PR-transfected cells may give further clues. 
Moreover, increased E2 uptake could also be regulated by some other cell membrane 
components instead of mER. 
E2 metabolism relative to estrogen-dependent ER activity suppression should be 
analyzed. If it is caused by formation of metabolites, the anti-proliferative effect of 
PR can be targeted by the production of antiestrogenic E2 metabolites. Hence, further 
analysis of the metabolites using mass spectrometry methods could shed light on the 
identity and quantity of the metabolites. 
Furthermore, since PR-B is the critical PR isoform to exert antiestrogenic effect in 
MCF-7 cells, investigation of the unique AF-3 domain of PR-B will provide more 
information on the mechanism of antiestrogenic potential of PR and the cross-talk 
between PR isoforms. 
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Investigation of the effects of exogenous PR in subcloned MCF-7 cells with 
tamoxifen resistance or the tamoxifen-induced antiestrogen-resistant MCF-7 cells will 
provide strong evidence in support of a potential therapeutic strategy for 
endocrine-resistant breast cancers. 
Moreover, this in vitro study could also lead to in vivo studies by using adenoviruses 
mediated PR genes delivery. Injecting the mice carrying MCF-7 formed tumor(s) with 
Ad/PRA or Ad/PRB viruses will provide primary evidence for possible gene therapies 
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RECIPE OF SOLUTIONS 
 
1X PBS (pH 7.4) 
NaCl           9.00g/L 
Na2HPO4·7H2O         0.795g/L 
KH2PO4           0.144g/L 
ddH2O 
 
1X DPBS (pH 7.4) 
KCl            0.20g/L 
NaCl           8.00g/L 
KH2PO4           0.20g/L 
Na2HPO4          1.15g/L 
ddH2O 
 
Adenovirus dialysis and storage buffer 
Tris-HCl (pH 8.0)        20mM 
NaCl           25mM 






Cell lysis buffer 
NaF           100mM 
HEPES (pH 7.5)         50mM 
NaCl           150mM 
PMSF           1mM 
Na3VO4           1mM 
pepstatin A          5μg/ml 
leupeptin          5μg/ml 
aprotinin          2μg/ml 
Triton X-100         1% 
ddH2O 
 
5X sample buffer for immunoblotting 
Tris-HCl (pH 6.8)        0.625M 
SDS           10% 
Glycerol          50% 
β-mercapthoethanol        5% 
bromophenol blue        pinch 
ddH2O 
 
1X running buffer for immunoblotting 
Tris            6g/L 
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Glycine           28.8g/L 
SDS           1g/L 
ddH2O 
 
1X transferring buffer for immunoblotting 
Glycine           14.41g/L 
Tris base          3.03g/L 
Methanol          10% (v/v) 
ddH2O 
 
1X wash buffer for immunoblotting (TBST) 
Tris pH 7.5          10mM 
NaCl           100mM 
TWEEN 20          0.1% 
ddH2O 
 
Striping buffer for immunoblotting 
Tris-HCl (pH 6.8)        62.5mM 
SDS           2% 





1X TBE buffer (pH 8.35) 
Tris            90M 
Boric acid          50M 
EDTA           2mM 
ddH2O 
 
1X PI (propidium iodide) Vindelov’s cocktail 
Tris-HCl pH 8.0         10mM 
NaCl           10mM 
PI            50mg/L 
RNase A          10mg/L 
NP-40           0.1% 
ddH2O 
 
HPLC mobile phase A 
Acetonitrile          21% 
Methanol          22% 
ddH2O           57% 
Acetic acid          0.1% 
 
HPLC mobile phase B 
Acetonitrile          40% 
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ddH2O           60% 
Acetic acid          0.33% 
 
HPLC wash and column storage buffer 
Methanol          66% 
ddH2O           34% 
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The expression of progesterone receptor (PR) is nor-
mally estrogen-dependent, and progesterone is only ac-
tive in target cells following estrogen exposure. This
study revealed that the effect of estrogen was markedly
disrupted by estrogen-independent expression of PR.
Transfection of PR in estrogen receptor (ER)-positive
MCF-7 cells abolished the estradiol-17 growth stimula-
tory effect that was observed in the parental cells and
the vector-transfected controls in a ligand-independent
manner. The antiestrogenic effect was also observed at
the level of gene transcription. Estradiol-17 (E2)-in-
duced gene expression of pS2 and GREB1 was impaired
by 50–75% after 24–72 h of E2 treatment in PR-trans-
fected cells. Promoter interference assay revealed that
PR transfection drastically inhibited E2-mediated ER
binding to estrogen response elements (ERE). The an-
tiestrogenic effects of transfected PR are associated
with enhanced metabolism of E2. HPLC analysis of
[3H]E2 in the samples indicated that the percentage of
[3H]E2 metabolized by PR-transfected cells in 6 h is sim-
ilar to that by vector-transfected control cells in 24 h (77
and 80%, respectively). The increased metabolism of E2
may, in turn, be caused by increased cellular uptake of
E2, as demonstrated by whole cell binding of [3H]E2. The
findings open up a new window for a hitherto unknown
functional relationship between the PR and ER. The
antiestrogenic effect of transfected PR also provides a
potential therapeutic strategy for estrogen-dependent
breast cancer.
Ovarian steroid hormones estrogen and progesterone are
essential for the normal growth and development of the breast.
The two hormones also play critical roles in the regulation of
breast cancer development. It has been established that estro-
gen stimulates the growth of breast cancer cells both in vivo
and in vitro (1–3). Antiestrogens have been the front-line ther-
apy for hormone-dependent breast cancers (4), which are estro-
gen receptor (ER)1- and progesterone receptor (PR)-positive.
Nonetheless, antiestrogen-induced remissions are often fol-
lowed by acquisition of antiestrogen resistance and ultimately
disease relapse (5). The acquired resistance is mostly mani-
fested by insensitivity to antiestrogens such as tamoxifen and
increased ER activity (6). It has been shown that signaling via
the epidermal growth factor receptor and HER-2/neu can acti-
vate both ER and the important ER coactivator AIB1 (7).
Breast tumors with high levels of AIB1 and HER-2 may be
resistant to tamoxifen because of an increase in its estrogen
agonist activity. The development of strategies for the effective
treatment of tamoxifen-resistant breast cancer is one of the
main challenges for breast cancer research.
Whereas it is established that estrogen stimulates the
growth of breast cancer cells, the function of progesterone in
breast cancer remains controversial. Progestins were found to
stimulate growth, have no effect, or inhibit growth depending
on the experimental conditions and the status of hormone
receptors (8–11). This controversy reflects our insufficient un-
derstanding of progesterone biology and has hampered effec-
tive applications of progestins or antiprogestins in breast can-
cer treatment.
The controversies over the effect of progesterone in breast
cancer are due to several complexities in the PR system. One of
the complexities is that PR is an estrogen receptor-dependent
gene product (12, 13), and the action of progesterone requires
priming treatment of estrogen to induce PR. It is conceivable
that the prior presence of estrogen may significantly confound
assessment of the role of progesterone on growth and other
cellular processes in breast cancer cells. On the other hand, the
effects of progesterone also depend on a complex interaction
between estrogen, progesterone, and their receptors. Studies
have demonstrated the suppression of estrogen-stimulated ER
activity by agonist- and antagonist-occupied PR (14–15). How-
ever, ER can transmit signals received from the agonist-acti-
vated PR to the Src/p21 (ras)/Erk pathway (16), suggesting a
synergistic interaction between the ER and PR.
Our previous work has shown that estrogen-independent
expression of PR by transfection in the ER- and PR-negative
breast cancer cells MDA-MB-231, facilitated a striking inhibi-
tion of cell growth by progesterone in vivo and in vitro (11, 17).
Progesterone also induced remarkable focal adhesions in the
PR-transfected MDA-MB-231 cells (18). This present study
reveals that estrogen-independent expression of PR in MCF-7
cells exhibited strong antiestrogenic and antiproliferative ef-
fect that is independent of PR ligands. The antiestrogenic effect
is associated with a marked decrease of estradiol-17 (E2) in
the culture medium of PR-transfected cells. This suggests that
the transfected PR exerted the antiestrogenic effect by modu-
lating cellular uptake and metabolism of E2. The study pro-
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vides the basis for a novel antiestrogenic mechanism that may
be used for breast cancer treatment.
MATERIALS AND METHODS
Chemicals—All tissue culture reagents were from Invitrogen. Pro-
pidium iodide (PI), progesterone, 17-estradiol, estrone, estriol, 6-
hydroxyestradiol, and 16-hydroxyestrone were purchased from Sigma.
Trichloroacetic acid was purchased from Fisher Scientific. Nonidet P-40
was purchased from USB Corp. (Cleveland, OH). [2,4,6,7,16,17-3H]Es-
tradiol-17 (149 Ci/mmol) was from Amersham Biosciences.
Cell Culture—MCF-7 cells were obtained from the American Type
Culture Collection in 1995 at passage 147. Cells were routinely main-
tained in phenol red-containing Dulbecco’s modified Eagle’s medium
supplemented with 7.5% fetal calf serum (Hyclone, Logan, UT), 2 mM
glutamine, and 40 mg/liter gentamicin. For all experiments involving
cell culture, phenol red-free medium containing 5% dextran-coated
charcoal-fetal calf serum (DCC-FCS), and 2 mM glutamine was used,
and this medium will be referred as Test Medium in the subsequent
description.
Transfection—PR expression vectors hPR1 and hPR2 contain human
PR cDNA coding for PR isoform B and A, respectively, in pSG5 plasmid
(18). Vector pBK-CMV (Stratagene) containing the neomycin-resistant
gene was cotransfected with hPR1 and hPR2 into MCF-7 cells using
Lipofectin reagent (Invitrogen). Neomycin-resistant clones selected in
medium containing G418 (500 g/ml) were further screened for vector
pSG5 sequence by PCR using primers specific for pSG5. Cells stably
transfected with both pBK-CMV and pSG5 (Stratagene) plasmids were
used as transfection controls.
Western Blotting Analysis—Total proteins were extracted from the
cells by three cycles of freezing (liquid nitrogen) and thawing (37 °C
water bath) in buffer containing 0.25 M Tris-HCl, pH 6.8, 4% SDS, 20%
glycerol, and 2% -mercapthoethanol. Lysates containing 50 g of pro-
tein were separated on 8.5% SDS-PAGE and transferred to nitrocellu-
lose membranes (Amersham Biosciences). Human PR isoforms A and B
were probed with anti-PR antibody Ab-8 from Neomarker (Fremont,
CA); human ER was probed with anti-ER antibody Ab-15 from Neo-
marker; human glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
probed by anti-GAPDH antibody (Ambion) was used as loading control.
Cell Growth Assay—1  104 cells were seeded onto 6-well plates in
Test Medium. Two days later, the cells were treated with 109 M E2 in
fresh medium from 1000-fold stock in ethanol, which gave a final
concentration of ethanol of 0.1%. Treatment controls received 0.1%
ethanol only. The medium with the test compounds was changed every
2 days, and cells were counted with a hemocytometer.
Cell Cycle Analysis—Cells plated onto 6-well plates were grown in
Test Medium for 48 h before they were treated with E2 or progesterone
for the indicated periods of time. Trypsinized cells were stained with PI
in Vindelov’s mixture (10 mM Tris-HCl, pH 8.0, 10 mM NaCl, 50 mg
PI/liter, 10 mg/liter RNaseA, and 0.1% Nonidet P-40) for 1 h in the dark.
The stained cells were analyzed in FACS Caliber flow cytometer (BD
Biosciences) with excitation wavelength of 488 nm. The resulting his-
tograms were analyzed by program MODFIT for cell cycle distribution.
Real Time RT-PCR—cDNAs were synthesized from 5 g of total
RNA. Real time PCR was performed with SYBR Green Master Mix on
an ABI Prism 7700 Sequence Detection System (Applied Biosystems,
Foster City, CA). The primers for pS2 are 5-ATGGCCACCATGGAGA-
ACAAGG-3 (forward) and 5-CTAAAATTCACACTCCTCTTCTGG-3
(reverse). The primers for GREB1 are 5-CCCCGTGGCCCCGCAGA-
G-3 (forward) 5-AGGATGAGCCCGAGGAGGAGGACA-3 (reverse).
36B4 (forward: 5-GATTGGCTACCCAACTGTTGCA-3 and reverse: 5-
CAGGGGCAGCAGCCACAAAGGC-3), which codes for human acidic
ribosomal phosphoprotein, was used as internal control for normalizing
the quantity of cDNA analyzed. PCR for each gene fragment were
performed in triplicates, and each experiment was repeated twice. The
relative amount of PCR products generated from each primer set was
determined on the basis of threshold cycle (Ct).
Promoter Interference Assay—Cells were grown in Test Medium for
48 h before they were transfected with 2 g of CMV-TATA-ERE2-CAT
(cytomegalovirus-estrogen response element-chloramphenicol acetyl-
transferase) or 2 g of control vector CMV-TATA-CAT. 16 h later, cells
were given fresh medium and treated with 109 M E2 or 0.1% ethanol as
control. Cells were harvested at 16, 24, and 48 h after E2 treatment.
CAT activity was measured using the CAT-ELISA kit (Roche Applied
Sciences, Indianapolis, IN).
Cellular Uptake of [3H]E2—Cells (1  105) were grown on 12-well
plates in Test Medium for 48 h before they were incubated with 109 M
[3H]E2 in phenol red-free Dulbecco’s modified Eagle’s medium for 1 h.
Nonspecific uptake was determined by incubating 109 M [3H]E2 in the
presence of 200-fold excess of unlabeled E2. Following incubation, the
cells were washed with cold Mg2- and Ca2-free DBPS three times,
and cellular [3H]E2 was extracted with 500 l of absolute ethanol and
measured by a Microbeta liquid scintillation counter (PerkinElmer
Life Sciences).
Analysis of Estradiol Metabolism by HPLC—Cells were seeded in
6-well plates for 48 h before they were treated with 109 M [3H]E2. The
conditioned media were harvested following 3, 6, and 24 h treatment.
Cell-free media incubated with 109 M [3H]E2 were used as controls for
each time point.
The proteins in the media were precipitated with 10% trichloroacetic
acid followed by washing with acetone twice. The pH of the deprotein-
ated medium was adjusted to 5.0 with 10 N NaOH. HPLC was per-
formed on a Supercosil LC-18-DB column (5 m, 25 cm  4.6 mm,
Supelco Bellefonte, PA) at room temperature. The mobile phase A
contains 21% acetonitrile, 22% methanol, 57% water, 0.1% acetic acid;
B contains 40% acetonitrile, 60% water, 0.33% acetic acid. The gradient
was as follows: 0–15 min, 100% solvent A; 15–25 min, a linear increase
to 19% solvent B; 25–30 min, a linear increase to 20% solvent B; 30–53
min, a linear increase to 100% solvent B; 53–60 min, 100% solvent B.
The flow rate was 1.5 ml/min. 0.5 min flow fractions were collected and
the radioactivity was measured on a Microbeta liquid scintillation
counter.
Statistical Analysis—Differences among treatment groups with re-
gard to cell proliferation and growth were analyzed by analysis of
variance followed by the least significant difference (LSD) test. Differ-
ences of gene expression, reporter gene activity, and E2 concentration
between control and E2-treated cells were tested by Student’s t test.
FIG. 1. Levels of PR and ER in MCF-7 cells, vector-transfected MCF-7 cells (MCF-7-C8), and PR-transfected MCF-7 cells
(MCF-7-PR8 and MCF-7-PR26). Cell lysates were collected from cells treated with 0.1% ethanol () or 109 M E2 () for 24 or 72 h, and analyzed
for PR and ER by Western blot. GAPDH was used as loading control. ER- and PR-negative breast cancer cell line MDA-MB-231 and ABC28 cells
(MDA-MB-231 cells transfected with PR-A and PR-B) were used as negative and positive controls, respectively.
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RESULTS
Characterization of PR Transfectants—Fig. 1 shows the lev-
els of PR and ER proteins in the parental cells MCF-7, the
vector-transfected control cells MCF-7-C8 and in PR-trans-
fected cells MCF-7-PR8 and MCF-7-PR26. MCF-7-PR8 and
MCF-7-PR26 cells express 3–5 times more PR than MCF-7
and MCF-7-C8 cells in the absence of E2. MCF-7-PR8 cells
express three times as much PR-B as PR-A, whereas MCF-
7-PR26 express twice as much PR-A as PR-B. Despite the
expression of estrogen-independent PR (eiPR), E2 was able to
induce endogenous PR in PR-transfected cells. Fig. 1 also re-
vealed that the ER protein was reduced by 20% following E2
treatment in all the cell lines. On the other hand, PR transfec-
tion did not affect the levels of ER in the presence or absence
of E2.
PR-transfected MCF-7 cell clones MCF-7-PR8 and MCF-7-
PR26 were studied for their responses to progesterone and
estrogen. The MCF-7 parental cells and the vector-transfected
MCF-7 clones 8 (MCF-7-C8) served as control cells.
E2 Inhibited Cell Cycle Progression in PR-transfected MCF-7
Cells after 72 h of Treatment—The experiment depicted in Fig.
2 was designed to determine the effect of progesterone on cell
cycle progression in MCF-7 cells transfected with PR. The cells
had been treated with either 0.05% ethanol or 109 M E2 for
24 h before they were treated with various concentrations (0,
1012 M, 109 M, and 106 M) of progesterone for 48 h. The
duration of E2 treatment is thus 72 h. The estradiol treatment
was to induce PR so that the effect of progesterone can be
compared between PR-transfected cells and the control cells.
The results revealed that increase of PR protein by transfection
in MCF-7 cells did not affect the action of progesterone on cell
proliferation. Whereas having no affect at lower concentra-
tions, progesterone at 106 M elicited about an 8–10% increase
of the S-phase fraction in both PR-transfected cells (MCF-7-
PR8 and MCF-7-PR26 cells) and control cells (MCF-7 and
MCF-7-C8) (p  0.01) (Fig. 2). However, the affect of E2 on
PR-transfected MCF-7 cells is the opposite of that on control
cells. In accordance with the known effect, E2 increased the
S-phase fraction of MCF-7 and vector-transfected control MCF-
7-C8 cells by an average of 35% regardless of the presence or
absence of progesterone. In contrast, E2 decreased S-phase
cells by an average of 30–40% in PR-transfected cells MCF-7-
PR8 and MCF-7-PR26. This effect of transfected PR is ligand-
independent as progesterone at various concentrations did not
modify this antiproliferative effect of E2 in PR-transfected
MCF-7 cells.
PR Transfection in MCF-7 Cells Abolished the Growth Stim-
ulatory Effect of E2—Fig. 3 shows that the numbers of E2-
treated MCF-7 and MCF-7-C8 cells were double that of vehicle-
treated controls after 8 days. In contrast, the cell numbers of
E2-treated MCF-7-PR8 and MCF-7-PR26 cells were the same
as that of vehicle-treated cells. Although the cell numbers of
PR-transfected cell clones appears to be higher than that of
control cells after 8 days in culture, this does not necessarily
indicate an increased rate of cell growth in PR-transfected
cells. As shown by Fig. 6, the S-phase fraction of PR-transfected
cells receiving control vehicle is similar to that of parental and
vector-transfected cells (19 versus 22%).
Antiestrogenic Effect of PR Transfection Is Also Exerted at the
Level of Gene Transcription—ER is a transcription factor, and
the effect of E2 is mediated by ER through its gene regulation
activities. To determine if transfected PR inhibits the effect of
E2 by modifying the transcriptional activity of ER, the expres-
sion of two well known estrogen target genes pS2 and GREB1
were studied by real-time RT-PCR analysis (Fig. 4). E2 induced
the increase of pS2 expression by 6–10-fold after 24 h of treat-
ment in all cell lines tested. This induction of pS2 gene expres-
sion was sustained in MCF-7 and MCF-7-C8 cells after 48 and
72 h of treatment. In MCF-7-PR8 and MCF-7-PR26 cells; how-
FIG. 2. E2 inhibited cell cycle progression in PR-transfected
MCF-7 cells. Cells were treated with 0.05% ethanol (f) or 109 M E2 (▫)
for 24 h before they were treated with 0, 1012 M, 109 M, or 106 M
progesterone for 48 h. They were then harvested, stained, and analyzed
for cell cycle distribution using flow cytometry. Results are expressed as
mean  S.D., n 	 3.
FIG. 3. The growth stimulatory effect of E2 was abolished in
PR-transfected MCF-7 cells. Cells were treated with 109 M E2 or
0.1% ethanol for various periods of time. The cell numbers were deter-
mined by counting on a hemocytometer at 0, 2, 4, 6, and 8 days after the
initial treatment. Results are expressed as mean  S.D., n 	 4.
Novel Antiestrogenic Mechanism17482
ever, the induction of pS2 gene expression by E2 was impaired
by 50–75% after 48 and 72 h of treatment (p  0.001). Simi-
larly, estradiol-induced GREB1 expression following 48 and
72 h of treatment was impaired by 70% compared with that at
the 24 h time point in PR-transfected cells. In contrast, the
induction of gene expression in MCF-7 and MCF-7-C8 cells for
both pS2 and GREB1 remained statistically similar at all time
points studied. It is interesting to note that the inhibition of
transcription activity of ER by PR transfection at 24 h was not
as prominent as that at 48 and 72 h.
Transfected PR Interferes with ER Binding to Estrogen Re-
sponse Elements (ERE)—To determine if the transfected PR
modify the effect of E2 by interfering with ER binding to
specific ERE, we conducted promoter interference assay by
transient transfection. The reporter plasmid (CMV-ERE2-CAT)
contains two ERE sequences positioned between the TATA box
and the start of transcription. The ER binding to ERE will
disrupt the assembly of the general transcription complex,
resulting in the reduction of the CMV promoter-driven CAT
reporter gene expression. It has been validated that insertion of
up to three ERE into CMV-TATA-CAT plasmids did not disrupt
the expression of CAT activity in the absence of ER (20, 21).
Cells transfected with CMV-TATA-CAT reporter construct
were used as transfection controls for each treatment. The
result of each treatment in Fig. 5 was expressed as the per-
centage of CAT expression by CMV-TATA-ERE2-CAT relative
to that by CMV-TATA-CAT. CAT expression by CMV-TATA-
ERE2-CAT in vehicle-treated cells is on the average 50% of that
by CMV-TATA-CAT, suggesting some intrinsic interference of
CMV promoter activity by cellular proteins. In MCF-7 and
vector-treated MCF-7-C8 cells, E2 treatment for 16, 24, and
48 h caused a 40–60% reduction in CAT activity compared
with vehicle-treated controls. In contrast, estradiol-17-medi-
ated promoter interference activity was largely abolished in
PR-transfected cells at these time points. Hence transfected PR
inhibited ER binding to ERE. This effect appeared as early as
16 h after treatment.
The Antiestrogenic Effect of Transfected PR on Cell Prolifer-
ation Exhibited a Delay of 60 h—We have shown earlier that
the inhibitory effect of E2 on cell cycle was demonstrated after
72 h of treatment (Fig. 2). Gene expression studies showed that
the antiestrogenic effect of transfected PR appeared following a
delay of 24 h. Further studies were carried out to determine
if this delay also occurs in cell cycle regulation. Surprisingly,
the effect of E2 on cell cycle progression was stimulatory in
these PR-transfected cells up to the time point of 60 h after
treatment. The S-phase fraction of these cells plunged to about
60% of the vehicle-treated controls only after 72 h of treatment
(Fig. 6A). In contrast, S-phase fractions of E2-treated MCF-7
and MCF-7-C8 cells were consistently higher than that in
vehicle-treated control cells throughout the 72-h period exam-
ined. These results suggest E2 treatment turned growth inhib-
itory after 72 h.
Studies of both gene expression and cell cycle suggest that
E2 functions normally during the first 24–48 h of treatment
depending on the parameter tested. We asked the question
whether PR transfection affected the metabolism of E2 such
that E2 is short-lived. In this scenario, a second dose of E2
should still be growth stimulatory initially. This hypothesis
was tested by studying cells in culture over a period of 7 days,
and the culture medium was replaced by fresh medium with E2
after 72 and 120 h. Fig. 6B shows that freshly added E2 was
able to induce an increase of S-phase fraction after 24 h in
culture in PR-transfected cells. But it again turned antimito-
genic after 48 h in culture. The same stimulatory and inhibi-
tory pattern occurred following the third addition of E2. This is
in sharp contrast to the effect of E2 on vector-transfected cells
MCF-7-C8 cells in which the number of S-phase cells was
FIG. 4. Induction of the gene expression of pS2 and GREB1 by
E2 was repressed in PR-transfected MCF-7 cell. Cells were treated
with 0.1% ethanol or 109 M E2 in 0.1% ethanol, and total RNA was
extracted from the cells at 24, 48, and 72 h after treatments. The
expression of pS2 (A) and GREB1 (B) was analyzed by real time RT-
PCR. The expression of each gene is expressed relative to vehicle-
treated controls, which are given the value of 1. The results are the
means of three replicates. Asterisk indicates that the gene expression at
48 and 72 h time points are significantly (p  0.01) less than the
expression at the 24-h time point.
FIG. 5. Effect of PR transfection in MCF-7 cells on ER-ERE
binding in the promoter interference assay. Cells were transfected
with CMV-TATA-ERE2-CAT or CMV-TATA-CAT for 16 h before they
were treated with 0.1% ethanol or 109 M E2. CAT activity was meas-
ured by ELISA assay at 16, 24, and 48 h after E2 treatment. The CAT
activity in CMV-TATA-ERE2-CAT-transfected cells was calculated as
the percentages of that in cells transfected with CMV-TATA-CAT. Re-
sults are means  S.E., n 	 3. Asterisk indicates that CMV-driven CAT
activity in E2-treated cells is significantly (p  0.01) less than that in
vehicle-treated control cells.
Novel Antiestrogenic Mechanism 17483
higher in E2-treated cells than that of vehicle-treated control
cells throughout the 7-day period. These data support the hy-
pothesis that E2 in PR-transfected cells may be metabolized at
a faster rate than that in control cells, and E2 may be converted
to a growth inhibitory compound in PR-transfected MCF-7
cells.
Heightened Metabolism of E2 in PR-transfected MCF-7
Cells—The metabolic changes of [3H]E2 in the media of MCF-
7-PR8 and MCF-7-C8 cells were monitored by scintillation
counting of radioactivity in the fractions of eluate following
HPLC separation (Fig. 7). The whole media were analyzed
without solvent extraction so that metabolites of both a hydro-
phobic and hydrophilic nature were present in the sample. The
protein components were removed by trichloroacetic acid pre-
cipitation to prevent interference in separation. [3H]E2 was
eluted as peak y since it was the only peak in cell-free medium,
and its retention time also matched that of E2 standard (23.9
1.5 min). Peak x is a mixture of [3H]E2 metabolites, and this
peak was not present in cell-free medium. There was a progres-
sive decrease of the [3H]E2 peak and increase of the metabo-
lites peak xwith time in both cell lines. However, these changes
occurred more rapidly in culture medium of MCF-7-PR8 cells
compared with that of MCF-7-C8 cells. After 3 h of treatment,
58% of [3H]E2 was metabolized by MCF-7-PR8 cells compared
with 26% (Table I) by MCF-7-C8 cells. Following 6 h of treat-
ment, 77% of [3H]E2 was metabolized by MCF-7-PR8 cells
compared with 40% by MCF-7-C8 cells. It is remarkable that
the percentage of [3H]E2 metabolized by MCF-7-PR8 cells in
6 h (77%) is similar to that by MCF-7-C8 cells in 24 h (80%),
suggesting a much faster metabolic conversion of E2 in PR-
transfected cells than the vector-transfected controls.
The retention time of [3H]E2 metabolites in peak x is be-
tween 4 and 9 min. This overlaps the retention time for 6-
hydroxyestradiol (4.3 min), estriol (5.1 min), and 16-hy-
droxyestrone (7.9 min) (Table II). Although these three
compounds are some of the major metabolites of E2, there are
insufficient data for us to confirm the identities of the metab-
olites in peak x.
We also determined whether the heightened E2 metabolism
is caused by enhanced cellular uptake. Fig. 8 shows that after
just 1 h of incubation with [3H]E2, cellular [3H]E2 in MCF-7-
PR8 and MCF-7-PR26 cells was 32% higher (p  0.05) than
that in control cells MCF-7 and MCF-7-C8. It appears that
enhanced cellular uptake of E2 in PR-transfected cells is pos-
sibly one of the mechanisms for increased metabolism of E2.
DISCUSSION
Phylogenetic analysis and genome mapping of steroid recep-
tors revealed that the first steroid receptor to evolve is the ER,
followed by the progesterone receptor (22, 23). Estrogen-de-
pendent expression of PR in target tissues may carry selective
advantages from an evolutionary point of view. The emergence
of PR before estrogen may inflict certain threats to homeostasis
of cells. This study demonstrates that the expression of PR
prior to estrogenic signal severely hampered the function of
estrogen. eiPR inhibited E2-mediated gene expression and
abolished its growth stimulatory effect. While the antiestro-
genic effects of progestin have been documented (14, 15, 24),
the antiestrogenic effects of these eiPR are ligand-independent.
Neither progesterone nor antiprogestins such as RU486 or
ZK98299 were able to modify the antiestrogenic property of
these PR-transfected MCF-7 cells (data not shown).
Several lines of evidence suggest that the antiestrogenic
effect of eiPR may be mediated through enhancing the metab-
olism of E2. The first indication was that the affect of E2 on
gene expression and cell proliferation was only impaired fol-
lowing 48 or 72 h of treatment. Because Western blotting
analysis revealed no difference in the ER levels between PR-
transfected cells and control cells, we speculate that this an-
tiestrogenic effect may be caused by the depletion of E2. In-
deed, when the S-phase fraction of E2-treated PR-transfected
cells fell to 40% below vehicle-treated controls at the 72-h point,
freshly added E2 was able to resume the growth stimulatory
effect in these cells. Results of HPLC analysis of [3H]E2 in the
conditioned media strongly supported the notion of enhanced
metabolism of [3H]E2 in PR-transfected cells; MCF-7-PR8 cells
metabolized 77% [3H]E2 in 6 h compared with a similar per-
centage metabolized (80%) by MCF-7-C8 cells in 24 h. The
study also suggests that increased cellular uptake of E2 is one
of the mechanisms for the increased E2 metabolism in PR-
transfected cells. This is conceivable as the metabolism of E2 in
culture occurs mainly inside the cells (25).
Though the retention time of 6-hydroxyestradiol, estriol,
and 16-hydroxyestrone match that of the metabolite peak, the
true identities of the metabolites in the mixture remain to be
determined. It has been suggested that estriol and 6-hy-
droxyestradiol are among the main end products of follicular
metabolism (26). On the other hand, studies in MCF-7 cells
suggested estrone, 2-hydroxyestrone, and estradiol 3-sulfate as
the main metabolites of E2 (27–30). All three compounds were
not detectable in our study based on their retention time (27,
31). The discrepancies may be because of many differences in
experimental conditions such as the position and the amount of
tritium labeling in E2, the concentration of E2 used, and the
FIG. 6. A, the effect of E2 on cell cycle progression as a function of
time. Cells were treated with 0.1% ethanol as vehicle control (f) or 109
M E2 (▫) for various time before were harvested and analyzed for cell
cycle distribution by flow cytometer. Results are expressed as mean 
S.D., n	 3. B, effect of replacement of fresh E2 on cell cycle progression.
Cells were treated with 0.1% ethanol as vehicle control (f) or 109 M E2
(▫) for various periods of time and analyzed for cell cycle distribution.
Medium was changed with fresh E2 at 72 and 120 h after the initial
treatment. Results are expressed as mean  S.D., n 	 3.
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method of extraction.
The time lag between the antiestrogenic effects on gene
expression and on cell cycle progression also supports the the-
ory of heightened metabolism of E2 in PR-transfected cells. The
effect of E2 during the first few hours has probably initiated the
genomic events that were sufficient to commit cells to 2 rounds
of accelerated cell cycles. That explains why the antiestrogenic
effect on cell cycle distribution was only observed following 72 h
of treatment. In contrast, E2 induction of gene expression is a
relatively early event, and the effect can be observed at 6–12 h
following E2 depletion. Because 77–94% E2 was metabolized in
PR-transfected cells between 6 and 24 h following E2 treat-
ment, a decline in E2-activated gene transcription of cell cycle
genes would be seen after 24–48 of E2 treatment, as is shown
in Fig. 4.
It is intriguing that the S-phase fraction of E2-treated PR-
transfected cells at 72 h is 40% lower than vehicle-treated
controls. It seems to suggest that E2 has been converted to
growth inhibitory metabolites that can counteract the effect of
E2. Compounds such as estriol and 2-methoxyestradiol have
FIG. 7. Estradiol metabolic profiles in vector-transfected and PR-transfected MCF-7 cells. The vector-transfected and PR-transfected
MCF-7 cells were incubated with 109 M [3H]E2 for 3, 6, or 24 h. The conditioned media were harvested and analyzed by reverse-phase HPLC as
described under “Materials and Methods.” The radioactivity in 0.5-min flow fractions were counted on a liquid scintillation counter. The data are
presented as counts per minute (cpm) in each fraction versus the retention time. Peak x is a mixture of [3H]E2 metabolites, and [3H]E2 was eluted
in peak y.
TABLE I
The percentage of radioactivity in peak x and peak y for the
histogram presented in Fig. 7
The percent radioactivity is calculated as the sum of the counts of all
the fractions in each peak as a percentage of the total counts detected.
E2 and E2 metabolite(s)
Radioactivity
3 h 6 h 24 h
%
Cell-free control media
Peak x – – –
Estradiol (Peak y) 92.0 92.8 93.9
MCF-7-C8 cell media
Peak x 25.8 40.4 80.4
Estradiol (Peak y) 67.6 55.3 13.2
MCF-7-PR8 cell media
Peak x 57.9 77.0 93.4
Estradiol (Peak y) 38.8 17.5 2.0
TABLE II
The retention time of unlabeled E2 and E2 metabolite standards
Results are expressed as mean  S.D. n 	 3.
Steroid Retention time
min
6-Hydroxyestradiol 4.3  0.5
Estriol 5.1  0.8
16-Hydroxyesterone 7.9  0.8
17-Estradiol 23.9  1.5
Estrone 30.2  1.3
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been shown to inhibit the growth of breast cancer cells, but
these effects were only exhibited at high concentrations (
106
M) (32, 33). The E2 concentration of 109 M used in this study is
unlikely to generate higher concentrations of metabolites.
E2-mediated promoter interference was abolished as early as
16 h after treatment in eiPR-expressing cells. This antiestro-
genic event seems to be too early to be attributable to the
depletion of E2. Therefore, there may be additional mecha-
nisms leading to the impaired ER-ERE interaction. In this
regard, the mechanism of competition for cofactors between
eiPR and ER is more plausible. It has been reported (34) that
transcriptional activity of ER was inhibited in HeLa cells by
co-expressing ER and PR in a ligand-dependent manner. This
inhibition could be relieved by increasing the expression level
of ER. The above study appears to suggest that PR may com-
pete with ER for transcription cofactors or co-regulators so as
to impair the ER transcriptional activity. It is also possible that
eiPR compete for binding with chaperone proteins such as heat
shock protein 90 and various immunophilins that are required
to maintain the receptor in a favorable conformation for ligand
binding (35).
It is presently unclear how transfected PR mediates in-
creased cellular uptake of E2. Early studies showed that the
relative binding affinity of E2 for PR is less than 0.3% of
progesterone (36). With a dissociation constant of 109 M for
progesterone binding, the estimated dissociation constant for
E2 would be in the range of 106 M. It is thus theoretically not
possible for E2 at 109 M to bind to PR significantly. However,
we observed that E2 treatments facilitate an inhibition of the
PR progesterone response element binding in the promoter
interference assay,2 suggesting an inhibitory effect of E2 on
PR-DNA interaction. Whether this is mediated through E2-PR
binding remains to be investigated.
Evidence supporting the antiestrogenic potential of eiPR has
been recently reported in an in vivo study. Breast cancer cells
T47D expressing eiPR grew into smaller estrogen-dependent
tumors in nude mice than PR-negative cells, and this phenom-
enon is independent of the PR ligand (37). The effect was PR
isoform-selective as tumors expressing PR-A were only half the
size of PR-B-expressing tumors. However, there was no indica-
tion of one PR isoform being more potent than the other in our
study. Although MCF-7-PR8 expresses more PR-B than PR-A
and MCF-7-PR26 expresses more PR-A than PR-B, the two cell
lines have similar potential to abolish the growth stimulatory
effect of E2. Studies of gene expression of pS2 and GREB1
indicate that the antiestrogenic potential of MCF-7-PR8 is
greater than that in MCF-7-PR26. This may be related to the
higher level of PR in MCF-7-PR8 cells instead of the relative
expression of PR isoforms.
In summary, the study demonstrated that estrogen-inde-
pendent expression of PR in MCF-7 cells antagonized the
stimulatory effect of E2 on cell proliferation and on gene
expression in a PR ligand-independent manner, and inter-
fered with ER binding to ERE. This antiestrogenic effect of
eiPR is associated with an accelerated metabolism of E2 in
PR-transfected MCF-7 cells, which is likely mediated
through increased cellular uptake of E2. Squelching of cofac-
tors by transfected PR may explain the reduced ER-ERE
interaction in a promoter interference assay. The findings
open up a new window for a hitherto unknown functional
relationship between the PR and ER. This antiestrogenic
mechanism is also of therapeutic relevance to the group of
ER-positive breast tumors, which do not respond to anties-
trogen therapy, and to the antiestrogen-resistant tumors that
remain ER-positive and estrogen-responsive.
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